Anti-SIGLEC-5 antibodies and methods of use thereof
By developing specific anti-Siglec-5 antibodies, the cell surface level and activity of Siglec-5 are reduced, and the problem of poor treatment effect of Siglec-5-related diseases in the prior art is solved, and the immune response is enhanced and various diseases are improved. Treatment effect.
Patent Information
- Application Number
- CN201980062880.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-07-27
- Filing Date
- 2019-07-26
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2039-07-26
AI Technical Summary
The prior art is difficult to effectively reduce the cell surface expression and activity of Siglec-5, resulting in poor therapeutic effects of related diseases.
Develop specific anti-Siglec-5 antibodies to induce neutrophils to produce reactive oxygen species (ROS) by reducing Siglec-5's cell surface level, promote the formation of extraneutrophilic traps (NETs) and increase macrophages phagocytosis activity of cells and regulates the function of immunosuppressive cells.
Effectively reduces the cell surface expression and activity of Siglec-5, enhances the immune response, and improves the therapeutic effect of a variety of diseases, including dementia, cancer and inflammatory diseases.
Smart Images

Figure CN112752768B_ABST
Abstract
Description
[0001] Cross-references to related applications
[0002] This application claims the benefit of U.S. Provisional Application No. 62 / 711,405, filed July 27, 2018, which is hereby incorporated by reference in its entirety.
[0003] Submitting sequence lists as ASCII text files
[0004] The following content, submitted as an ASCII text file, is incorporated herein by reference in its entirety: Computer-readable form of a sequence list (CRF) (filename: 735022002740SEQLIST.TXT, record date: July 25, 2019, size: 106KB). Technical Field
[0005] This disclosure relates to anti-Siglec-5 antibodies and the therapeutic use of such antibodies. Background Technology
[0006] Sialic acid-binding Ig-like lectin-5 (Siglec-5) is a type 1 immunoglobulin-like transmembrane protein expressed on immune and hematopoietic cells, including mature myeloid cells such as monocytes, macrophages, dendritic cells, neutrophils, and microglia, as well as lymphoid cells (Crocker et al. (2007) Nat Rev Immunol. 7:255-266; Macauley et al. (2014) Nat. Rev. Imm. 14:653-666; Cornish et al. (1998) Blood 92(6):2123-2132; Yamanaka et al. (2009) Glycobiology. 19:841-846). Siglec-5 is a member of the Siglec family of lectins that bind sialic acid residues to glycoproteins and glycolipids. One potential binding target of Siglec proteins is gangliosides; that is, glycolipids composed of ceramides linked to sialylated glycans. Most gangliosides share a common lactose-ceramide core and one or more sialic acid residues. The diversity of Siglec ligands arises from the addition of other neutral sugars and sialic acid to different bonds at the branches or ends, as well as from the modification of sialic acid itself.
[0007] Fourteen Siglec proteins have been identified in humans and nine in mice. They consist of 2–17 extracellular Ig domains, including an N-terminal V-set domain containing a sialic acid binding site. The sialic acid binding region is located on the V-set Ig-like domain, which contains two aromatic residues and an arginine motif that are highly conserved in all Siglecs (Crocker et al. (2007) Nat Rev Immunol. 7:255-266; McMillan and Crocker (2008) Carbohydr Res. 343:2050-2056; Von Gunten and Bochner (2008) Ann NY Acad Sci. 1143:61-82; May et al. (1998) Mol. Cell 1:719-728; Crocker et al. (1999) Biochem J. 341:355-361; and Crocker and Varki (2001) Trends Immunol. 2:337-342). The binding sites for sialylated ligands have been located using crystal structures of ligands with and without binding (Attrill et al., (2006) J. Biol. Chem. 28132774-32783; Alphey et al., (2003) J. Biol. Chem. 278:53372-3377; Varki et al., Glycobiology, pp. 161R-27R; May et al., (1998) Mol. Cell 1:5:719-728; Zhuravleva et al., (2008) J. Mol. Biol. 375:437-447). Because the cell membrane is rich in sialic acid, ligand binding via Siglec can occur in both cis and trans configurations, both of which affect their functional properties. Each Siglec exhibits different preferences for binding to different types of sialylated glycans found on the surface of mammalian cells (Crocker et al. (2007) Nat Rev Immunol. 7:255-266). Most Siglecs contain one or more immunoreceptor tyrosine-based inhibitory motif (ITIM) sequences in their cytoplasmic tail regions, enabling them to function as inhibitory receptors and negative regulators of immune function by recruiting tyrosine phosphatases SHP1 and SHP2 (Crocker et al. (2007) Nat Rev Immunol. 7:255-266; McMillan and Crocker (2008) Carbohydr Res. 343:2050-2056; and Von Gunten and Bochner (2008) Ann NY Acad Sci. 1143:61-82).Some Siglec proteins contain an immune receptor tyrosine-based activation motif (ITAM) sequence in their cytoplasmic tail region, enabling them to act as activating receptors and positive regulators of immune function through predicted recruitment of spleen tyrosine kinase (Syk) (Macauley SM. et al., (2014) Nature Reviews Immunology 14, 653-666). The Siglec protein family is associated with a variety of human diseases, including autoimmunity, susceptibility to infection, various types of cancer including lymphoma, leukemia and acute myeloid leukemia, systemic lupus erythematosus, rheumatoid arthritis, neurodegenerative diseases, asthma, allergies, sepsis, chronic obstructive pulmonary disease, graft-versus-host disease, eosinophilia, and osteoporosis (Macauley SM. et al., (2014) Nature Reviews Immunology 14, 653-666).
[0008] Siglec-5 contains an extracellular N-terminal Ig-like (immunoglobulin-like) V-type domain, an Ig-like C2-set domain, and a shared ITIM motif within its cytoplasmic domain. Expression of Siglec-5 in COS cells has shown sialic acid-dependent binding to erythrocytes, mediated by terminal α2-3 or α2-6 sialic acid linkages (Cornish et al. (1998) Blood 92(6):2123-2132). Ligand binding within the N-terminal V-set Ig-like domain of Siglec-5 has been localized to highly variable GG' linker and CC' loop regions. Ligand interactions were investigated using crystal structures of the Ig-V and first Ig-C set domains with and without bound sialic acid ligands (Zhuravleva et al. (2008) J. Mol. Biol. 375; 437-447). It has been shown that group B streptococci bind to Siglec-5 on human neutrophils in a Sia-independent manner via cell wall anchoring β protein (Carlin et al. (2009) J. Exp. Med. 206(8) 1691-1699). GBSβ protein bound to Siglec-5 leads to the recruitment of SHP phosphatase and inhibits functions such as phagocytosis, oxidative burst, and extracellular trap formation (Carlin et al. (2009) J. Exp. Med. 206(8) 1691-1699).
[0009] Siglec-5 recruits tyrosine phosphatases SHP-1 and SHP-2 via phosphorylation of Tyr-520 and Tyr-544 via tyrosine kinases, thereby mediating its function as an inhibitory receptor (Avril et al. (2005) J. Biol. Chem. 280: 19843-19851). Following phosphorylation at proximal Tyr-520 in the ITIM domain, Siglec-5 binds to SHP-2 / PTPN11 and SHP-1 / PTPN6. Siglec-5 was shown to inhibit FcεRI-mediated activity in rat basophilic leukemia cells previously used to characterize an inhibitory receptor class (cytotoxic Ig-like receptors) called KIR (Avril et al., (2005) J. Biol. Chem. 280: 19843-19851). Phosphatase activity is associated with reduced intracellular calcium mobilization and decreased tyrosine phosphorylation on various proteins (Ulyanova, T. et al., (1999) Eur J lmmunol 29, 3440-3449; Paul, SP et al., (2000) Blood 96, 483-490), and with blocking of signal transduction and immune responses, partly through dephosphorylation of signaling molecules on neighboring activation receptors (including those containing the ITAM motif), pattern recognition receptors, Toll-like receptors, and damage-associated molecular pattern (DAMP) receptors. Some inhibitory functions of Siglec-5 have been shown to occur in the absence of tyrosine phosphorylation. Siglec-5 can activate SHP-1 or SHP-2 in a phosphotyrosine-independent manner, which may be sufficient for inhibitory signaling (Avril et al., (2005) J. Biol. Chem. 280: 19843-19851).
[0010] Siglec ligand or antibody-mediated receptor binding induces endocytosis of many Siglec family members, suggesting that this is a general biological characteristic of this group of receptors (Tateno et al., (2007) Mol. Cell. Bio. 27(16): 5699-5710; Macauley SM. et al., (2014) Nature Reviews Immunology 14, 653-666). For tyrosine kinase receptors (Monsonego-Oran et al., (2002) Febs letters 528, 83-89; and Fasen et al., (2008) Cell & Molecular Biology 9, 251-266) and steroid receptors (Callige et al., (2005) Mol.Cell.Biol.25, 4349-4358; and Pollenz et al., (2006) Chemico-Biological Interactions.164, 49-59), similar mechanisms of ligand-induced receptor endocytosis and subsequent degradation have been reported.
[0011] Antibodies against Siglec-5 have been described in, for example, WO2007120815, US20070244038, WO2002008257, Erickson-Miller et al. (2003) Exp. Hemat. 31:382-388 and Cornish et al. (1998) Blood 92(6):2123-2132.
[0012] Therefore, there is a need to develop therapeutic antibodies that specifically bind to Siglec-5 and reduce Siglec-5 expression on the cell surface and / or reduce the activity of one or more Siglec-5s in order to treat one or more diseases, conditions and disorders associated with undesirable Siglec-5 activity.
[0013] All references cited in this article (including patents, patent applications and publications) are hereby incorporated in their entirety by reference. Summary of the Invention
[0014] This disclosure generally relates to anti-Siglec-5 antibodies and methods of using such anti-Siglec-5 antibodies. The methods provided herein can be used for the prevention, risk reduction, or treatment of individuals with the following conditions: dementia, frontotemporal dementia, Alzheimer's disease, vascular dementia, mixed dementia, Creutzfeldt-Jakob disease, normobaric hydrocephalus, amyotrophic lateral sclerosis, Huntington's disease, tau proteinosis, Nasu-Hakola disease, stroke, acute trauma, chronic trauma, lupus, acute and chronic colitis, rheumatoid arthritis, wound healing, Crohn's disease, inflammatory bowel disease, ulcerative colitis, obesity, malaria, essential tremor, central nervous system lupus, Behcet's disease, Parkinson's disease, and Lewy body dementia. Multiple system atrophy, Shy-Drager syndrome, progressive supranuclear palsy, corticobasal ganglia degeneration, acute disseminated encephalomyelitis, granulomatous diseases, sarcoidosis, age-related diseases, epileptic seizures, spinal cord injury, traumatic brain injury, age-related macular degeneration, glaucoma, retinitis pigmentosa, retinal degeneration, respiratory infections, sepsis, eye infections, systemic infections, lupus, arthritis, multiple sclerosis, low bone density, osteoporosis, bone formation, osteosclerotic diseases, Paget's disease of bone. Solid tumors and blood cancers, including bone cancer, bladder cancer, brain cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, renal cell carcinoma, renal pelvis cancer, leukemia, lung cancer, melanoma, non-Hodgkin's lymphoma, pancreatic cancer, prostate cancer, ovarian cancer, fibrosarcoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), multiple myeloma, polycythemia vera, idiopathic thrombocythemia, primary or idiopathic myelofibrosis, primary or idiopathic myelosclerosis, myeloid tumors, tumors expressing Siglec-5 and / or Siglec-5 ligands, thyroid cancer, infections, CNS herpes, parasitic infections, trypanosomiasis infections, Cruzi infections, Pseudomonas aeruginosa infections, and Leishmania donovani. Infections include group A streptococcal infection, Campylobacter jejuni infection, Neisseria meningiditis infection, HIV type I, and Haemophilus influenzae.The methods described herein can also be used to induce or promote the survival, maturation, function, migration, or proliferation of one or more immune cells in individuals in need. The methods described herein can be further used to reduce the activity, function, or survival of regulatory T cells, tumor-embedded immunosuppressive dendritic cells, tumor-embedded immunosuppressive macrophages, neutrophils, natural killer (NK) cells, myeloid-derived suppressor cells, tumor-associated macrophages, neutrophils, NK cells, acute myeloid leukemia (AML) cells, chronic lymphocytic leukemia (CLL) cells, or chronic myeloid leukemia (CML) cells in individuals in need. The methods described herein can also be used to reduce Siglec-5 cellular levels.
[0015] Certain aspects of this disclosure are based, at least in part, on anti-Siglec-5 antibodies that have been identified as capable of reducing cell surface levels of Siglec-5 in cells such as human primary immune cells and Siglec-5-expressing cell lines, not inhibiting or blocking the binding of Siglec-5 ligands to Siglec-5, not cross-reacting with Siglec-14, inducing reactive oxygen species (ROS) production, inducing extracellular trap (NET) formation in neutrophils, and / or increasing the phagocytic activity of macrophages.
[0016] Therefore, certain aspects of this disclosure relate to isolated monoclonal anti-Siglec-5 antibodies, wherein said anti-Siglec-5 antibodies reduce cellular levels of Siglec-5. Other aspects of this disclosure relate to isolated monoclonal anti-Siglec-5 antibodies, wherein said anti-Siglec-5 antibodies reduce cellular levels of Siglec-5 and do not inhibit the interaction between Siglec-5 and one or more Siglec-5 ligands. Still other aspects of this disclosure relate to isolated monoclonal anti-Siglec-5 antibodies, wherein said anti-Siglec-5 antibodies reduce cellular levels of Siglec-5 and do not bind to Siglec-14.
[0017] In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody reduces the cell surface level of Siglec-5, reduces the intracellular level of Siglec-5, reduces the total level of Siglec-5, or any combination thereof. In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody induces Siglec-5 degradation, Siglec-5 cleavage, Siglec-5 internalization, Siglec-5 shedding, downregulation of Siglec-5 expression, or any combination thereof. In some embodiments that can be combined with any of the foregoing embodiments, the antibody reduces the cellular level of Siglec-5 in vitro. In some embodiments that can be combined with any of the foregoing embodiments, the antibody reduces the cellular level of Siglec-5 in vivo. In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody induces the production of reactive oxygen species (ROS) in neutrophils. In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody induces the formation of neutrophil extracellular traps (NETs) in neutrophils. In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody induces neutrophil activation in neutrophils. In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody increases the phagocytic activity of macrophages.
[0018] In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody increases CD86 expression in myeloid-derived suppressor cells. In some embodiments, the anti-Siglec-5 antibody increases the cell surface level of CD86 in myeloid-derived suppressor cells. In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody increases CCL4 expression in myeloid-derived suppressor cells. In some embodiments, the anti-Siglec-5 antibody increases the cell surface level of CCL4 in myeloid-derived suppressor cells.
[0019] In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody binds to a linear Siglec-5 epitope. In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody binds to a discontinuous or conformational Siglec-5 epitope. In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody binds to an epitope selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H6, S5-174-H1, S5-174 One or more antibodies from the group consisting of -H2, S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8 and S5-G-03-H9 and any combination thereof compete for binding with Siglec5. In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody is combined with S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H6, S5-174-H1, S5-174-H2, S One or more antibodies from the group consisting of S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8 and S5-G-03-H9 and any combination thereof bind to the same or overlapping epitopes of Siglec-5.
[0020] In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody binds to one or more amino acid residues within amino acid residues 268-278 of SEQ ID NO:1 or to amino acid residues on the Siglec-5 protein corresponding to amino acid residues 268-278 of SEQ ID NO:1. In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody binds to one or more amino acid residues within the amino acid sequence LSWFQGSPALN (SEQ ID NO:221). In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody binds to one or more amino acid residues within amino acid residues 226-244 of SEQ ID NO:1 or to amino acid residues on the Siglec-5 protein corresponding to amino acid residues 226-244 of SEQ ID NO:1. In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody binds to one or more amino acid residues within the amino acid sequence QTITIFRNGIALEILQNTS (SEQ ID NO:220). In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody binds to one or more amino acid residues within amino acid residues 228-238 of SEQ ID NO:1, or amino acid residues corresponding to amino acid residues 228-238 of SEQ ID NO:1. In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody binds to the amino acid sequence ITIFRNGIALE (SEQ ID NO:219).
[0021] In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the light chain variable domain, the heavy chain variable domain, or both comprise at least one, two, three, four, five, or six HVRs selected from the group consisting of monoclonal antibodies HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3, wherein the monoclonal antibody is selected from the group consisting of: S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5- G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172 -H6, S5-174-H1, S5-174-H2, S5-174-H3, S5-174-H4, S5-174-H5, S5-174- H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G- 03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8 and S5-G-03-H9. In some embodiments that can be combined with any of the foregoing embodiments: (a) HVR-L1 comprises an amino acid sequence selected from the group consisting of SEQ ID NO:103-115; (b) HVR-L2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO:127-135; (c) HVR-L3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO:153-163; (d) HVR-H1 comprises an amino acid sequence selected from the group consisting of SEQ ID NO:20-28; (e) HVR-H2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO:39-51; or (f) HVR-H3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO:70-79. In some embodiments that can be combined with any of the foregoing embodiments: (a) HVR-H1 contains the amino acid sequence of SEQ ID NO:20, HVR-H2 contains the amino acid sequence of SEQ ID NO:39, HVR-H3 contains the amino acid sequence of SEQ ID NO:70, HVR-L1 contains the amino acid sequence of SEQ ID NO:103, HVR-L2 contains the amino acid sequence of SEQ ID NO:127, and HVR-L3 contains the amino acid sequence of SEQ ID NO:153;(b) HVR-H1 contains the amino acid sequence of SEQ ID NO:21, HVR-H2 contains the amino acid sequence of SEQ ID NO:40, HVR-H3 contains the amino acid sequence of SEQ ID NO:71, HVR-L1 contains the amino acid sequence of SEQ ID NO:104, HVR-L2 contains the amino acid sequence of SEQ ID NO:128, and HVR-L3 contains the amino acid sequence of SEQ ID NO:154; (c) HVR-H1 contains the amino acid sequence of SEQ ID NO:22, HVR-H2 contains the amino acid sequence of SEQ ID NO:41, HVR-H3 contains the amino acid sequence of SEQ ID NO:72, HVR-L1 contains the amino acid sequence of SEQ ID NO:105, HVR-L2 contains the amino acid sequence of SEQ ID NO:129, and HVR-L3 contains the amino acid sequence of SEQ ID NO:155; (d) HVR-H1 contains the amino acid sequence of SEQ ID NO:23, HVR-H2 contains the amino acid sequence of SEQ ID NO:23, HVR-H2 contains the amino acid sequence of SEQ ID NO:40, HVR-H3 contains the amino acid sequence of SEQ ID NO:71, HVR-L1 contains the amino acid sequence of SEQ ID NO:104, HVR-L2 contains the amino acid sequence of SEQ ID NO:128, and HVR-L3 contains the amino acid sequence of SEQ ID NO:155; (e) HVR-H1 contains the amino acid sequence of SEQ ID NO:42, HVR-H2 contains the amino acid sequence of SEQ ID NO:73, HVR-L1 contains the amino acid sequence of SEQ ID NO:106, HVR-L2 contains the amino acid sequence of SEQ ID NO:127, and HVR-L3 contains the amino acid sequence of SEQ ID NO:156; (f) HVR-H1 contains the amino acid sequence of SEQ ID NO:25, HVR-H2 contains the amino acid sequence of SEQ ID NO:44, HVR-H3 contains the amino acid sequence of SEQ ID NO:75, and HVR-L1 contains the amino acid sequence of SEQ ID NO:156; The amino acid sequence NO:108, HVR-L2 contains the amino acid sequence of SEQ ID NO:131, and HVR-L3 contains the amino acid sequence of SEQ ID NO:158;(g) HVR-H1 contains the amino acid sequence of SEQ ID NO:20, HVR-H2 contains the amino acid sequence of SEQ ID NO:39, HVR-H3 contains the amino acid sequence of SEQ ID NO:70, HVR-L1 contains the amino acid sequence of SEQ ID NO:109, HVR-L2 contains the amino acid sequence of SEQ ID NO:127, and HVR-L3 contains the amino acid sequence of SEQ ID NO:159; (h) HVR-H1 contains the amino acid sequence of SEQ ID NO:25, HVR-H2 contains the amino acid sequence of SEQ ID NO:45, HVR-H3 contains the amino acid sequence of SEQ ID NO:76, HVR-L1 contains the amino acid sequence of SEQ ID NO:110, HVR-L2 contains the amino acid sequence of SEQ ID NO:132, and HVR-L3 contains the amino acid sequence of SEQ ID NO:160; (i) HVR-H1 contains the amino acid sequence of SEQ ID NO:26, HVR-H2 contains the amino acid sequence of SEQ ID NO:26, HVR-H2 contains the amino acid sequence of SEQ ID NO:20, HVR-H2 contains the amino acid sequence of SEQ ID NO:39, HVR-H3 contains the amino acid sequence of SEQ ID NO:70, HVR-L1 contains the amino acid sequence of SEQ ID NO:109, HVR-L2 contains the amino acid sequence of SEQ ID NO:127, and HVR-L3 contains the amino acid sequence of SEQ ID NO:159; HVR-H3 contains the amino acid sequence of SEQ ID NO:46, HVR-H3 contains the amino acid sequence of SEQ ID NO:77, HVR-L1 contains the amino acid sequence of SEQ ID NO:111, HVR-L2 contains the amino acid sequence of SEQ ID NO:133, and HVR-L3 contains the amino acid sequence of SEQ ID NO:161; (j) HVR-H1 contains the amino acid sequence of SEQ ID NO:27, HVR-H2 contains the amino acid sequence of SEQ ID NO:47, HVR-H3 contains the amino acid sequence of SEQ ID NO:78, HVR-L1 contains the amino acid sequence of SEQ ID NO:112, HVR-L2 contains the amino acid sequence of SEQ ID NO:134, and HVR-L3 contains the amino acid sequence of SEQ ID NO:162; (k) HVR-H1 contains the amino acid sequence of SEQ ID NO:28, HVR-H2 contains the amino acid sequence of SEQ ID NO:48, HVR-H3 contains the amino acid sequence of SEQ ID NO:79, and HVR-L1 contains the amino acid sequence of SEQ ID NO:161. The amino acid sequence of NO:113, HVR-L2 contains the amino acid sequence of SEQ ID NO:135, and HVR-L3 contains the amino acid sequence of SEQ ID NO:163;(l) HVR-H1 contains the amino acid sequence of SEQ ID NO:20, HVR-H2 contains the amino acid sequence of SEQ ID NO:49, HVR-H3 contains the amino acid sequence of SEQ ID NO:70, HVR-L1 contains the amino acid sequence of SEQ ID NO:114, HVR-L2 contains the amino acid sequence of SEQ ID NO:127, and HVR-L3 contains the amino acid sequence of SEQ ID NO:153; (m) HVR-H1 contains the amino acid sequence of SEQ ID NO:21, HVR-H2 contains the amino acid sequence of SEQ ID NO:50, HVR-H3 contains the amino acid sequence of SEQ ID NO:71, HVR-L1 contains the amino acid sequence of SEQ ID NO:115, HVR-L2 contains the amino acid sequence of SEQ ID NO:128, and HVR-L3 contains the amino acid sequence of SEQ ID NO:154; and (n) HVR-H1 contains the amino acid sequence of SEQ ID NO:26, HVR-H2 contains the amino acid sequence of SEQ ID NO:26, HVR-H2 contains the amino acid sequence of SEQ ID NO:20, HVR-H2 contains the amino acid sequence of SEQ ID NO:49, HVR-H3 contains the amino acid sequence of SEQ ID NO:70, HVR-L1 contains the amino acid sequence of SEQ ID NO:114, HVR-L2 contains the amino acid sequence of SEQ ID NO:127, and HVR-L3 contains the amino acid sequence of SEQ ID NO:154; The amino acid sequence NO:51 is present in HVR-H3; the amino acid sequence NO:77 is present in HVR-L1; the amino acid sequence NO:111 is present in HVR-L2; the amino acid sequence NO:133 is present in HVR-L3; and the amino acid sequence NO:161 is present in HVR-L3.
[0022] In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody comprises: a light chain variable domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 194-211; and / or a heavy chain variable domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 174-193. In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody comprises a light chain variable domain of a monoclonal antibody selected from the group consisting of: S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5 -172-H5, S5-172-H6, S5-174-H1, S5-174-H2, S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5 -174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-0 3-H8 and S5-G-03-H9; and / or the heavy chain variable domains of monoclonal antibodies selected from the group consisting of: S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H 6. S5-174-H1, S5-174-H2, S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03- H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8 and S5-G-03-H9.
[0023] Other aspects of this disclosure relate to isolated monoclonal anti-Siglec-5 antibodies, wherein the anti-Siglec-5 antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the light chain variable domain, the heavy chain variable domain, or both comprise at least one, two, three, four, five, or six HVRs selected from HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3 of the monoclonal antibody, wherein the monoclonal antibody is selected from the group consisting of: S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, and S5-G-07. , S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5- 172-H6, S5-174-H1, S5-174-H2, S5-174-H3, S5-174-H4, S5-174-H5, S5-17 4-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G -03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8 and S5-G-03-H9. In some implementations: (a) HVR-L1 contains an amino acid sequence selected from the group consisting of SEQ ID NO:103-115; (b) HVR-L2 contains an amino acid sequence selected from the group consisting of SEQ ID NO:127-135; (c) HVR-L3 contains an amino acid sequence selected from the group consisting of SEQ ID NO:153-163; (d) HVR-H1 contains an amino acid sequence selected from the group consisting of SEQ ID NO:20-28; (e) HVR-H2 contains an amino acid sequence selected from the group consisting of SEQ ID NO:39-51; or (f) HVR-H3 contains an amino acid sequence selected from the group consisting of SEQ ID NO:70-79. In some embodiments: wherein (a) HVR-H1 contains the amino acid sequence of SEQ ID NO:20, HVR-H2 contains the amino acid sequence of SEQ ID NO:39, HVR-H3 contains the amino acid sequence of SEQ ID NO:70, HVR-L1 contains the amino acid sequence of SEQ ID NO:103, HVR-L2 contains the amino acid sequence of SEQ ID NO:127, and HVR-L3 contains the amino acid sequence of SEQ ID NO:153;(b) HVR-H1 contains the amino acid sequence of SEQ ID NO:21, HVR-H2 contains the amino acid sequence of SEQ ID NO:40, HVR-H3 contains the amino acid sequence of SEQ ID NO:71, HVR-L1 contains the amino acid sequence of SEQ ID NO:104, HVR-L2 contains the amino acid sequence of SEQ ID NO:128, and HVR-L3 contains the amino acid sequence of SEQ ID NO:154; (c) HVR-H1 contains the amino acid sequence of SEQ ID NO:22, HVR-H2 contains the amino acid sequence of SEQ ID NO:41, HVR-H3 contains the amino acid sequence of SEQ ID NO:72, HVR-L1 contains the amino acid sequence of SEQ ID NO:105, HVR-L2 contains the amino acid sequence of SEQ ID NO:129, and HVR-L3 contains the amino acid sequence of SEQ ID NO:155; (d) HVR-H1 contains the amino acid sequence of SEQ ID NO:23, HVR-H2 contains the amino acid sequence of SEQ ID NO:23, HVR-H2 contains the amino acid sequence of SEQ ID NO:40, HVR-H3 contains the amino acid sequence of SEQ ID NO:71, HVR-L1 contains the amino acid sequence of SEQ ID NO:104, HVR-L2 contains the amino acid sequence of SEQ ID NO:128, and HVR-L3 contains the amino acid sequence of SEQ ID NO:155; (e) HVR-H1 contains the amino acid sequence of SEQ ID NO:42, HVR-H2 contains the amino acid sequence of SEQ ID NO:73, HVR-L1 contains the amino acid sequence of SEQ ID NO:106, HVR-L2 contains the amino acid sequence of SEQ ID NO:127, and HVR-L3 contains the amino acid sequence of SEQ ID NO:156; (f) HVR-H1 contains the amino acid sequence of SEQ ID NO:25, HVR-H2 contains the amino acid sequence of SEQ ID NO:44, HVR-H3 contains the amino acid sequence of SEQ ID NO:75, and HVR-L1 contains the amino acid sequence of SEQ ID NO:156; The amino acid sequence of SEQ ID NO:108, HVR-L2 contains the amino acid sequence of SEQ ID NO:131, and HVR-L3 contains the amino acid sequence of SEQ ID NO:158;(g) HVR-H1 contains the amino acid sequence of SEQ ID NO:20, HVR-H2 contains the amino acid sequence of SEQ ID NO:39, HVR-H3 contains the amino acid sequence of SEQ ID NO:70, HVR-L1 contains the amino acid sequence of SEQ ID NO:109, HVR-L2 contains the amino acid sequence of SEQ ID NO:127, and HVR-L3 contains the amino acid sequence of SEQ ID NO:159; (h) HVR-H1 contains the amino acid sequence of SEQ ID NO:25, HVR-H2 contains the amino acid sequence of SEQ ID NO:45, HVR-H3 contains the amino acid sequence of SEQ ID NO:76, HVR-L1 contains the amino acid sequence of SEQ ID NO:110, HVR-L2 contains the amino acid sequence of SEQ ID NO:132, and HVR-L3 contains the amino acid sequence of SEQ ID NO:160; (i) HVR-H1 contains the amino acid sequence of SEQ ID NO:26, HVR-H2 contains the amino acid sequence of SEQ ID NO:26, HVR-H2 contains the amino acid sequence of SEQ ID NO:20, HVR-H2 contains the amino acid sequence of SEQ ID NO:39, HVR-H3 contains the amino acid sequence of SEQ ID NO:70, HVR-L1 contains the amino acid sequence of SEQ ID NO:109, HVR-L2 contains the amino acid sequence of SEQ ID NO:127, and HVR-L3 contains the amino acid sequence of SEQ ID NO:159; HVR-H3 contains the amino acid sequence of SEQ ID NO:46, HVR-H3 contains the amino acid sequence of SEQ ID NO:77, HVR-L1 contains the amino acid sequence of SEQ ID NO:111, HVR-L2 contains the amino acid sequence of SEQ ID NO:133, and HVR-L3 contains the amino acid sequence of SEQ ID NO:161; (j) HVR-H1 contains the amino acid sequence of SEQ ID NO:27, HVR-H2 contains the amino acid sequence of SEQ ID NO:47, HVR-H3 contains the amino acid sequence of SEQ ID NO:78, HVR-L1 contains the amino acid sequence of SEQ ID NO:112, HVR-L2 contains the amino acid sequence of SEQ ID NO:134, and HVR-L3 contains the amino acid sequence of SEQ ID NO:162; (k) HVR-H1 contains the amino acid sequence of SEQ ID NO:28, HVR-H2 contains the amino acid sequence of SEQ ID NO:48, HVR-H3 contains the amino acid sequence of SEQ ID NO:79, and HVR-L1 contains the amino acid sequence of SEQ ID NO:161. The amino acid sequence of NO:113, HVR-L2 contains the amino acid sequence of SEQ ID NO:135, and HVR-L3 contains the amino acid sequence of SEQ ID NO:163;(l) HVR-H1 contains the amino acid sequence of SEQ ID NO:20, HVR-H2 contains the amino acid sequence of SEQ ID NO:49, HVR-H3 contains the amino acid sequence of SEQ ID NO:70, HVR-L1 contains the amino acid sequence of SEQ ID NO:114, HVR-L2 contains the amino acid sequence of SEQ ID NO:127, and HVR-L3 contains the amino acid sequence of SEQ ID NO:153; (m) HVR-H1 contains the amino acid sequence of SEQ ID NO:21, HVR-H2 contains the amino acid sequence of SEQ ID NO:50, HVR-H3 contains the amino acid sequence of SEQ ID NO:71, HVR-L1 contains the amino acid sequence of SEQ ID NO:115, HVR-L2 contains the amino acid sequence of SEQ ID NO:128, and HVR-L3 contains the amino acid sequence of SEQ ID NO:154; and (n) HVR-H1 contains the amino acid sequence of SEQ ID NO:26, HVR-H2 contains the amino acid sequence of SEQ ID NO:26, HVR-H2 contains the amino acid sequence of SEQ ID NO:20, HVR-H2 contains the amino acid sequence of SEQ ID NO:49, HVR-H3 contains the amino acid sequence of SEQ ID NO:70, HVR-L1 contains the amino acid sequence of SEQ ID NO:114, HVR-L2 contains the amino acid sequence of SEQ ID NO:127, and HVR-L3 contains the amino acid sequence of SEQ ID NO:154; The amino acid sequence of SEQ ID NO:51 is present in HVR-H3; the amino acid sequence of SEQ ID NO:77 is present in HVR-L1; the amino acid sequence of SEQ ID NO:111 is present in HVR-L2; the amino acid sequence of SEQ ID NO:133 is present in HVR-L3; and the amino acid sequence of SEQ ID NO:161 is present in HVR-L3.
[0024] Other aspects of this disclosure relate to isolated monoclonal anti-Siglec-5 antibodies, wherein the anti-Siglec-5 antibody comprises: a light chain variable domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:194-211 and / or a heavy chain variable domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:174-193. Other aspects of this disclosure relate to isolated monoclonal anti-Siglec-5 antibodies, wherein the anti-Siglec-5 antibody comprises a light chain variable domain of a monoclonal antibody selected from the group consisting of: S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-1 72-H4, S5-172-H5, S5-172-H6, S5-174-H1, S5-174-H2, S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174 -H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S 5-G-03-H8 and S5-G-03-H9; and / or the heavy chain variable domains of monoclonal antibodies selected from the group consisting of: S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-17 2-H6, S5-174-H1, S5-174-H2, S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03 -H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8 and S5-G-03-H9.Other aspects of this disclosure relate to isolated monoclonal anti-Siglec-5 antibodies, wherein the anti-Siglec-5 antibodies are selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H6, S5-174-H1, S5 One or more antibodies from the group consisting of -174-H2, S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8 and S5-G-03-H9 and any combination thereof compete for binding with Siglec-5. Other aspects of this disclosure relate to isolated monoclonal anti-Siglec-5 antibodies that bind substantially the same Siglec-5 epitopes to monoclonal antibodies selected from the group consisting of: S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172- H5, S5-172-H6, S5-174-H1, S5-174-H2, S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5- G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8 and S5-G-03-H9.
[0025] Other aspects of this disclosure relate to isolated monoclonal anti-Siglec-5 antibodies that bind to one or more amino acid residues selected from the group consisting of: amino acid residues 268-278 of SEQ ID NO:1 or amino acid residues on the Siglec-5 protein corresponding to amino acid residues 268-278 of SEQ ID NO:1, amino acid residues 226-244 of SEQ ID NO:1 or amino acid residues on the Siglec-5 protein corresponding to amino acid residues 226-244 of SEQ ID NO:1, and amino acid residues 228-238 of SEQ ID NO:1 or amino acid residues on the Siglec-5 protein corresponding to amino acid residues 228-238 of SEQ ID NO:1. Other aspects of this disclosure relate to isolated monoclonal anti-Siglec-5 antibodies that bind to one or more amino acid residues within an amino acid sequence selected from the group consisting of: amino acid sequence LSWFQGSPALN (SEQ ID NO:221), amino acid sequence QTITI FRNGIALEILQNTS (SEQ ID NO:220), and amino acid sequence ITIFRNGIALE (SEQ ID NO:219).
[0026] In some embodiments that can be combined with any of the foregoing embodiments, the antibody belongs to the IgG, IgM, or IgA class. In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody has an IgG1, IgG2, IgG3, or IgG4 isotype. In some embodiments that can be combined with any of the foregoing embodiments, the antibody binds to an inhibitory Fc receptor. In some embodiments that can be combined with any of the foregoing embodiments, the inhibitory Fc receptor is an inhibitory Fc-γ receptor IIB (FcγIIB). In some embodiments that can be combined with any of the foregoing embodiments: (a) the anti-Siglec-5 antibody has a human or mouse IgG1 isotype and contains one or more amino acid substitutions at residue positions selected from the group consisting of the following in the Fc region: N297A, D265A, D270A, L234A, L235A, G237A, P238D, L328E, E233D, G237D, H268D, P271G, A330R, C226S, C229S, E233P, L234V, L234F, L235E, P331S, S267E, L328F, A330L, M252Y, S254T, T256E, N297Q, P238S, P238A, A327Q, A327G, P329A, K322A, T394D, E430G, V263L, V266L, V273C, V273E, V273F, V273L, V273M, V273S, V273Y, V305K, V305W, and any combination thereof, wherein the residues are numbered according to the EU numbering system, or contain an amino acid deletion at the position corresponding to glycine 236 in the Fc region; (b) the anti-Siglec-5 antibody has an IgG1 isotype and contains an IgG2 isotype heavy chain constant domain 1 (CH1) and a hinge region, wherein optionally the IgG2 isotype CH1 and hinge region contain ASTKGPSVFP. The amino acid sequence of LAPCSRSTSESTAALGCLVK DYFPEPVTVS WNSGALTSGVHTFPAVLQSS GLYSLSSVVT VPSSNFGTQT YTCNVDHKPSNTKVDKTVERKCCVECPPCP (SEQ ID NO:218), wherein the antibody Fc region optionally contains an S267E amino acid substitution, an L328F amino acid substitution, or both and / or an N297A or N297Q amino acid substitution, wherein the residues are numbered according to the EU numbering system;(c) The anti-Siglec-5 antibody is of the IgG2 isotype and contains one or more amino acid substitutions at residue positions selected from the group consisting of: P238S, V234A, G237A, H268A, H268Q, V309L, A330S, P331S, C214S, C232S, C233S, S267E, L328F, M252Y, S254T, T256E, H268E, N297A, N297Q, A330L, C127S, E430G, and any combination thereof, wherein the residues are numbered according to the EU numbering system; (d) The anti-Siglec-5 antibody is of the human or mouse IgG4 isotype and contains one or more amino acid substitutions at residue positions selected from the group consisting of: Multiple amino acid substitutions: L235A, G237A, S228P, L236E, S267E, E318A, L328F, M252Y, S254T, T256E, E233P, F234V, L234A / F234A, S228P, S241P, L248E, T394D, N297A, N297Q, L235E and any combination thereof, wherein the residues are numbered according to EU numbering scheme; or (e) the anti-Siglec-5 antibody has a heterozygous IgG2 / 4 isotype, and optionally the antibody comprises an amino acid sequence comprising amino acids 118 to 260 of human IgG2 and amino acids 261 to 447 of human IgG4, wherein the residues are numbered according to EU or Kabat numbering scheme. In some embodiments that can be combined with any of the foregoing embodiments: (a) the anti-Siglec-5 antibody has a human or mouse IgG1 isotype and contains one or more amino acid substitutions at residue positions selected from the group consisting of the following in the Fc region: N297A, N297Q, D270A, D265A, L234A, L235A, C226S, C229S, P238S, E233P, L234V, P238A, A327Q, A327G, P329A, K322A, L234F, L235E, P331S, T394D, A330L, M252Y, S254 (a) The anti-Siglec-5 antibody has an IgG2 isotype and contains one or more amino acid substitutions at residue positions selected from the following groups in the Fc region: P238S, V234A, G237A, H268A, H268Q, H268E, V309L, N297A, N297Q, A330S, P331S, C232S, C233S, M252Y, S254T, T256E, C127S, E430G and any combination thereof, wherein the residue numbers are in accordance with the EU numbering system;Alternatively, (c) the anti-Siglec-5 antibody has an IgG4 isotype and contains one or more amino acid substitutions at residue positions selected from the group consisting of: E233P, F234V, L234A / F234A, L235A, G237A, E318A, S228P, L236E, S241P, L248E, T394D, M252Y, S254T, T256E, N297A, N297Q, and any combination thereof, wherein the residues are numbered according to the EU numbering scheme. In some embodiments that can be combined with any of the foregoing embodiments: (a) the Fc region further comprises one or more additional amino acid substitutions at positions selected from the group consisting of A330L, L234F; L235E, P331S, and any combination thereof, wherein the residues are numbered according to EU numbering schemes; (b) the Fc region further comprises one or more additional amino acid substitutions at positions selected from the group consisting of M252Y, S254T, T256E, and any combination thereof, wherein the residues are numbered according to EU numbering schemes; or (c) the Fc region further comprises an S228P amino acid substitution according to EU numbering schemes. In some embodiments that can be combined with any of the foregoing embodiments, the antibody has an IgG4 isotype. In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody comprises an S228P amino acid substitution at residue position 228, an F234A amino acid substitution at residue position 234, and an L235A amino acid substitution at residue position 235, wherein the residue positions are numbered according to EU numbering schemes.
[0027] In some embodiments that can be combined with any of the foregoing embodiments, the Siglec-5 protein is a mammalian protein or a human protein. In some embodiments that can be combined with any of the foregoing embodiments, the Siglec-5 protein is a wild-type protein. In some embodiments that can be combined with any of the foregoing embodiments, the Siglec-5 protein is a naturally occurring variant. In some embodiments that can be combined with any of the foregoing embodiments, the Siglec-5 protein is expressed on one or more cells selected from the group consisting of human dendritic cells, human macrophages, human neutrophils, human NK cells, human monocytes, human osteoclasts, human B cells, human T cells, human helper T cells, human cytotoxic T cells, human granulocytes, and human microglia. In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody specifically binds to the human Siglec-5 protein. In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody is an antibody fragment that binds to an epitope containing an amino acid residue from human Siglec-5. In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody is an antibody fragment that binds to one or more human proteins selected from the group consisting of human Siglec-5, naturally occurring variants of human Siglec-5, and disease variants of human Siglec-5. In some embodiments that can be combined with any of the foregoing embodiments, the antibody fragment is cross-linked with a second antibody fragment that binds to one or more human proteins selected from the group consisting of human Siglec-5, naturally occurring variants of human Siglec-5, and disease variants of human Siglec-5. In some embodiments that can be combined with any of the foregoing embodiments, the fragment is a Fab, Fab', Fab'-SH, F(ab')2, Fv, or scFv fragment. In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody is a mouse antibody. In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody is a humanized antibody, a bispecific antibody, a multivalent antibody, a conjugated antibody, or a chimeric antibody. In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody is a bispecific antibody that recognizes a first antigen and a second antigen.In some embodiments that can be combined with any of the foregoing embodiments, the first antigen is Siglec-5, and the second antigen is: (a) an antigen that promotes transport across the blood-brain barrier; (b) an antigen that promotes transport across the blood-brain barrier selected from the group consisting of transferrin receptor (TR), insulin receptor (HIR), insulin-like growth factor receptor (IGFR), low-density lipoprotein receptor-associated proteins 1 and 2 (LPR-1 and 2), diphtheria toxin receptor, CRM197, llama single-domain antibody, TMEM 30(A), protein transduction domain, TAT, Syn-B, penetrantin, polyarginine peptide, angiopeppeptide, and ANG1005; and (c) a pathogenic factor selected from the group consisting of pathogenic peptides, proteins, or pathogenic nucleic acids, wherein the pathogenic nucleic acid is antisense GGCCCC(G2C4) (SEQ ID NO). NO:225) Repeated amplified RNA, wherein the pathogenic protein is selected from amyloid β, oligoamyloid β, amyloid β plaque, amyloid precursor protein or fragment thereof, Tau, IAPP, α-synuclein, TDP-43, FUS protein, C9orf72 (chromosome 9 open reading frame 72), c9RAN protein, prion protein, PrPSc, huntingtin protein, calcitonin, superoxide dismutase, ataxia protein, ataxia protein 1, and ataxia protein 2. Ataxia protein 2, ataxia protein 3, ataxia protein 7, ataxia protein 8, ataxia protein 10, Lewy body, atrial natriuretic factor, pancreatic amyloid polypeptide, insulin, apolipoprotein AI, serum amyloid A, medin, prolactin, thyroxine transporter, lysozyme, β2-microglobulin, coagulant, corneal epithelial protein, cystatin, immunoglobulin light chain AL, S-IBM protein, repeat-associated non-ATG (RAN) translation products, dipeptide repeat (D) (d) The group consisting of PR peptide, glycine-alanine (GA) repeating peptide, glycine-proline (GP) repeating peptide, glycine-arginine (GR) repeating peptide, proline-alanine (PA) repeating peptide, ubiquitin, and proline-arginine (PR) repeating peptide; and (d) ligands and / or proteins expressed on immune cells, wherein the ligands and / or proteins are selected from PD1 / PDL1, CD40, OX40, ICOS, CD28, CD137 / 4-1BB, CD27, and GI. The group consisting of TR, PD-L1, CTLA4, PD-L2, PD-1, B7-H3, B7-H4, HVEM, LIGHT, BTLA, CD30, TIGIT, VISTA, KIR, GAL9, TIM1, TIM3, TIM4, A2AR, LAG3, DR-5, CD2, CD5, CD39, CD73 and phosphatidylserine; and (e) proteins, lipids, polysaccharides or glycolipids expressed on one or more tumor cells.In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody is a conjugated antibody. In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody is conjugated to a detectable label, toxin, or therapeutic agent. In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody is selected from ricin, ricin A chain, doxorubicin, doxorubicin, maytansine, paclitaxel, ethidium bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin, diphtheria toxin, pseudomonad exotoxin (PE)A, PE40, abrin, abrin A chain, modisocyanate A chain, α-acinthin, white tree toxin, mitogellin, retstrictocin, phenolmycin, enoxacin, curicin, crotin, calicheamicin, and saponaria. The toxin conjugate consists of an inhibitor of cisplatin, glucocorticoids, olistatin, chlortetracycline, yttrium, bismuth, comprestatin, duocarmycin, dolastatin, cc1065, and cisplatin.In some embodiments that can be combined with any of the foregoing embodiments, the anti-Siglec-5 antibody is used in combination with one or more antibodies that specifically bind to a pathogenic protein, wherein the pathogenic protein is selected from amyloid-β, oligoamyloid-β, amyloid-β plaque, amyloid precursor protein or fragments thereof, Tau, IAPP, α-synuclein, TDP-43, FUS protein, C9orf72 (chromosome 9 open reading frame 72), prion protein, PrPSc, huntingtin protein, calcitonin, superoxide dismutase, ataxia protein, etc. Ataxia protein 1, Ataxia protein 2, Ataxia protein 3, Ataxia protein 7, Ataxia protein 8, Ataxia protein 10, Lewy body, atrial natriuretic factor, pancreatic amyloid peptide, insulin, apolipoprotein AI, serum amyloid A, medin, prolactin, thyroxine transporter, lysozyme, β2-microglobulin, coagulant, corneal epithelial protein, cystatin, immunoglobulin light chain AL, S-IBM protein, repeat-associated non-ATG (RAN) translation product, dipeptide repeat (DPR) peptide, glycine-alanine (GA) The group consisting of repeating peptides, glycine-proline (GP) repeating peptides, glycine-arginine (GR) repeating peptides, proline-alanine (PA) repeating peptides, ubiquitin, and proline-arginine (PR) repeating peptides, and any combination thereof; or used in combination with one or more antibodies that bind immunomodulatory proteins selected from the group consisting of: PD1 / PDL1, CD40, OX40, ICOS, CD28, CD137 / 4-1BB, CD27, GITR, PD-L1, CTLA4, PD-L2, PD-1, B 7-H3, B7-H4, HVEM, LIGHT, BTLA, CD30, TIGIT, VISTA, KIR, GAL9, TIM1, TIM3, TIM4, A2AR, LAG3, DR-5, CD2, CD5, CD39, CD73, TREM1, TREM2, CD33, Siglec-6, Siglec-7, Siglec-9, Siglec-10, Siglec-11, phosphatidylserine, pathogenic nucleic acid, antisense GGCCCC(G2C4) (SEQ ID NO:225) repeat amplified RNA, and any combination thereof. In some embodiments that can be combined with any of the foregoing embodiments, the dissociation constant (K) of the anti-Siglec-5 antibody for human Siglec-5 is specified. D In the range of about 0.42 nM to about 79 nM, about 79 nM to about 61 nM, about 15 nM to about 5.3 nM, or about 1.7 nM to about 0.42 nM, wherein K D It was measured at a temperature of approximately 25°C.
[0028] Other aspects of this disclosure relate to isolated nucleic acids comprising a nucleic acid sequence encoding an anti-Siglec-5 antibody of any of the foregoing embodiments. Other aspects of this disclosure relate to vectors comprising nucleic acids of any of the foregoing embodiments. Other aspects of this disclosure relate to isolated host cells comprising vectors of any of the foregoing embodiments. Other aspects of this disclosure relate to methods for generating anti-Siglec-5 antibodies, comprising culturing host cells of any of the foregoing embodiments to generate the anti-Siglec-5 antibody. In some embodiments, the method further comprises recovering the anti-Siglec-5 antibody generated by the host cells. Other aspects of this disclosure relate to isolated anti-Siglec-5 antibodies generated by methods of any of the foregoing embodiments. Other aspects of this disclosure relate to pharmaceutical compositions comprising an anti-Siglec-5 antibody of any of the foregoing embodiments and a pharmaceutically acceptable vector.
[0029] Other aspects of this disclosure relate to methods for preventing, reducing the risk of, or treating diseases, conditions, or injuries selected from dementia, frontotemporal dementia, Alzheimer's disease, vascular dementia, mixed dementia, Creutzfeldt-Jakob disease, normobaric hydrocephalus, amyotrophic lateral sclerosis, Huntington's disease, tau proteinosis, Nasu-Hakola disease, stroke, acute trauma, chronic trauma, lupus, acute and chronic colitis, rheumatoid arthritis, wound healing, Crohn's disease, inflammatory bowel disease, ulcerative colitis, obesity, malaria, and idiopathic diseases. Tremor, lupus encephalitis, Behcet's disease, Parkinson's disease, Lewy body dementia, multiple system atrophy, Shy-Drager syndrome, progressive supranuclear palsy, corticobasal ganglia degeneration, acute disseminated encephalomyelitis, granulomatous diseases, sarcoidosis, age-related diseases, epileptic seizures, spinal cord injury, traumatic brain injury, age-related macular degeneration, glaucoma, retinitis pigmentosa, retinal degeneration, respiratory infections, sepsis, eye infections, systemic infections, lupus, arthritis, multiple sclerosis, low bone density, osteoporosis, bone formation, osteosclerosis Sexually transmitted diseases, Paget's disease of bone and cancer, bladder cancer, brain cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, renal cell carcinoma, renal pelvis cancer, leukemia, lung cancer, melanoma, non-Hodgkin's lymphoma, pancreatic cancer, prostate cancer, ovarian cancer, fibrosarcoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), multiple myeloma, polycythemia vera, idiopathic thrombocythemia, primary or idiopathic myelofibrosis, primary or idiopathic myelofibrosis The group comprising primary myeloid sclerosis, myeloid-derived tumors, tumors expressing Siglec-5, tumors expressing one or more Siglec-5 ligands, thyroid cancer, infections, CNS herpes, parasitic infections, trypanosomiasis infections, Cruzi infections, Pseudomonas aeruginosa infections, Leishmania donovani infections, Group B streptococcal infections, Campylobacter jejuni infections, Neisseria meningitidis infections, HIV type I, and Haemophilus influenzae, wherein the method comprises administering a therapeutically effective amount of an anti-Siglec-5 antibody that reduces cellular levels of Siglec-5 to an individual in need.Other aspects of this disclosure relate to anti-Siglec-5 antibodies that reduce cellular levels of Siglec-5 for the prevention, risk reduction, or treatment of diseases, conditions, or injuries selected from the group consisting of: dementia, frontotemporal dementia, Alzheimer's disease, vascular dementia, mixed dementia, Creutzfeldt-Jakob disease, normobaric hydrocephalus, amyotrophic lateral sclerosis, Huntington's disease, tau proteinosis, Nasu-Hakola disease, stroke, acute trauma, chronic trauma, lupus, acute and chronic colitis, and rheumatoid arthritis. Arthritis, wound healing, Crohn's disease, inflammatory bowel disease, ulcerative colitis, obesity, malaria, essential tremor, lupus, Behcet's disease, Parkinson's disease, Lewy body dementia, multiple system atrophy, Shy-Drager syndrome, progressive supranuclear palsy, corticobasal ganglia degeneration, acute disseminated encephalomyelitis, granulomatous diseases, sarcoidosis, age-related diseases, seizures, spinal cord injury, traumatic brain injury, age-related macular degeneration, glaucoma, retinitis pigmentosa, retinal degeneration, respiratory infections, seizures. Eye infections, systemic infections, lupus, arthritis, multiple sclerosis, low bone density, osteoporosis, bone formation, osteosclerotic diseases, Paget's disease of bone and cancer, bladder cancer, brain cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, renal cell carcinoma, renal pelvis cancer, leukemia, lung cancer, melanoma, non-Hodgkin's lymphoma, pancreatic cancer, prostate cancer, ovarian cancer, fibrosarcoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CLL) Multiple myeloma, polycythemia vera, idiopathic thrombocythemia, primary or idiopathic myelofibrosis, primary or idiopathic myelosclerosis, myeloid tumors, tumors expressing Siglec-5, tumors expressing one or more Siglec-5 ligands, thyroid cancer, infections, CNS herpes, parasitic infections, trypanosomiasis infections, Cruzi infections, Pseudomonas aeruginosa infections, Leishmania donovani infections, Group B streptococcal infections, Campylobacter jejuni infections, Neisseria meningitidis infections, HIV type I, and Haemophilus influenzae.Other aspects of this disclosure relate to the use of anti-Siglec-5 antibodies that reduce cellular levels of Siglec-5 in the preparation of medicaments for the prevention, risk reduction, or treatment of diseases, conditions, or injuries selected from the group consisting of: dementia, frontotemporal dementia, Alzheimer's disease, vascular dementia, mixed dementia, Creutzfeldt-Jakob disease, normobaric hydrocephalus, amyotrophic lateral sclerosis, Huntington's disease, tau proteinosis, Nasu-Hakola disease, stroke, acute trauma, chronic trauma, lupus, acute and chronic colitis. Inflammation, rheumatoid arthritis, wound healing, Crohn's disease, inflammatory bowel disease, ulcerative colitis, obesity, malaria, essential tremor, lupus erythematosus, Behcet's disease, Parkinson's disease, Lewy body dementia, multiple system atrophy, Shy-Drager syndrome, progressive supranuclear palsy, corticobasal ganglia degeneration, acute disseminated encephalomyelitis, granulomatous diseases, sarcoidosis, age-related diseases, epileptic seizures, spinal cord injury, traumatic brain injury, age-related macular degeneration, glaucoma, retinitis pigmentosa, retinal degeneration, respiratory infections, Sepsis, eye infections, systemic infections, lupus, arthritis, multiple sclerosis, low bone density, osteoporosis, bone formation, osteosclerotic diseases, Paget's disease of bone and cancer, bladder cancer, brain cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, renal cell carcinoma, renal pelvis cancer, leukemia, lung cancer, melanoma, non-Hodgkin's lymphoma, pancreatic cancer, prostate cancer, ovarian cancer, fibrosarcoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), multiple myeloma, polycythemia vera, idiopathic thrombocythemia, primary or idiopathic myelofibrosis, primary or idiopathic myelosclerosis, myeloid tumors, tumors expressing Siglec-5, tumors expressing one or more Siglec-5 ligands, thyroid cancer, infections, CNS herpes, parasitic infections, trypanosomiasis infections, Cruzi infections, Pseudomonas aeruginosa infections, Leishmania donovani infections, Group B streptococcal infections, Campylobacter jejuni infections, Neisseria meningitidis infections, HIV type I, and Haemophilus influenzae. Other aspects of this disclosure relate to methods for preventing, reducing the risk of, or treating diseases, conditions, or injuries selected from the group consisting of dementia, frontotemporal dementia, Alzheimer's disease, vascular dementia, mixed dementia, tau proteinosis, infections, and cancer, wherein the methods include administering a therapeutically effective amount of an agent that reduces cellular levels of Siglec-5 to an individual in need.Other aspects of this disclosure relate to anti-Siglec-5 antibodies that reduce cellular levels of Siglec-5 for the prevention, risk reduction, or treatment of diseases, conditions, or injuries selected from the group consisting of dementia, frontotemporal dementia, Alzheimer's disease, vascular dementia, mixed dementia, tau proteinosis, infections, and cancer. Other aspects of this disclosure relate to the use of anti-Siglec-5 antibodies that reduce cellular levels of Siglec-5 in the preparation of medicaments for the prevention, risk reduction, or treatment of diseases, conditions, or injuries selected from the group consisting of dementia, frontotemporal dementia, Alzheimer's disease, vascular dementia, mixed dementia, tau proteinosis, infections, and cancer. In some embodiments, the anti-Siglec-5 antibody is any of the anti-Siglec-5 antibodies described in the foregoing embodiments.
[0030] Other aspects of this disclosure relate to methods for reducing cellular levels of Siglec-5 on one or more cells in an individual in need, comprising administering a therapeutically effective amount of an isolated anti-Siglec-5 antibody to said individual. Other aspects of this disclosure relate to isolated anti-Siglec-5 antibodies for reducing cellular levels of Siglec-5 on one or more cells in an individual in need. Other aspects of this disclosure relate to the use of isolated anti-Siglec-5 antibodies in the preparation of medicaments for reducing cellular levels of Siglec-5 on one or more cells in an individual in need. In some embodiments, the anti-Siglec-5 antibody is any of the anti-Siglec-5 antibodies described in the foregoing embodiments.
[0031] Other aspects of this disclosure relate to a method for inducing the production of reactive oxygen species (ROS) in one or more neutrophils in an individual in need, comprising administering a therapeutically effective amount of an isolated anti-Siglec-5 antibody to said individual. Other aspects of this disclosure relate to an isolated anti-Siglec-5 antibody for inducing the production of reactive oxygen species (ROS) in one or more neutrophils in an individual in need. Other aspects of this disclosure relate to the use of the isolated anti-Siglec-5 antibody in the preparation of a medicament for inducing the production of reactive oxygen species (ROS) in one or more neutrophils in an individual in need. In some embodiments, the anti-Siglec-5 antibody is any of the anti-Siglec-5 antibodies described in the foregoing embodiments.
[0032] Other aspects of this disclosure relate to a method of inducing the formation of neutrophil extracellular traps (NETs) in one or more neutrophils in an individual in need, comprising administering a therapeutically effective amount of an isolated anti-Siglec-5 antibody to said individual. Other aspects of this disclosure relate to an isolated anti-Siglec-5 antibody for inducing the formation of neutrophil extracellular traps (NETs) in one or more neutrophils in an individual in need. Other aspects of this disclosure relate to the use of the isolated anti-Siglec-5 antibody in the preparation of a medicament for inducing the formation of neutrophil extracellular traps (NETs) in one or more neutrophils in an individual in need. In some embodiments, the anti-Siglec-5 antibody is any of the anti-Siglec-5 antibodies described in the foregoing embodiments.
[0033] Other aspects of this disclosure relate to a method of inducing neutrophil activation in one or more neutrophils in an individual in need, comprising administering a therapeutically effective amount of an isolated anti-Siglec-5 antibody to said individual. Other aspects of this disclosure relate to an isolated anti-Siglec-5 antibody for inducing neutrophil activation in one or more neutrophils in an individual in need. Other aspects of this disclosure relate to the use of an isolated anti-Siglec-5 antibody in the preparation of a medicament for inducing neutrophil activation in one or more neutrophils in an individual in need. In some embodiments, the anti-Siglec-5 antibody is any of the anti-Siglec-5 antibodies described in the foregoing embodiments.
[0034] Other aspects of this disclosure relate to methods for alleviating one or more immunosuppressed neutrophils in an individual in need, comprising administering a therapeutically effective amount of an isolated anti-Siglec-5 antibody to said individual. Other aspects of this disclosure relate to an isolated anti-Siglec-5 antibody for alleviating one or more immunosuppressed neutrophils in an individual in need. Other aspects of this disclosure relate to the use of an isolated anti-Siglec-5 antibody in the preparation of a medicament for alleviating one or more immunosuppressed neutrophils in an individual in need. In some embodiments, the anti-Siglec-5 antibody is any of the anti-Siglec-5 antibodies described in the foregoing embodiments.
[0035] Other aspects of this disclosure relate to methods for enhancing the phagocytic activity of macrophages in individuals in need, including administering a therapeutically effective amount of isolated anti-Siglec-5 antibody to said individual.
[0036] In some embodiments that can be combined with any of the foregoing embodiments, the method further includes administering to the individual at least one antibody that specifically binds to an inhibitory checkpoint molecule and / or one or more standard or investigational anticancer therapies. In some embodiments that can be combined with any of the foregoing embodiments, the at least one antibody that specifically binds to an inhibitory checkpoint molecule is administered in combination with the anti-Siglec-5 antibody. In some embodiments that can be combined with any of the foregoing embodiments, the at least one antibody that specifically binds to an inhibitory checkpoint molecule is selected from anti-PD-L1 antibody, anti-CTLA4 antibody, anti-PD-L2 antibody, anti-PD-1 antibody, anti-B7-H3 antibody, anti-B7-H4 antibody, and anti-HVEM antibody, anti-B and T lymphocyte attenuator (BTLA) antibody, anti-killer cell inhibitory receptor (KIR) antibody, anti-GAL9 antibody, anti-TIM-1 antibody, anti-TIM3 antibody, and anti-TIM... Anti-4 antibody, anti-A2AR antibody, anti-CD39 antibody, anti-CD73 antibody, anti-LAG-3 antibody, anti-phosphatidylserine antibody, anti-CD27 antibody, anti-CD30 antibody, anti-TNFa antibody, anti-CD33 antibody, anti-Siglec-6 antibody, anti-Siglec-7 antibody, anti-Siglec-9 antibody, anti-Siglec-10 antibody, anti-Siglec-11 antibody, antagonistic anti-TREM1 antibody, antagonistic anti-TREM2 antibody, and any combination thereof. In some embodiments that can be combined with any of the foregoing embodiments, the one or more standard or investigational anticancer therapies are selected from the group consisting of radiotherapy, cytotoxic chemotherapy, targeted therapy, imatinib therapy, trastuzumab therapy, etanercept therapy, adoptive cell transfer (ACT) therapy, chimeric antigen receptor T-cell transfer (CAR-T) therapy, vaccine therapy, and cytokine therapy. In some embodiments that can be combined with any of the foregoing embodiments, the method further includes administering at least one antibody that specifically binds to an inhibitory cytokine to the individual. In some embodiments that can be combined with any of the foregoing embodiments, the at least one antibody that specifically binds to an inhibitory cytokine is administered in combination with the anti-Siglec-5 antibody. In some embodiments that can be combined with any of the foregoing embodiments, the at least one antibody that specifically binds to an inhibitory cytokine is selected from the group consisting of anti-CCL2 antibody, anti-CSF-1 antibody, anti-IL-2 antibody, and any combination thereof. In some embodiments that can be combined with any of the foregoing embodiments, the method further includes administering to the individual at least one agonist antibody that specifically binds to a stimulating checkpoint protein. In some embodiments that can be combined with any of the foregoing embodiments, the at least one agonist antibody that specifically binds to a stimulating checkpoint protein is administered in combination with the anti-Siglec-5 antibody.In some embodiments that can be combined with any of the foregoing embodiments, the at least one agonist antibody that specifically binds to a stimulating checkpoint protein is selected from the group consisting of agonist anti-CD40 antibody, agonist anti-OX40 antibody, agonist anti-ICOS antibody, agonist anti-CD28 antibody, agonist anti-TREM1 antibody, agonist anti-TREM2 antibody, agonist anti-CD137 / 4-1BB antibody, agonist anti-CD27 antibody, agonist anti-glucocorticoid-induced TNFR-related protein GITR antibody, agonist anti-BTLA antibody, agonist HVEM antibody, agonist anti-CD30 antibody, agonist anti-CD2 antibody, agonist anti-CD5 antibody, and any combination thereof. In some embodiments that can be combined with any of the foregoing embodiments, the method further includes administering at least one stimulating cytokine to the individual. In some embodiments that can be combined with any of the foregoing embodiments, the at least one stimulating cytokine is administered in combination with the anti-Siglec-5 antibody. In some embodiments that can be combined with any of the foregoing embodiments, the at least one stimulating cytokine is selected from the group consisting of IFN-□4, IFN-□, IL-1β, TNF-α, IL-6, IL-8, CRP, IL-20 family members, LIF, IFN-γ, OSM, CNTF, GM-CSF, IL-11, IL-12, IL-17, IL-18, IL-23, CXCL10, IL-33, MCP-1, MIP-1-β, and any combination thereof. Attached Figure Description
[0037] Figure 1A This displays the amino acid sequence alignment between human Siglec-5 (SEQ ID NO:1) and cynomolgus monkey Siglec-5 (SEQ ID NO:2). An asterisk (“*”) indicates a position with a single, completely conserved residue; a colon (“:”) indicates conservation between groups with strong similarity – a score > 0.5 in the Gonnet PAM 250 matrix; and a period (“.”) indicates conservation between groups with weak similarity – a score < 0.5 in the Gonnet PAM 250 matrix. Figure 1B This displays the amino acid alignment between human Siglec-5 (SEQ ID NO:1) and human Siglec-14 (SEQ ID NO:3). An asterisk ("*") indicates a position with a single, completely conserved residue; a colon (":") indicates conservation between groups with strong similarity—a score > 0.5 in the Gonnet PAM 250 matrix; and a period (".") indicates conservation between groups with weak similarity—a score < 0.5 in the Gonnet PAM 250 matrix.
[0038] Figure 2AThe results of FACS analysis show the binding of anti-Siglec-5 antibodies to CHO cells expressing recombinant human Siglec-5 or recombinant human Siglec-14. Figure 2B The results of FACS analysis of anti-Siglec-5-specific antibodies binding to primary human neutrophils are shown compared to isotype controls. Figure 2A and in Figure 2B In this study, antibody 1A5 recognizes both human Siglec-5 and human Siglec-14.
[0039] Figure 3 The results show that the anti-Siglec-5 antibody of this disclosure does not block the interaction between the fixed Siglec-5-Fc protein on erythrocytes and the Siglec-5 ligand.
[0040] Figure 4A The antibody showed that the cell surface Siglec-5 receptor on CHO-S5 transfected cells was downregulated in a Siglec-5-dependent manner. Figure 4B This indicates a Siglec-5 antibody-dependent downregulation of the cell surface Siglec-5 receptor on human primary B cells derived from a Siglec-14 ineffective donor. Figure 4C The study showed that Siglec-5 was downregulated in differentiated human macrophages M0, M1, and M2a in the presence of anti-Siglec-5 specific antibody.
[0041] Figure 5 The study showed that the presence of anti-Siglec-5 antibody induced the production of reactive oxygen species (ROS) in human primary neutrophils.
[0042] Figure 6 Human primary neutrophils incubated with anti-Siglec-5 antibody showed the formation of neutrophil extracellular traps (NETs).
[0043] Figure 7 This demonstrates the phagocytic activity of human macrophages differentiated in vitro on target cells in the presence of anti-Siglec-5 specific antibody.
[0044] Figure 8 The expression of Siglec-5 was shown on immune cells in blood and tumors isolated from mice with human Siglec-5 transgenic cells.
[0045] Figure 9The anti-Siglec-5 antibody of this disclosure binds to CHO cells expressing recombinant human Siglec-5 (CHO-ShSiglec-5), but not to parental CHO cells not expressing Siglec-5 (CHO-S parental) or CHO cells expressing recombinant human Siglec-14 (CHO-ShSiglec-14). As shown on the x-axis of each figure, CHO cells were incubated with increased concentrations of anti-Siglec-5 antibody. The binding of the anti-Siglec-5 antibody to the surface of the CHO cells was then measured by FACS. The y-axis provides the binding of each of the anti-Siglec-5 antibodies shown to the surface of the CHO cells relative to the hIgG1 isotype control antibody. S5-174-H2L1 refers to antibody S5-174-H3; S5-174-H3L1 refers to antibody S5-174-H5; S5-174-H3L2 refers to antibody S5-174-H6; S5-174-H4L1 refers to antibody S5-174-H7; S5-174-H4L2 refers to antibody S5-174-H8; S5-G03-H2L1 refers to antibody S5-G-03-H4; S5-G03-H2L2 refers to antibody S5-G-03-H5; S5-G03-H3L1 refers to antibody S5-G-03-H7; S5-G03-H3L2 refers to antibody S5-G-03-H8; and S5-G03-H3L3 refers to antibody S5-G-03-H9.
[0046] Figure 10The anti-Siglec-5 antibody of this disclosure downregulates the cell surface level of Siglec-5 in vitro. As shown on the x-axis of each figure, CHO cells expressing Siglec-5 (CHO-S5) were incubated with an increased concentration of anti-Siglec-5 antibody for 16–24 hours. Siglec-5 expression on the cell surface was then measured by FACS analysis. The percentage of remaining Siglec-5 expressed on the cell surface is provided on the y-axis of the figure (% control hSiglec-5) and calculated according to the following formula: (MFI of 1A5-PE in the presence of the test antibody) / (MFI of 1A5-PE in the absence of the test antibody) * 100%, where MFI is the mean fluorescence intensity, 1A5-PE refers to anti-Siglec-5-PE clone 1A5 (Biolegend), and the test antibody refers to the anti-Siglec-5 antibody of this disclosure being tested. hIgG1 refers to the allotype control antibody; S5-174-H2L1 refers to antibody S5-174-H3; S5-174-H3L1 refers to antibody S5-174-H5; S5-174-H3L2 refers to antibody S5-174-H6; S5-174-H4L1 refers to antibody S5-174-H7; S5-174-H4L2 refers to antibody S5-174... -H8; S5-G03-H2L1 refers to antibody S5-G-03-H4; S5-G03-H2L2 refers to antibody S5-G-03-H5; S5-G03-H3L1 refers to antibody S5-G-03-H7; S5-G03-H3L2 refers to antibody S5-G-03-H8; and S5-G03-H3L3 refers to antibody S5-G-03-H9.
[0047] Figure 11 The anti-Siglec-5 antibody of this disclosure increases CD86 expression in primary human myeloid-derived suppressor cells. As shown on the x-axis of the figure (maximum 10 μg / mL), human myeloid-derived suppressor cells (MDSCs) obtained from two blood donors (donor 849 and donor 851) were treated with increased concentrations of anti-Siglec-5 antibody for 48 hours. CD86 expression on the MDSCs was then quantified by FACS using an anti-CD86 (IT2.2) antibody. The y-axis of the figure provides the median mean fluorescence intensity (MFI) of CD86. mIgG1 and hIgG1 refer to allotype control antibodies; S5-174-H3L2 refers to antibody S5-174-H6; S5-G03-H3L1 refers to antibody S5-G-03-H7; S5-7A5.3 and S5-8A1.3 refer to antibodies 7A5 and 8A1, respectively.
[0048] Figure 12The anti-Siglec-5 antibody of this disclosure increases CCL4 expression in primary human myeloid-derived suppressor cells. As shown on the x-axis (up to 10 μg / mL), human myeloid-derived suppressor cells (MDSCs) obtained from two blood donors (donor 849 and donor 851) were treated with increased concentrations of anti-Siglec-5 antibody. Changes in CCL4 expression in conditioned medium were assessed 48 hours after antibody treatment. CCL4 expression levels were measured using a Quantikine ELISA kit (R&D Systems) or via Human Chemokine Legendplex (Biolegend) according to the manufacturer's protocol and are presented on the y-axis (pg / ml). mIgG1 and hIgG1 refer to allotype control antibodies; S5-174-H3L2 refers to antibody S5-174-H6; S5-G03-H3L1 refers to antibody S5-G-03-H7; S5-7A5.3 and S5-8A1.3 refer to antibodies 7A5 and 8A1, respectively.
[0049] Figure 13 The anti-Siglec-5 antibody of this disclosure increases CD86 expression in primary human myeloid-derived suppressor cells. The x-axis indicates the treatment of human myeloid-derived suppressor cells (MDSCs) obtained from two blood donors (donor 910 and donor 911) with anti-Siglec-5 antibody (10 μg / mL) for 48 hours. MDSCs from donor 910 were also used as a control treatment without antibody treatment (“no treatment”). CD86 expression on MDSCs was then quantified by FACS using an anti-CD86 (IT2.2) antibody. The y-axis of the figure provides the median mean fluorescence intensity (MFI) of CD86. mIgG1, mIgG2a, and hIgG1 refer to allotype control antibodies; S5-7A5.3 and S5-8A1.3 refer to antibodies 7A5 and 8A1, respectively; S5-1A5 is an antibody that binds both Siglec-5 and Siglec-14 (BioLegend).
[0050] Figure 14The anti-Siglec-5 antibody of this disclosure increases CCL4 expression in primary human myeloid-derived suppressor cells. The x-axis indicates the treatment of human myeloid-derived suppressor cells (MDSCs) obtained from two blood donors (donor 910 and donor 911) with anti-Siglec-5 antibody (10 μg / mL) for 48 hours. A control treatment without antibody treatment (“no treatment”) was also performed. Changes in CCL4 expression in conditioned medium after 48 hours of antibody treatment were assessed. CCL4 expression levels were measured using a Quantikine ELISA kit (R&D Systems) or by Human Chemokine Legendplex (Biolegend) according to the manufacturer’s protocol and are presented on the y-axis (pg / ml). mIgG1, mIgG2a, and hIgG1 refer to isotype control antibodies; S5-7A5.3 and S5-8A1.3 refer to antibodies 7A5 and 8A1, respectively; S5-1A5 is an antibody that binds both Siglec-5 and Siglec-14 (BioLegend). Detailed Implementation
[0051] General Technology
[0052] The techniques and procedures described or cited in this article are generally well understood and commonly used by those skilled in the art using conventional methods, such as the widely used methods described in the following literature: Sambrook et al., Molecular Cloning: A Laboratory Manual 3rd Edition (2001), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Current Protocols in Molecular Biology (edited by F.M. Usubel et al., (2003)); Methods in Enzymology series (Academic Press, Inc.): PCR 2: A Practical Approach (edited by M.J. MacPherson, B.D. Hames, and G.G. Taylor, (1995)); Harlow and Lane (edited by Harlow and Lane, (1988); Antibodies, A Laboratory Manual, and Animal Cell Culture (edited by R.R. Freshney, (1987)); Oligonucleotide Synthesis (edited by M.J. Gait, 1984); Methods in Molecular Biology, Humana Press; Cell Biology: A Laboratory Manual. Notebook (JECellis, 1998) Academic Press; Animal Cell Culture (RIFreshney), 1987); Introduction to Cell and Tissue Culture (JPMather and PERoberts, 1998) Plenum Press; Cell and TissueCulture:Laboratory Procedures (A.Doyle, JBGriffiths and DG Newell, 1993-8) J.Wiley and Sons; Handbook of Experimental Immunology (eds. DMWeir and CC Blackwell); Gene Transfer Vectors for Mammalian Cells (JMMiller and MPCalos, 1987); PCR: The Polymerase Chain Reaction, (Mullis et al., 1994); Current Protocols in Immunology (JEColigan et al., 1991); Short Protocols in Molecular Biology (Wileyand Sons, 1999); Immunobiology (CA Janeway and P. Travers, 1997); Antibodies (P. Finch, 1997); Antibodies: A Practical Approach (edited by D. Catty., IRL Press, 1988-1989); Monoclonal Antibodies: A Practical Approach (edited by P. Shepherd and C. Dean, Oxford University Press, 2000); Using Antibodies: A Laboratory Manual (E. Harlow and D. Lane (Cold Spring Harbor Laboratory Press, 1999); The Antibodies (edited by M. Zanetti and JD. Capra, Harwood Academic Publishers, 1995); and Cancer: Principles and Practice of Oncology (edited by VT DeVita et al., JBLippincott Company, 1993).
[0053] definition
[0054] As used herein, the term "prevention" includes providing prevention against the onset or recurrence of a particular disease, condition, or disorder in an individual. An individual may be predisposed to a particular disease, condition, or disorder, or at risk of developing such a disease, condition, or disorder, but has not yet been diagnosed with it.
[0055] As used herein, an individual who is “at risk” of developing a particular disease, condition, or disorder may or may not have a detectable disease or disease symptom, and may or may not exhibit a detectable disease or disease symptom prior to the treatments described herein. “At risk” means that an individual has one or more risk factors, which are measurable parameters known in the art associated with the development of a particular disease, condition, or disorder. Individuals with one or more of these risk factors are more likely to develop a particular disease, condition, or disorder than individuals without one or more of these risk factors.
[0056] As used herein, the term "treatment" refers to a clinical intervention designed to alter the natural course of the disease in the treated individual during the clinicopathological process. Ideal outcomes of treatment include a reduction in the rate of progression of a particular disease, condition, or disorder; a lessening or mitigation of the pathological state; and a reduction or improvement in prognosis. An individual is successfully "treated" if, for example, one or more symptoms associated with a particular disease, condition, or disorder are reduced or eliminated.
[0057] "Effective amount" refers to the amount necessary to effectively achieve the desired therapeutic or preventive outcome, at least in terms of dosage and duration. An effective amount may be provided in one or more administrations. The effective amount described herein can vary depending on a variety of factors, such as an individual's disease state, age, sex, and weight, as well as the ability of the treatment to elicit the desired response in the individual. An effective amount is also the amount in which the beneficial effects of treatment outweigh any toxic or adverse effects of treatment. For preventive use, beneficial or desired outcomes include a variety of results, such as eliminating or reducing the risk of disease, reducing the severity of disease, or delaying the onset of disease, including the biochemical, histological, and / or behavioral symptoms of the disease, its complications, and intermediate pathological phenotypes presented during disease development. For therapeutic use, beneficial or desired outcomes include a variety of clinical results, such as reducing one or more symptoms caused by the disease, improving the quality of life of patients with the disease, reducing the dosage of other medications required to treat the disease, enhancing the effect of another medication, such as through targeting, delaying disease progression, and / or prolonging survival. An effective amount of a drug, compound, or pharmaceutical composition is the amount sufficient to directly or indirectly achieve a preventive or therapeutic treatment. In a clinical context, an effective amount of a drug, compound, or pharmaceutical composition can be achieved with or without combination with another drug, compound, or pharmaceutical composition. Therefore, an "effective amount" can be considered in the context of administering one or more therapeutic agents, and an effective amount of a single agent can be considered if the desired result can be obtained or achieved in combination with one or more other agents.
[0058] "Therapeutic effective dose" is the minimum concentration required to achieve at least a measurable improvement in a specific disease, condition, or disorder. The therapeutic effective dose described herein can vary depending on a variety of factors, such as the patient's disease state, age, sex, and weight, as well as the ability of the Siglec-5 protein antagonist to elicit the desired response in an individual. Therapeutic effective dose is also the amount at which the beneficial therapeutic effect outweighs any toxic or adverse effects of the Siglec-5 protein antagonist.
[0059] As used herein, “combined” administration with another compound or composition includes simultaneous administration and / or administration at different times. Combined administration also covers administration as a co-preparation or as a single composition, including administration at different frequencies or intervals, and administration via the same or different routes.
[0060] For the purposes of treatment, prevention, or risk reduction, "individual" means any animal classified as a mammal, including humans, livestock, and draft animals, as well as zoo animals, racing animals, or pet animals, such as dogs, horses, rabbits, cattle, pigs, hamsters, gerbils, mice, ferrets, rats, cats, etc. Preferably, the individual is a human.
[0061] The term “immunoglobulin” (Ig) is used interchangeably with “antibody” in this document. The term “antibody” is used in the broadest sense in this document, specifically covering monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies) formed from at least two complete antibodies, and antibody fragments, provided they exhibit the desired biological activity.
[0062] The basic 4-chain antibody unit is a heterotetrameric glycoprotein composed of two identical light (L) chains and two identical heavy (H) chains. V H and V L They pair together to form a single antigen-binding site. For information on the structure and properties of different classes of antibodies, see, for example, Basic and Clinical Immunology, 8th ed., Daniel P. Stites, Abba I. Terr and Tristram G. Parslow, Appleton & Lange, Norwalk, CT, 1994, p. 71 and Chapter 6.
[0063] L-chains from any vertebrate species can be classified into one of two distinct types, known as kappa (“κ”) and lambda (“λ”), based on the amino acid sequence of their constant domain. Immunoglobulins can be classified into different classes or isotypes based on the amino acid sequence of their heavy chain (CH) constant domain. There are five classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, which have heavy chains named alpha (“α”), delta (“δ”), epsilon (“ε”), gamma (“γ”), and mu (“μ”), respectively. Based on relatively minor differences in CH sequence and function, the γ and α classes are further subdivided into subclasses (isotypes), for example, humans express the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The subunit structures and three-dimensional conformations of different types of immunoglobulins are well known and are generally described, for example, in Abbas et al., Cellular and Molecular Immunology, 4th edition (WBSaunders Co., 2000).
[0064] "Natural antibodies" are typically heterotetrameric glycoproteins of approximately 150,000 Daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each light chain is linked to the heavy chain by a covalent disulfide bond, the number of which varies among heavy chains of different immunoglobulin isoforms. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has a variable domain (V) at one end. H Following this are several constant structural domains. Each light chain has a variable structural domain (V0) at one end. L The light chain has a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the variable domain of the light chain is aligned with the variable domain of the heavy chain. It is believed that specific amino acid residues form an interface between the variable domains of the light chain and the variable domains of the heavy chain.
[0065] "Isolated" antibodies, such as the anti-Siglec-5 antibody of this disclosure, are antibodies that have been identified, isolated, and / or recovered from their environment of origin (e.g., natural or recombinant). Preferably, the isolated polypeptide does not associate with any other contaminant components from its environment of origin. Contaminant components from its environment of origin, such as components derived from recombinant transfected cells, are substances that typically interfere with the research, diagnostic, or therapeutic use of the antibody and may include enzymes, hormones, and other protein or non-protein solutes. In a preferred embodiment, the polypeptide is purified to: (1) greater than 95% by weight as determined by, for example, the Lowry method, and in some embodiments to greater than 99% by weight; (2) to a degree sufficient to obtain an N-terminal or internal amino acid sequence of at least 15 residues using a rotary cup sequencer; or (3) homogenized by SDS-PAGE determination using Coomassie blue staining or preferably silver staining under non-reducing or reducing conditions. Isolated antibodies include in situ antibodies within recombinant T cells, since at least one component of the antibody's natural environment will not be present. However, isolated polypeptides or antibodies are typically prepared by at least one purification step.
[0066] The "variable region" or "variable domain" of an antibody, such as the anti-Siglec-5 antibody disclosed herein, refers to the amino-terminal domain of the heavy or light chain of the antibody. The variable domains of the heavy and light chains can be referred to as "V" and "V" respectively. H " and "V L These domains are typically the most variable parts of an antibody (relative to other antibodies of the same class) and contain antigen-binding sites.
[0067] The term "variable" refers to the fact that certain segments of the variable domain vary significantly in sequence between antibodies, such as the anti-Siglec-5 antibody disclosed herein. The V domain mediates antigen binding and defines the specificity of a particular antibody for its specific antigen. However, variability is not uniformly distributed across the entire span of the variable domain. Instead, it is concentrated in three segments in the light and heavy chain variable domains, referred to as hypervariable regions (HVRs). The more highly conserved portions of the variable domain are referred to as framework regions (FRs). The variable domains of the natural heavy and light chains each contain four FRs, predominantly in a β-sheet configuration, linked by three HVRs forming loops that connect the β-sheet structure and, in some cases, form part of the β-sheet structure. The HVRs in each chain are held together tightly by the FR regions and, together with HVRs from the other chain, contribute to the formation of the antigen-binding site of the antibody (see Kabat et al., Sequences of Immunological Interest, 5th ed., National Institute of Health, Bethesda, MD (1991)). Constant domains do not directly participate in the binding of antibodies to antigens, but they exhibit various effector functions, such as antibody participation in antibody-dependent cytotoxicity.
[0068] As used herein, the term "monoclonal antibody" refers to an antibody derived from a substantially homogeneous population of antibodies, such as the anti-Siglec-5 antibody of this disclosure, meaning that the individual antibodies constituting said population are identical except for possibly small amounts of naturally occurring mutations and / or post-translational modifications (e.g., isomerization, amidation). Monoclonal antibodies exhibit high specificity against one or more antigenic sites. In some embodiments, the monoclonal antibodies of this disclosure may be bispecific antibodies. In contrast to polyclonal antibody formulations, which typically comprise different antibodies targeting different determinants (epitopes), each monoclonal antibody targets a single determinant at one or more antigenic sites. The modifier "monoclonal" indicates that the antibody is characterized by being derived from a substantially homogeneous population of antibodies and should not be construed as requiring the antibody to be produced by any particular method. For example, monoclonal antibodies to be used according to this disclosure can be prepared by a variety of techniques, including, for example, phage display techniques (see, for example, Clackson et al., Nature, 352:624-628 (1991); Marks et al., J. Mol. Biol. 222:581-597 (1992); Sidhu et al., J. Mol. Biol. 338(2):299-310 (2004); Lee et al., J. Mol. Biol. 340(5):1073-1093 (2004); Fellouse, Proc. Nat'l Acad. Sci. USA 101(34):12467-472 (2004); and Lee et al., J. Immunol. Methods 284(1-2):119-132 (2004), hybridoma methods (e.g., Kohler and Milstein., Nature, 256:495-97 (1975); Hongo et al., Hybridoma, 14(3):253-260 (1995); Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd edition, 1988); Hammerling et al.: Monoclonal Antibodies and T-Cell Hybridomas 563-681 (Elsevier, NY, 1981)), recombinant DNA methods (see, for example, U.S. Patent No. 4,816,567), and techniques for producing human or human-like antibodies in animals having some or all of the human immunoglobulin loci or genes encoding human immunoglobulin sequences (see, for example, WO 1998 / 24893; WO 1996 / 34096; WO 1996 / 33735; WO 1991 / 10741; Jakobovits et al., Proc.Nat'l Acad. Sci. USA 90:2551 (1993); Jakobovits et al., Nature 362:255-258 (1993); Bruggemann et al., Year in Immunol. 7:33 (1993); US Patent Nos. 5,545,807, 5,545,806, 5,569,825, 5,625,126, 5,633,425, and 5,661,016; Marks et al., Bio / Technology 10:779-783 (1992); Lonberg et al., Nature 368:856-859 (1994); Morrison, Nature 368:812-813 (1994); Fishwild et al., Nature Biotechnol. 14:845-851 (1996); Neuberger, Nature Biotechnol. 14:826 (1996); and Lonberg and Huszar, Intern. Rev. Immunol. 13:65-93 (1995). .
[0069] The terms "full-length antibody," "intact antibody," or "whole antibody" are used interchangeably to refer to an antibody that is in a substantially complete form, the opposite of an antibody fragment, such as the anti-Siglec-5 antibody of this disclosure. Specifically, whole antibodies include antibodies having a heavy chain and a light chain including an Fc region. The constant domain can be a native sequence constant domain (e.g., a human native sequence constant domain) or a variant of its amino acid sequence. In some cases, an intact antibody may have one or more effector functions.
[0070] An "antibody fragment" comprises a portion of a complete antibody, preferably the antigen-binding and / or variable region of the complete antibody. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; biantibodies; linear antibodies (see U.S. Patent 5,641,870, Example 2; Zapata et al., Protein Eng. 8(10):1057-1062(1995)); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
[0071] Antibodies such as the anti-Siglec-5 antibody disclosed herein, when digested with papain, produce two identical antigen-binding fragments, referred to as the "Fab" fragment and the residual "Fc" fragment, names reflecting their ease of crystallization. The Fab fragment consists of the entire L chain along with the variable region domain (V) of the H chain. H ) and the first constant structural domain of a heavy chain (C H1) Composition. Each Fab fragment is monovalent for antigen binding, meaning it has a single antigen-binding site. Pepsin treatment of the antibody produces a single large F(ab')2 fragment, which roughly corresponds to two disulfide-linked Fab fragments with different antigen-binding activities, and is still capable of cross-linking the antigen. The difference between Fab' fragments and Fab fragments lies in the C... H The carboxyl terminus of the 1 domain has several additional residues, including one or more cysteine residues from the antibody hinge region. The Fab' with a free thiol group at the cysteine residue in the constant domain is referred to herein as Fab'-SH. F(ab')2 antibody fragments are initially generated as Fab' fragment pairs with a hinge cysteine residue between them. Other chemical conjugations of antibody fragments are also known.
[0072] The Fc fragment contains the carboxyl-terminal portions of two H chains held together by disulfide bonds. The effector function of an antibody is determined by the sequence in the Fc region, which is also recognized by the Fc receptor (FcR) found on certain types of cells.
[0073] "Fv" is the smallest antibody fragment containing a complete antigen recognition and binding site. This fragment consists of a dimer of a tightly non-covalently associated heavy chain variable region domain and a light chain variable region domain. Folding from these two domains produces six hypervariable rings (three from each of the H and L chains), which contribute amino acid residues to antigen binding and confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv containing only three antigen-specific HVRs) can recognize and bind antigens, although with lower affinity than a complete binding site.
[0074] A "single-chain Fv," also abbreviated as "sFv" or "scFv," is an antibody fragment containing VH and VL antibody domains linked to a single polypeptide chain. Preferably, the sFv polypeptide contains VH and VL antibody domains linked to a single polypeptide chain. H With V L The domains further contain peptide linkers, which enable sFv to form the structures required for antigen binding. For a review of sFv, see Pluckthun, The Pharmacology of Monoclonal Antibodies, Vol. 113, edited by Rosenburg and Moore, Springer-Verlag, New York, pp. 269–315 (1994).
[0075] An antibody, such as the anti-Siglec-5 antibody of this disclosure, comprises a portion of the complete antibody and typically includes the antigen-binding region or variable region of the complete antibody, or the F region of the antibody that retains or has modified FcR binding capability. Examples of antibody fragments include linear antibodies, single-chain antibody molecules, and multispecific antibodies formed from antibody fragments.
[0076] The term "biantibody" refers to a small antibody fragment prepared in a manner that is constructed on V... H With V L An sFv fragment (see previous section) with short linkers (approximately 5-10 residues) between its domains achieves interchain rather than intrachain pairing of the V domains, resulting in a bivalent fragment, i.e., a fragment with two antigen-binding sites. A bispecific biantibody is a heterodimer of two "crossover" sFv fragments, where the V domains of the two antibodies... H and V L The domains are located on different polypeptide chains. Biantibodies are described in more detail, for example, in EP 404,097; WO93 / 11161; Hollinger et al., Proc. Nat'l Acad. Sci. USA 90:6444-48 (1993).
[0077] As used herein, a “chimeric antibody” refers to an antibody (immunoglobulin), such as the anti-Siglec-5 antibody of this disclosure, wherein a portion of the heavy chain and / or light chain is identical or homologous to the corresponding sequence in an antibody derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain is identical or homologous to the corresponding sequence in an antibody derived from another species or belonging to another antibody class or subclass, and fragments of such antibodies, provided they exhibit the desired biological activity (US Patent No. 4,816,567; Morrison et al., Proc. Nat'l Acad. Sci. USA, 81:6851-55 (1984)). Chimeric antibodies of interest herein include Antibodies, wherein the antigen-binding region of an antibody is derived from antibodies produced by immunizing a macaque with, for example, the antigen of interest. As used herein, the “humanized antibody” is a subset of the “chimeric antibody.”
[0078] A “humanized” form of a non-human (e.g., mouse) antibody, such as the anti-Siglec-5 antibody of this disclosure, is a chimeric antibody containing a minimal sequence derived from a non-human immunoglobulin. In one embodiment, the humanized antibody is a human immunoglobulin (receptor antibody) in which residues of the receptor's HVR are replaced by residues of the HVR from a non-human species (donor antibody) having the desired specificity, affinity, and / or ability. In some cases, FR residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, the humanized antibody may contain residues not found in the receptor or donor antibody. These modifications can be made to further improve antibody properties, such as binding affinity. Generally, humanized antibodies will contain at least one and usually two variable domains, wherein all or almost all hypervariable loops correspond to hypervariable loops of non-human immunoglobulin sequences, and all or almost all FR regions are FR regions of human immunoglobulin sequences, although the FR regions may include one or more individual FR residue substitutions that enhance antibody performance (e.g., binding affinity, isomerization, immunogenicity, etc.). The number of these amino acid substitutions in the FRs is generally no more than 6 in the H chain and no more than 3 in the L chain. Humanized antibodies will optionally also contain at least a portion of the immunoglobulin constant region (Fc), typically the constant region of human immunoglobulins. For further details, see, for example, Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992). See also, for example, Vaswani and Hamilton, Ann. Allergy, Asthma & Immunol. 1:105-115 (1998); Harris, Biochem. Soc. Transactions 23:1035-1038 (1995); Hurle and Gross, Curr. Op. Biotech. 5:428-433 (1994); and U.S. Patent Nos. 6,982,321 and 7,087,409.
[0079] "Human antibody" is an antibody having an amino acid sequence corresponding to an antibody produced by humans and / or prepared using any technique for preparing human antibodies as disclosed herein, such as the anti-Siglec-5 antibody of this disclosure. This definition of human antibody specifically excludes humanized antibodies containing non-human antigen-binding residues. Human antibodies can be produced using a variety of techniques known in the art, including phage display libraries. The methods described in Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991). The methods described in Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985); Boerner et al., J. Immunol., 147(1):86-95 (1991) can also be used to prepare human monoclonal antibodies. See also van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5:368-74 (2001). Human antibodies can be prepared by administering antigens to transgenic animals that have been modified to produce such antibodies in response to antigen challenge, but whose endogenous loci have been disabled, for example, in immunized xenogeneic mice (regarding XENOMOUSE). TM For example, see U.S. Patent Nos. 6,075,181 and 6,150,584. Regarding human antibodies produced via human B-cell hybridoma technology, see also, for example, Li et al., Proc. Nat'l Acad. Sci. USA, 103:3557-3562 (2006).
[0080] The terms “hypervariant region,” “HVR,” or “HV,” as used herein, refer to a region of the antibody variable domain, such as the region of the antibody variable domain of the anti-Siglec-5 antibody of this disclosure, which is sequence-hypervariant and / or forms a structurally defined loop. Typically, antibodies contain six HVRs; three in the VH (H1, H2, H3) and three in the VL (L1, L2, L3). In native antibodies, H3 and L3 exhibit the greatest diversity among the six HVRs, and H3 is particularly considered to play a unique role in conferring good specificity to the antibody. See, for example, Xu et al., Immunity 13:37-45 (2000); Johnson and Wu, Methods in Molecular Biology 248:1-25 (Lo ed., Human Press, Totowa, NJ, 2003). Indeed, naturally occurring camel antibodies consisting only of heavy chains are functional and stable in the absence of light chains. See, for example, Hamers-Casterman et al., Nature 363:446-448 (1993) and Sheriff et al., Nature Struct. Biol. 3:733-736 (1996).
[0081] Many HVR descriptions are in use and covered in this paper. HVRs of the EU or Kabat complementarity-determining region (CDR) are based on sequence variability and are the most commonly used (Kabat et al., ibid.). Chothia, on the other hand, refers to the location of the structural loop (Chothia and Lesk J.Mol.Biol.196:901-917(1987)). AbM HVRs represent a compromise between the EU or Kabat CDR and the Chothia structural loop and are used by Oxford Molecular's AbM antibody modeling software. "Contact" HVRs are based on analysis of the available complex crystal structures. Residues from each of these HVRs are shown below.
[0082]
[0083] HVRs may include the following “extended HVRs”: 24-36 or 24-34 (L1), 46-56 or 50-56 (L2), and 89-97 or 89-96 (L3) in VL; and 26-35 (H1), 50-65 or 49-65 (preferred embodiment) (H2), and 93-102, 94-102, or 95-102 (H3) in VH. For each of these extended HVR definitions, the variable domain residues are numbered as above, according to Kabat et al.
[0084] “Frame” or “FR” residues are those variable domain residues other than HVR residues as defined in this paper.
[0085] As used herein, a “recipient human frame” is a frame containing the amino acid sequence of a VL or VH frame derived from a human immunoglobulin frame or a human common frame. A recipient human frame “derived from” a human immunoglobulin frame or a human common frame may contain the same amino acid sequence, or it may contain pre-existing amino acid sequence variations. In some embodiments, the number of pre-existing amino acid variations is 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, or 2 or fewer. Where pre-existing amino acid variations are present in the VH, these variations preferably occur only at three, two, or one of the 71H, 73H, and 78H positions; for example, the amino acid residues at these positions may be 71A, 73T, and / or 78A. In one embodiment, the VL recipient human frame is sequence-identical to the VL human immunoglobulin frame sequence or the human common frame sequence.
[0086] The “human common framework” is the framework representing the most common amino acid residues in the selection of the human immunoglobulin VL or VH framework sequence. Generally, the selection of the human immunoglobulin VL or VH sequence is based on a subgroup of the variable domain sequence. Typically, the subgroups are those described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991). For VL, examples include subgroups κI, κII, κIII, or κIV, as described in Kabat et al., as above. Similarly, for VH, subgroups can be subgroup I, subgroup II, or subgroup III, as described in Kabat et al., as above.
[0087] In the context of the anti-Siglec-5 antibody of this disclosure, "amino acid modification" at a specified position refers to the substitution or deletion of a specified residue, or the insertion of at least one amino acid residue adjacent to a specified residue. An insertion "adjacent" to a specified residue means insertion within one or two residues thereto. Insertion can occur at the N-terminus or C-terminus of the specified residue. Substitution is the preferred amino acid modification described herein.
[0088] Affinity-matured antibodies, such as the anti-Siglec-5 antibody of this disclosure, are antibodies with one or more alterations in one or more of their HVRs, which result in increased affinity of the antibody for the antigen compared to the parent antibody without these alterations. In one embodiment, the affinity-matured antibody has nanomolar or even picomolar affinity for the target antigen. Affinity-matured antibodies are produced by methods known in the art. For example, Marks et al., Bio / Technology 10:779-783 (1992) describe affinity maturation via VH and VL domain shuffling. Random mutagenesis of HVR and / or framework residues is described in, for example, the following literature: Barbas et al., Proc Nat. Acad. Sci. USA 91:3809-3813 (1994); Schier et al., Gene 169:147-155 (1995); Yelton et al., J. Immunol. 155:1994-2004 (1995); Jackson et al., J. Immunol. 154(7):3310-9 (1995); and Hawkins et al., J. Mol. Biol. 226:889-896 (1992).
[0089] As used herein, the terms “specific recognition” or “specific binding” refer to a measurable and reproducible interaction, such as the attraction or binding between a target and an antibody, such as the anti-Siglec-5 antibody of this disclosure, which determines the presence of the target in the presence of a heterogeneous population of molecules, including biomolecules. For example, an antibody that specifically or preferentially binds to a target or epitope, such as the anti-Siglec-5 antibody of this disclosure, is an antibody that binds to this target or epitope with greater affinity, stronger affinity, easier binding, and / or longer duration than it binds to other targets or other epitopes of a target. It should also be understood from this definition that an antibody (or part thereof) that specifically or preferentially binds to a first target may or may not specifically or preferentially bind to a second target. Thus, “specific binding” or “preferential binding” does not necessarily require (although it may include) exclusive binding. The binding constant of an antibody that specifically binds to a target can be at least about 10. 3 M -1 Or 10 4 M -1 Sometimes it is about 10 5 M -1 Or 10 6 M -1 In other cases, it is approximately 10. 6 M -1 Or 10 7 M -1 Approximately 10 8 M -1 Up to 109 M -1 Or about 10 10 M -1 Up to 10 11 M -1 Or higher. Various immunoassays can be used to select antibodies that will produce a specific immune response to a particular protein. For example, solid-phase ELISA is routinely used to select monoclonal antibodies that will produce a specific immune response to a protein. For a description of immunoassays and conditions that can be used to determine specific immunoreactivity, see, for example, Harlow and Lane (1988), Antibodies, A Laboratory Manual, Cold Spring Harbor Publications, New York.
[0090] As used herein, the “interaction” between the Siglec-5 protein and the second protein includes, but is not limited to, protein-protein interactions, physical interactions, chemical interactions, binding, covalent binding, and ion binding. As used herein, an antibody “inhibits the interaction between the two proteins” when it disrupts, reduces, or completely eliminates the interaction between the two proteins. When an antibody or fragment thereof of this disclosure binds to one of the two proteins, the antibody or fragment thereof “inhibits the interaction between the two proteins.”
[0091] "Agonist" antibodies or "activating" antibodies are antibodies that induce (e.g., increase) one or more activities or functions of an antigen after binding to it, such as the agonist anti-Siglec-5 antibody disclosed herein.
[0092] "Blocking" antibodies, "antagonist" antibodies, or "inhibitory" antibodies are antibodies that, upon binding to an antigen, inhibit or reduce (e.g., decrease) the binding of the antigen to one or more ligands and / or inhibit or reduce (e.g., decrease) one or more activities or functions of the antigen, such as the anti-Siglec-5 antibody of this disclosure. In some embodiments, blocking antibodies, antagonist antibodies, or inhibitory antibodies substantially or completely inhibit the binding of the antigen to one or more ligands and / or one or more activities or functions of the antigen.
[0093] Antibody "effector function" refers to those biological activities attributable to the Fc region of the antibody (the native Fc region or the Fc region of an amino acid sequence variant), and varies with antibody isotype.
[0094] The term "Fc region" used herein is used to define the C-terminal region of an immunoglobulin heavy chain, including native sequence Fc regions and variant Fc regions. While the boundaries of Fc regions of immunoglobulin heavy chains may vary, the human IgG heavy chain Fc region is generally defined as extending from an amino acid residue at the Cys226 position or from Pro230 to its carboxyl terminus. The C-terminal lysine (residue 447 according to the EU numbering system) of the Fc region may be removed, for example, during antibody production or purification or by recombinant engineering of the nucleic acid encoding the heavy chain of the antibody. Therefore, the composition of a complete antibody may comprise a population of antibodies with all K447 residues removed, a population of antibodies without K447 residues removed, and a mixture of antibodies with and without K447 residues removed. Suitable native sequence Fc regions for the antibodies of this disclosure include human IgG1, IgG2, IgG3, and IgG4.
[0095] The “natural sequence Fc region” contains the same amino acid sequence as the Fc region found in nature. The natural sequence human Fc regions include the natural sequence human IgG1 Fc region (non-A and A allotypes); the natural sequence human IgG2 Fc region; the natural sequence human IgG3 Fc region; and the natural sequence human IgG4 Fc region, as well as their naturally occurring variants.
[0096] The “variant Fc region” comprises an amino acid sequence that differs from the native Fc region due to at least one amino acid modification (preferably one or more amino acid substitutions). Preferably, the variant Fc region has at least one amino acid substitution compared to the native Fc region or the Fc region of the parent polypeptide, for example, about one to about ten amino acid substitutions, preferably about one to about five amino acid substitutions, in the native Fc region or the Fc region of the parent polypeptide. The variant Fc region described herein will preferably have at least about 80% homology with the native Fc region and / or the Fc region of the parent polypeptide, most preferably at least about 90% homology, and more preferably at least about 95% homology.
[0097] The term "Fc receptor" or "FcR" describes a receptor that binds to the Fc region of an antibody. Preferred FcRs are naturally occurring human FcRs. Furthermore, preferred FcRs are those that bind to IgG antibodies (γ receptors) and include receptors of the FcγRI, FcγRII, and FcγRIII subclasses, including allelic variants and alternative splice forms of these receptors. FcγRII receptors include FcγRIIA ("activating receptor") and FcγRIIB ("inhibiting receptor"), which have similar amino acid sequences, differing primarily in their cytoplasmic domains. The activating receptor FcγRIIA contains an activation motif ("ITAM") based on the immunoreceptor tyrosine residue in its cytoplasmic domain. The inhibiting receptor FcγRIIB contains an inhibitory motif ("ITIM") based on the immunoreceptor tyrosine residue in its cytoplasmic domain (see, for example, M). Annu. Rev. Immunol. 15:203-234 (1997)). FcRs are reviewed in Ravetch and Kinet, Annu. Rev. Immunol. 9:457-92 (1991); Capel et al., Immunomethods 4:25-34 (1994); and de Haas et al., J. Lab. Clin. Med. 126:330-41 (1995). The term “FcR” used in this paper encompasses other FcRs, including those to be identified in the future. FcRs can also increase the serum half-life of antibodies.
[0098] The in vivo binding and serum half-life of human FcRn high-affinity binding peptides to FcRn can be determined, for example, in transgenic mice expressing human FcRn or in transfected human cell lines or in primates administered peptides with variant Fc regions. WO 2004 / 42072 (Presta) describes antibody variants that enhance or weaken binding to FcR. See also, for example, Shields et al., J. Biol. Chem. 9(2):6591-6604 (2001).
[0099] As used herein, “percentage of amino acid sequence identity (%)” and “homology” for peptide, polypeptide, or antibody sequences refer to the percentage of amino acid residues in a candidate sequence that are identical to amino acid residues in a specific peptide or polypeptide sequence, after sequence alignment and, where necessary, the introduction of vacancies to achieve the maximum percentage of sequence identity, and without regard to any conserved substitutions as part of sequence identity. Alignments for the purpose of determining the percentage of amino acid sequence identity can be performed in various ways within the scope of the art, for example using publicly available computer software such as BLAST, BLAST-2, ALIGN, or MEGALIGN. TM(DNASTAR) software. Those skilled in the art can determine the appropriate parameters for measuring alignment, including any algorithms known in the art required to achieve maximum alignment across the full length of the sequences being compared.
[0100] "Isolated" cells are molecules or cells identified and isolated from at least one contaminating cell, which typically associate with said contaminating cell in the environment in which they are generated. In some embodiments, the isolated cells do not associate with all components associated with the generating environment. The isolated cells are in a form different from their form or environment found in nature. The isolated cells are different from cells naturally occurring in tissues, organs, or individuals. In some embodiments, the isolated cells are the host cells of this disclosure.
[0101] The “isolated” nucleic acid molecule encoding an antibody, such as the anti-Siglec-5 antibody of this disclosure, is a nucleic acid molecule identified and isolated from at least one contaminating nucleic acid molecule, which typically associates with said contaminating nucleic acid molecule in its environment of origin. Preferably, the isolated nucleic acid does not associate with all components associated with the environment of origin. The isolated nucleic acid molecule encoding the polypeptides and antibodies described herein is in a form different from its form or environment found in nature. Therefore, the isolated nucleic acid molecule is different from the nucleic acids encoding the polypeptides and antibodies described herein that are naturally occurring in cells.
[0102] As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it is linked. One type of vector is a "plasmid," which is a circular double-stranded DNA molecule to which an additional DNA segment can be linked. Another type of vector is a bacteriophage vector. Yet another type of vector is a viral vector, in which an additional DNA segment can be linked to a viral genome. Some vectors are capable of autonomous replication in the host cells to which they are introduced (e.g., bacterial vectors with bacterial origins of replication and free mammalian vectors). Other vectors (e.g., non-free mammalian vectors) can be integrated into the host cell's genome after introduction into the host cell, and thus replicated along with the host genome. Furthermore, some vectors are capable of directing the expression of genes to which they are operatively linked. These types of vectors are referred to herein as "recombinant expression vectors" or simply "expression vectors." Generally, expression vectors useful in recombinant DNA technology are usually in plasmid form. In this specification, "plasmid" and "vector" are used interchangeably because plasmids are the most commonly used form of vector.
[0103] In this document, the terms "polynucleotide" or "nucleic acid" used interchangeably refer to a polymer of nucleotides of any length, including DNA and RNA. Nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases and / or their analogues, or any substrate that can be incorporated into the polymer by DNA or RNA polymerases or through a synthetic reaction. Polynucleotides may contain modified nucleotides, such as methylated nucleotides and their analogues. If modifications to the nucleotide structure are present, the nucleotide structure can be modified before or after polymer assembly. The sequence of nucleotides can be interrupted by non-nucleotide components. Polynucleotides may include modifications performed post-synthetically, such as tag conjugation. Other types of modifications include, for example, the substitution of one or more naturally occurring nucleotides with analog "caps"; internucleotide modifications, such as modifications with uncharged bonds (e.g., methylphosphonates, triphosphates, aminophosphates, carbamates, etc.) and charged bonds (e.g., thiophosphates, dithiophosphates, etc.); modifications containing side chain portions such as proteins (e.g., nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.); modifications with intercalating agents (e.g., acridine, psoralen, etc.); modifications with chelating agents (e.g., metals, radioactive metals, boron, oxidizing metals, etc.); modifications with alkylating agents; modifications with modified bonds (e.g., α-anomeric nucleic acids, etc.); and unmodified forms of polynucleotides. Furthermore, any hydroxyl groups typically present in sugars can be, for example, replaced by phosphonate groups, phosphate groups, protected by standard protecting groups, or activated to prepare additional bonds with other nucleotides, or can be conjugated to solid or semi-solid supports. The 5' and 3' terminal OH groups may be phosphorylated or partially substituted with amine or organic end-capping groups of 1 to 20 carbon atoms. Other hydroxyl groups may also be derived as standard protecting groups. The polynucleotide may also contain similar forms of ribose or deoxyribose known in the art, including, for example, 2'-O-methyl-, 2'-O-allyl-, 2'-fluoro-, or 2'-azido-ribose, carbocyclic sugar analogs, α-anomeric sugars, epimeric sugars such as arabinose, xylose, or lythose, pyranose, furanose, sedoheptulose, acyclic analogs, and basic nucleoside analogs such as methylriboside. One or more phosphodiester bonds may be replaced by alternative linking groups. These alternative linking groups include, but are not limited to, embodiments in which the phosphate ester is replaced by P(O)S (“thioester”), P(S)S (“dithioester”), (O)NR2 (“amid”), P(O)R, P(O)OR', CO, or CH2 (“methylal”), wherein each R or R' is independently H or optionally a substituted or unsubstituted alkyl group (1-20C) containing an ether (-O-) bond, aryl, alkenyl, cycloalkyl, cycloalkenyl, or araldyl. Not all bonds in a polynucleotide need to be identical. The preceding description applies to all polynucleotides mentioned herein, including RNA and DNA.
[0104] "Host cell" includes an individual cell or cell culture that may be, or is already, a recipient of a vector for incorporating a polynucleotide intercalation. Host cells include the offspring of a single host cell, and the offspring may not necessarily be identical to the original parent cell (in terms of morphological or genomic DNA complementarity) due to natural, accidental, or intentional mutation. Host cells include cells transfected in vivo with the polynucleotides of this disclosure.
[0105] As used herein, “carrier” includes pharmaceutically acceptable carriers, excipients, or stabilizers that are non-toxic to cells or mammals exposed to them at the doses and concentrations used. Physiologically acceptable carriers are typically pH-buffered aqueous solutions. Examples of physiologically acceptable carriers include buffers such as phosphates, citrates, and other organic acids; antioxidants, including ascorbic acid; low molecular weight (less than about 10 residues) peptides; proteins such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextran; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and / or nonionic surfactants such as TWEEN. TM Polyethylene glycol (PEG) and PLURONICS TM .
[0106] As used herein, the term “apoptosis” refers to a gene-directed intracellular cellular disruption process. Apoptosis differs from necrosis; it involves cytoskeleton disruption, cytoplasmic contraction and condensation, expression and vesicle formation of phosphatidylserine on the outer surface of the cell membrane, leading to the formation of membrane-bound vesicles or apoptotic bodies. This process is also known as “programmed cell death.” During apoptosis, characteristic phenomena are observed, such as a curved cell surface, condensation of nuclear chromatin, breaks in chromosomal DNA, and loss of mitochondrial function. Various known techniques can be used to detect apoptosis, such as staining cells with annexin V, propidium iodide, DNA fragmentation assays, and YO-PRO-1 (Invitrogen). In some implementations, staining with annexin V and propidium iodide can be used, and the combined percentages of annexin V+ / PI+, annexin V+ / PI-, and annexin V- / PI+ populations are considered as dead cells.
[0107] As used herein, the term "agent that reduces cellular levels of Siglec-5, inhibits the interaction between Siglec-5 and one or more Siglec-5 ligands, or both" refers to a molecule that reduces (including significantly), decreases, blocks, inhibits, or interferes with the biological activity of Siglec-5 (such as human Siglec-5) in vitro, in situ, and / or in vivo. The term "agent" does not imply any specific biological mechanism of action and explicitly includes and encompasses all possible pharmacological, physiological, and biochemical interactions with Siglec-5, whether direct or indirect, and whether involving Siglec-5, one or more of its ligands, or through another mechanism, and the results that can be achieved through a variety of different and chemically dissimilar combinations. Exemplary agents include, but are not limited to, anti-Siglec-5 antibodies that specifically bind to Siglec-5, soluble Siglec-5 receptor proteins, soluble Siglec-5-Fc fusion proteins (e.g., Siglec-5 immunoadhesins), soluble Siglec receptors that bind to Siglec-5 ligands, Siglec-Fc fusion proteins that bind to Siglec-5 ligands (e.g., Siglec immunoadhesins), antisense molecules targeting nucleic acids encoding Siglec-5, short interfering RNA (“siRNA”) molecules targeting nucleic acids encoding Siglec-5, Siglec-5 inhibitory compounds, RNA or DNA aptamers that bind to Siglec-5, and Siglec-5 structural analogs. In some embodiments, Siglec-5 inhibitors (e.g., antibodies) bind to agents that reduce cellular levels of Siglec-5 (physically interact with them), inhibit the interaction between Siglec-5 and one or more Siglec-5 ligands, or both bind to Siglec-5 ligands and / or inhibit (reduce) Siglec-5 synthesis or production. In other embodiments, the agents of this disclosure inhibit the binding of Siglec-5 and prevent it from binding to one or more of its ligands. In still other embodiments, the agents of this disclosure reduce or eliminate the expression (i.e., transcription or translation) of Siglec-5. Examples of agent types that reduce cellular levels of Siglec-5, inhibit the interaction between Siglec-5 and one or more Siglec-5 ligands, or both, are provided herein.
[0108] As used herein, the term "agent that binds to or interacts with Siglec-5" refers to a molecule that interacts directly or indirectly with the Siglec-5 protein. The term "agent" does not imply any specific biological mechanism of action and explicitly includes and encompasses all possible pharmacological, physiological, and biochemical interactions with Siglec-5, whether direct or indirect, and whether through direct interaction with Siglec-5 or via another mechanism, and the results that can be achieved through a variety of different and chemically dissimilar combinations. Exemplary agents include, but are not limited to, anti-Siglec-5 antibodies that specifically bind to Siglec-5.
[0109] As used herein, the term “RNA interference” or “RNAi” generally refers to a process in which a double-stranded RNA molecule or a short hairpin RNA molecule reduces or inhibits the expression of a nucleic acid sequence that shares basic or complete homology with the double-stranded or short hairpin RNA molecule. The terms “short interfering RNA” or “siRNA” or “RNAi agent” refer to an RNA sequence that causes RNA interference. See Kreutzer et al., WO 00 / 44895; Zernicka-Goetz et al., WO 01 / 36646; Fire, WO 99 / 32619; Mello and Fire, WO 01 / 29058. As used herein, siRNA molecules include RNA molecules encompassing both chemically modified nucleotides and non-nucleotides. The term “ddRNAi agent” refers to a DNA-directed RNAi agent transcribed from an exogenous vector. The term “short hairpin RNA” or “shRNA” refers to an RNA structure having a double-stranded region and a circular region. In some embodiments, the ddRNAi agent is initially expressed as shRNA.
[0110] As used herein, the term "aptamer" refers to a heteronucleotide that binds tightly and specifically to a desired molecular target, such as a common metabolic cofactor (e.g., coenzyme A, S-adenosylmethionine, etc.), a protein (e.g., complement protein C5, antibodies, etc.), or a conserved structural element in a nucleic acid molecule (e.g., a structure important for transcription factor binding, etc.). Aptamers typically comprise DNA or RNA nucleotide sequences ranging from about 10 to about 100 nucleotides in length, from about 10 to about 75 nucleotides in length, from about 10 to about 50 nucleotides in length, from about 10 to about 35 nucleotides in length, and from about 10 to about 25 nucleotides in length. Synthetic DNA or RNA oligonucleotides can be prepared using standard solid-phase phosphorus amide methods and equipment, such as the Applied Biosystems 3900 high-throughput DNA synthesizer (Foster City, CA). TMAptamers are often incorporated with derivatives or analogs of nucleotides commonly found in DNA and RNA (e.g., A, G, C, and T / U), including backbone or bond modifications (e.g., peptide nucleic acid (PNA) or phosphate thioester bonds) to increase resistance to nucleases, binding affinity, or otherwise alter their pharmacokinetic properties. Exemplary modifications are listed in U.S. Patent Nos. 6,455,308, 4,469,863, 5,536,821, 5,541,306, 5,637,683, 5,637,684, 5,700,922, 5,717,083, 5,719,262, 5,739,308, 5,773,601, 5,886,165, 5,929,226, 5,977,296, and 6,140,482; and in WIPO Publications WO 00 / 56746 and WO 01 / 14398. Methods for synthesizing oligonucleotides comprising such analogues or derivatives are disclosed in, for example, the patent publications cited above and U.S. Patent Nos. 6,455,308, 5,614,622, 5,739,314, 5,955,599, 5,962,674, 6,117,992, and WO 00 / 75372.
[0111] As used herein, the term "about" refers to the typical range of error for values that is readily known to those skilled in the art. The use of "about" in this document to refer to a value or parameter includes (and describes) embodiments relating to that value or parameter itself.
[0112] As used herein and in the appended claims, unless the context clearly indicates otherwise, the singular forms “a” and “the” include plural references. For example, reference to “antibody” means one or more antibodies, such as molar amounts, and includes equivalent amounts known to those skilled in the art, etc.
[0113] It should be understood that the aspects and implementations of this disclosure described herein include “comprising aspects and implementations”, “consisting of aspects and implementations”, and “substantially consisting of aspects and implementations”.
[0114] Overview
[0115] This disclosure relates to anti-Siglec-5 antibodies that reduce cellular levels of Siglec-5, induce or increase reactive oxygen species (ROS) production in neutrophils, induce or increase neutrophil extracellular trap (NET) formation in neutrophils, and / or increase macrophage phagocytic activity; methods for preparing and using such anti-Siglec-5 antibodies; pharmaceutical compositions containing such anti-Siglec-5 antibodies; nucleic acids encoding such anti-Siglec-5 antibodies; and host cells containing nucleic acids encoding such anti-Siglec-5 antibodies.
[0116] In some embodiments, the anti-Siglec-5 antibody of this disclosure may have one or more antagonistic activities, which are at least partly attributed to the ability of the antibody to reduce the cellular expression (e.g., cell surface expression) of Siglec-5 by inducing degradation, downregulation, cleavage, receptor desensitization and / or lysosomal targeting of Siglec-5.
[0117] In some embodiments, antibody-induced Siglec-5 activity can be determined or tested in vitro using any of the techniques disclosed herein, including but not limited to testing the plate binding of full-length anti-Siglec-5 antibodies to increase the density of antibodies exposed to Siglec-5, crosslinking anti-Siglec-5 antibodies with a second antibody, crosslinking anti-Siglec-5 antibodies with cells expressing one or more Fcg receptors (e.g., FcgRIIB), using Siglec-5 antibodies in solution, and using Fab fragments of Siglec-5 antibodies.
[0118] Certain aspects of this disclosure are based, at least in part, on the confirmation of anti-Siglec-5 antibodies that exhibit the ability to reduce cell surface levels of Siglec-5 on cells, resulting in reduction, cancellation, inhibition, or suppression of one or more Siglec-5 activities. Exemplary Siglec-5 activities include, but are not limited to, phosphorylation of Tyr-520 and Tyr-544 by Src family tyrosine kinases such as Syk, LCK, FYM, and / or ZAP70; recruitment and binding to tyrosine-specific protein phosphatases SHP1 and SHP2; recruitment and binding to PLC-γ1, which acts as a guanine nucleotide exchanger for Dynamini-1; recruitment and binding to proteins containing an SH2 domain (e.g., Crkl); recruitment and binding to spleen tyrosine kinase Syk; and recruitment and binding to SH3-SH2-SH3 growth factor receptor-binding protein 2 (Grb2). It binds to; recruits and binds to various SH2-containing proteins; regulates the expression of one or more pro-inflammatory cytokines, such as IFN-α4, IFN-β, IL-1β, IL-1α, TNF-α, IL-6, IL-8, CRP, IL-20 family members, LIF, IFN-γ, OSM, CNTF, GM-CSF, IL-11, IL-12, IL-17, IL-18, CRP, MCP-1, and MIP-1-β; and regulates the expression of one or more pro-inflammatory cytokines in one or more cell types selected from: macrophages, neutrophils, B cells, NK cells, etc. Cells, dendritic cells, bone marrow-derived dendritic cells, monocytes, osteoclasts, T cells, T helper cells, cytotoxic T cells, granulocytes, and microglia; increased expression of one or more anti-inflammatory cytokines, such as IL-4, IL-10, IL-13, IL-35, IL-16, TGF-β, IL-1Ra, G-CSF, and soluble receptors for TNF, IFN-β1a, IFN-β1b, or IL-6; regulated expression of one or more anti-inflammatory cytokines in one or more cell types selected from: macrophages, neutrophils, B cells, NK cells, dendritic cells, bone marrow cells, and microglia; increased expression of one or more anti-inflammatory cytokines, such as IL-4, IL-10, IL-13, IL-35, IL-16, TGF-β, IL-1Ra, G-CSF, and soluble receptors for TNF, IFN-β1a, IFN-β1b, or IL-6; and regulated expression of one or more anti-inflammatory cytokines in one or more cell types selected from: macrophages, neutrophils, B cells, NK cells, dendritic cells, bone marrow cells, and microglia. It targets dendritic cells, monocytes, osteoclasts, T cells, helper T cells, cytotoxic T cells, granulocytes, and microglia; regulates the expression of one or more proteins selected from the following: C1qa, C1qB, C1qC, C1s, C1R, C4, C2, C3, ITGB2, HMOX1, LAT2, CASP1, CSTA, VSIG4, MS4A4A, C3AR1, GPX1, TyroBP, ALOX5AP, ITGAM, SLC7A7, CD4, ITGAX, and PYCARD; and inhibits the phosphorylation of extracellular signal-regulated kinase (ERK).Reduce tyrosine phosphorylation on one or more cellular proteins, optionally one or more of which contain ZAP-70, and tyrosine phosphorylation occurs on Tyr-319 of ZAP-70; regulate expression of CC chemokine receptor 7 (CCR7); inhibit chemotaxis of microglia to CCL19-expressing and CCL21-expressing cells; reduce T cell proliferation induced by one or more of the following cell types: dendritic cells, bone marrow-derived dendritic cells, B cells, regulatory B cells, plasma cells, monocytes, microglia, M1 microglia, activated M1 microglia, M2 microglia, macrophages, neutrophils, NK cells, M1 macrophages, M1 neutrophils, M1 NK cells, activated M1 macrophages, activated M1 neutrophils, activated M1 NK cells, M2 macrophages, M2 neutrophils, and M2 NK cells; inhibit osteoclast production, reduce the rate of osteoclast formation, or both; reduce the survival rate of one or more of the following cell types: dendritic cells, bone marrow-derived dendritic cells, macrophages, neutrophils, NK cells, B cells, regulatory B cells, plasma cells, M1 macrophages, M1 neutrophils, M1 NK cells, activated M1 macrophages, activated M1 neutrophils, activated M1 NK cells, M2 macrophages, M2 neutrophils, M2 NK cells, monocytes, osteoclasts, T cells, T helper cells, cytotoxic T cells, granulocytes, neutrophils, microglia, M1 microglia, activated M1 microglia, and M2 microglia; reduce the proliferation of one or more of the following cell types: dendritic cells, bone marrow-derived dendritic cells, macrophages, neutrophils, NK cells, B cells, regulatory B cells, plasma cells, M1 macrophages, M1 neutrophils, M1 NK cells, activated M1 macrophages, activated M1 neutrophils, activated M1 NK cells, M2 macrophages, M2 neutrophils, M2 NK cells, monocytes, osteoclasts, T cells, T helper cells, cytotoxic T cells, granulocytes, neutrophils, microglia, M1 microglia, activated M1 microglia, and M2 microglia;Inhibit the migration of one or more of the following cell types: dendritic cells, bone marrow-derived dendritic cells, macrophages, neutrophils, NK cells, B cells, regulatory B cells, plasma cells, M1 macrophages, M1 neutrophils, M1 NK cells, activated M1 macrophages, activated M1 neutrophils, activated M1 NK cells, M2 macrophages, M2 neutrophils, M2 NK cells, monocytes, osteoclasts, T cells, T helper cells, cytotoxic T cells, granulocytes, neutrophils, microglia, M1 microglia, activated M1 microglia, and M2 microglia; Inhibit one or more functions of one or more of the following cell types: dendritic cells, bone marrow-derived dendritic cells, macrophages, neutrophils, NK cells, B cells, regulatory B cells, plasma cells, M1 macrophages, M1 neutrophils, M1 NK cells, activated M1 macrophages, activated M1 neutrophils, activated M1 NK cells, M2 macrophages, M2 neutrophils, M2 NK cells, monocytes, osteoclasts, T cells, T helper cells, cytotoxic T cells, granulocytes, neutrophils, microglia, M1 microglia, activated M1 microglia and M2 microglia; inhibiting the maturation of one or more of the following cell types: dendritic cells, bone marrow-derived dendritic cells, macrophages, neutrophils, NK cells, B cells, regulatory B cells, plasma cells, M1 macrophages, M1 neutrophils, M1 NK cells, activated M1 macrophages, activated M1 neutrophils, activated M1 NK cells, M2 macrophages, M2 neutrophils, M2 NK cells, monocytes, osteoclasts, T cells, T helper cells, cytotoxic T cells, granulocytes, neutrophils, microglia, M1 microglia, activated M1 microglia, and M2 microglia; inhibit clearance selected from one or more of the following types: apoptotic neuron clearance, neural tissue debris clearance, dysfunctional synapse clearance, non-neural tissue debris clearance, bacterial clearance, clearance of other foreign bodies, clearance of pathogenic proteins, clearance of pathogenic peptides, and clearance of tumor cells;The pathogenic proteins can be selected from amyloid-β, oligoamyloid-β, amyloid-β plaque, amyloid precursor protein or fragments thereof, Tau, IAPP, α-synuclein, TDP-43, FUS protein, C9orf72 (chromosome 9 open reading frame 72), c9RAN protein, prion protein, PrPSc, huntingtin protein, calcitonin, superoxide dismutase, ataxia protein, ataxia protein 1, ataxia protein 2, ataxia protein 3, ataxia protein 7, ataxia protein 8, ataxia protein 10, Lewy body, atrial natriuretic factor, pancreatic amyloid polypeptide, insulin, apolipoprotein AI, serum amyloid A, medin, prolactin, thyroxine transporter, lysozyme, β2-microglobulin, coagulant protein, corneal epithelial protein, cystatin, and immunoglobulins. The tumor cells are derived from cancers including: bladder cancer, brain cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, renal cell carcinoma, renal pelvis cancer, leukemia, lung cancer, melanoma, non-Hodgkin's lymphoma, pancreatic cancer, prostate cancer, ovarian cancer, fibrosarcoma, and thyroid cancer; and inhibit the phagocytic activity of one or more of apoptotic neurons, neural tissue debris, dysfunctional synapses, non-neural tissue debris, bacteria, other foreign bodies, pathogenic proteins, pathogenic peptides, pathogenic nucleic acids, or tumor cells.The pathogenic nucleic acid is selected from the antisense GGCCCC(G2C4) (SEQ ID NO:225) repeat amplified RNA. The pathogenic protein is selected from amyloid β, oligoamyloid β, amyloid β plaque, amyloid precursor protein or fragment thereof, Tau, IAPP, α-synuclein, TDP-43, FUS protein, C9orf72 (chromosome 9 open reading frame 72), c9RAN protein, prion protein, PrPSc, huntingtin protein, calcitonin, superoxide dismutase, ataxia protein, ataxia protein 1, ataxia protein 2, ataxia protein 3, ataxia protein 7, ataxia protein 8, ataxia protein 10, Lewy body, atrial natriuretic factor, pancreatic islet amyloid polypeptide, insulin, apolipoprotein AI, and blood The tumor cells contain amyloid A, medin, prolactin, thyroxine transporter, lysozyme, β2-microglobulin, coagulant, corneal epithelial protein, cystatin, immunoglobulin light chain AL, S-IBM protein, repeat-associated non-ATG (RAN) translation products, dipeptide repeat (DPR) peptide, glycine-alanine (GA) repeat peptide, glycine-proline (GP) repeat peptide, glycine-arginine (GR) repeat peptide, proline-alanine (PA) repeat peptide, ubiquitin, and proline-arginine (PR) repeat peptide, and the tumor cells are derived from cancers selected from the following: bladder cancer, brain cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, renal cell carcinoma, renal pelvis cancer, leukemia, and lung cancer. Melanoma, non-Hodgkin's lymphoma, pancreatic cancer, prostate cancer, ovarian cancer, fibrosarcoma, or thyroid cancer; binds to Siglec-5 ligands on tumor cells; binds to Siglec-5 ligands on cells selected from: neutrophils, dendritic cells, bone marrow-derived dendritic cells, monocytes, microglia, macrophages, and NK cells; inhibits the killing of tumor cells by one or more of microglia, macrophages, neutrophils, NK cells, dendritic cells, bone marrow-derived dendritic cells, neutrophils, B cells, regulatory B cells, plasma cells, T cells, T helper cells, or cytotoxic T cells; inhibits the killing of tumor cells by microglia, macrophages, neutrophils, and monocytes. Antitumor cell proliferation activity of one or more of the following: cells, NK cells, dendritic cells, bone marrow-derived dendritic cells, neutrophils, T cells, T helper cells, or cytotoxic T cells; inhibition of antitumor cell metastasis activity of one or more of the following: microglia, macrophages, neutrophils, NK cells, dendritic cells, bone marrow-derived dendritic cells, neutrophils, B cells, regulatory B cells, plasma cells, T cells, T helper cells, or cytotoxic T cells; inhibition of one or more receptors containing the ITAM motif, wherein one or more of the receptors containing the ITAM motif are selected from TREM1, TREM2, SIRPB1, FcgR, DAP10, and DAP12;Inhibit signaling via one or more pattern recognition receptors (PRRs), wherein one or more PRRs are optionally selected from receptors that recognize pathogen-associated molecular patterns (PAMPs), receptors that recognize damage-associated molecular patterns (DAMPs), and any combination thereof; inhibit one or more containing motifs D / Ex; 0-2 YxxL / IX 6-8Receptors of YxxL / I (SEQ ID NO:4); inhibition of signal transduction via one or more Toll-like receptors; inhibition of the JAK-STAT signaling pathway; inhibition of nuclear factor κ-light chain enhancer (NFκB) activating B cells; dephosphorylation of receptors containing the ITAM motif; regulation of the expression of one or more inflammatory receptor-complement cascade proteins and / or receptors expressed on immune cells, wherein one or more inflammatory receptor-complement cascade proteins and / or receptors expressed on immune cells include CD86, C1qa, C1qB, C1qC, C1s, C1R, C4, C2, C3, ITGB2, HMOX1, LAT2, CASP1, CSTA, VSIG4, MS4A4A, and C3AR1. GPX1, TyroBP, ALOX5AP, ITGAM, SLC7A7, CD4, ITGAX, and / or PYCARD, and one or more inflammatory receptor, complement cascade proteins, and / or receptors expressed on immune cells, expressed on microglia, macrophages, neutrophils, NK cells, dendritic cells, bone marrow-derived dendritic cells, neutrophils, B cells, regulatory B cells, plasma cells, T cells, T helper cells, or cytotoxic T cells; increased expression of one or more Siglec-5-dependent genes; normalization of disrupted Siglec-5-dependent gene expression; decreased expression of one or more ITAM-dependent genes, selected from these. One or more ITAM-dependent genes are activated by nuclear factors of activating T cell (NFAT) transcription factors; promoting or rescuing the function of one or more of the following: immunosuppressive dendritic cells, immunosuppressive macrophages, immunosuppressive neutrophils, immunosuppressive NK cells, myeloid-derived suppressor cells, tumor-associated macrophages, tumor-associated neutrophils, tumor-associated NK cells, regulatory B cells, and regulatory T cells; increasing the tumor-mediated transformation of one or more of these cells into the tumor. Infiltration; increasing the number of tumor-promoting myeloid / granulocyte immunosuppressive cells in tumors, peripheral blood, or other lymphoid organs; enhancing the tumor-promoting activity of myeloid-derived suppressor cells; increasing the expression of tumor-promoting cytokines in tumors or peripheral blood, optionally including VEGF, TGF-β, or IL-10; increasing tumor infiltration of tumor-promoting FoxP3+ regulatory T lymphocytes; enhancing the tumor-promoting activity of myeloid-derived suppressor cells (MDSCs); enhancing the tumor-promoting activity of regulatory B cells; enhancing the tumor-promoting activity of immunosuppressive neutrophils; reducing the activation of tumor-specific T lymphocytes with tumor-killing potential; reducing the infiltration of tumor-specific NK cells with tumor-killing potential.Reduces the tumor-killing potential of NK cells; decreases the infiltration of tumor-specific B lymphocytes with the potential to enhance immune responses; decreases the infiltration of tumor-specific T lymphocytes with the potential to kill tumors; increases tumor volume; increases tumor growth rate; increases metastasis; increases tumor recurrence rate; reduces the efficacy of one or more immunotherapies or one or more cancer vaccines that regulate anti-tumor T cell responses, wherein one or more of these immunotherapies are targeted at one or more of the following target proteins: PD1 / PDL1, CD40, OX40, ICOS, CD28, CD137 / 4- 1BB, CD27, GITR, PD-L1, CTLA4, PD-L2, PD-1, B7-H3, B7-H4, HVEM, LIGHT, BTLA, CD30, TIGIT, VISTA, KIR, GAL9, TIM1, TIM3, TIM4, A2AR, LAG3, DR-5, CD2, CD5, TREM1, TREM2, CD39, CD73, CSF-1 receptors and any combination thereof; inhibits PLCγ / PKC / calcium mobilization; and inhibits PI3K / Akt and Ras / MAPK signaling.
[0119] In some implementations, anti-Siglec-5 antibodies are used to treat cancer to: (i) directly or indirectly reduce the survival, proliferation, maturation, differentiation, and / or function of tumor-promoting myeloid / granulocytic immunosuppressive cells (MPMSCs) accumulated in tumors, peripheral blood, and lymphoid organs of cancer patients; (ii) reduce the number of MPMSCs in tumors, peripheral blood, and other lymphoid organs of cancer patients; (iii) block the tumor-promoting activity of myeloid-derived suppressor cells (MDSCs); (iv) reduce the number of tumor-promoting regulatory B cells in tumors, peripheral blood, and other lymphoid organs of cancer patients; (v) reduce the expression of tumor-promoting cytokines such as TGF-β and IL-10 in tumors and peripheral blood of cancer patients; (vi) reduce the infiltration of tumor-promoting FoxP3+ regulatory T lymphocytes in tumors; (vii) increase the infiltration and activation of T lymphocytes with tumor-killing potential; (viii) increase the infiltration of tumor-specific NK cells with tumor-killing potential; and (ix) increase the tumor-killing activity of NK cells. Potential: (x) Increase the infiltration of tumor-specific B lymphocytes with the potential to enhance immune responses; (xi) Reduce tumor volume; (xii) Reduce tumor growth rate; (xiii) Reduce and / or inhibit metastasis; (xiv) Reduce tumor recurrence rate; (xv) Increase the efficacy of immunotherapies that modulate anti-tumor T cell responses, such as PD1 / PDL1, CTLA4, CD40, OX40, ICOS, CD28, CD137 / 4-1BB, CD27, GITR, PD-L1, CTLA4, etc. Efficacy of PD-L2, PD-1, B7-H3, B7-H4, HVEM, LIGHT, BTLA, KIR, GAL9, CD2, CD5, CD39, CD73, CD30, TIGIT, VISTA, TIM1, TIM3, TIM4 and cancer vaccines; (xvi) inducing, activating or otherwise increasing PLCγ / PKC / calcium mobilization; and (xvii) inducing, activating or otherwise increasing PI3K / Akt, Ras / MAPK signaling.
[0120] Immunosuppressive cells are sometimes referred to as myeloid-derived suppressor cells (MDSCs). In humans, MDSCs can be defined by one of the following combinations of markers: (1) CD14 + HLA-DR 低 / - (2)CD14 + IL4Rα + (3)CD14 + HLA-DR - IL4Rα + (4)CD34 + CD14 + CD11b + Siglec-5+ ,(5)CD11b + CD14 + Siglec-5 + ,(6)Siglec-5 + HLA-DR - ,(7)Lin - HLA-DR - ,(8)Lin - HLA-DR - Siglec-5 + ,(9)Lin - HLA-DR - Siglec-5 + CD11b + ,(10)Lin - Siglec-5 + CD11b + CD15 + ,(11)Lin - HLA-DR - Siglec-5 + CD11b + CD14 - CD15 + ,(12)CD11b + CD14 - Siglec-5 + ,(13)CD11b + CD14 - HLA-DR - Siglec-5 + CD15 + ,(14)Siglec-5 + HLA-DR - CD15 + ,(15)CD15 + IL4Rα + ,(16)CD11b + CD15 + CD66b + ,(17)CD15 + FSC 低 SSC 高 ,(18)CD15 高 Siglec-5 + ,(19)CD11b + CD14 - CD15 + ,(20)CD66b + SSC 高, and (21)CD11b + CD15 + (See also Solito S et al., Annals of the NY Academy of Sciences, 2014). In mice, MDSCs can be generated by the surface marker CD45. + CD11b + Gr1 + and / or Il4Ra + The expression is used to define it. Another exemplary immunosuppressive monocyte lineage is CD45. + CD11b + Gr1 低 ; and CD45 + CD11c + .
[0121] This disclosure further relates to anti-Siglec-5 antibodies that bind to or interact with Siglec-5. In some embodiments, the anti-Siglec-5 antibody reduces the cell surface level of Siglec-5 and / or does not inhibit the interaction between Siglec-5 and one or more Siglec-5 ligands. In some embodiments, the anti-Siglec-5 antibody binds to human Siglec-5 but not to human Siglec-14. In some embodiments, the anti-Siglec-5 antibody binds to human Siglec-5 but not to cynomolgus monkey Siglec-5.
[0122] Siglec-5 protein
[0123] On one hand, this disclosure provides antibodies, such as isolated (e.g., monoclonal) antibodies, that interact with or otherwise bind to regions within the Siglec-5 protein of this disclosure. In some embodiments, the anti-Siglec-5 antibody of this disclosure binds to the Siglec-5 protein and, upon binding to the Siglec-5 protein, modulates one or more Siglec-5 activities, such as activities associated with Siglec-5 expression in cells. The Siglec-5 protein of this disclosure includes, but is not limited to, mammalian Siglec-5 protein, human Siglec-5 protein, mouse Siglec-5 protein, and rat Siglec-5 protein.
[0124] Siglec-5 is also known as Siglec-5 molecule, sialic acid-binding Ig-like lectin 5, CD170 antigen, CD170, OBBP2, CD33L2, and OB-BP2.
[0125] Siglec-5 is an immunoglobulin-like receptor primarily expressed on immune cells, including but not limited to macrophages, neutrophils, NK cells, B cells, dendritic cells, osteoclasts, monocytes, and microglia. In some embodiments, Siglec-5 forms a receptor-signaling complex with CD64. In some embodiments, Siglec-5 signaling leads to downstream inhibition of PI3K or other intracellular signals. On myeloid cells, such as in the context of an infection response, Toll-like receptor (TLR) signaling is important for inhibiting Siglec-5 activity. TLRs also play a crucial role in pathological inflammatory responses, such as those expressed on macrophages, neutrophils, NK cells, and dendritic cells.
[0126] Various Siglec-5 homologs are known, including but not limited to human Siglec-5, cynomolgus monkey Siglec-5, and mouse Siglec-5. The amino acid sequence of human Siglec-5 is shown below as SEQ ID NO:1:
[0127]
[0128] In some embodiments, Siglec-5 is a preprotein including a signaling sequence. In some embodiments, Siglec-5 is a mature protein. In some embodiments, the mature Siglec-5 protein does not include a signaling sequence. In some embodiments, the mature Siglec-5 protein is expressed on cells. In some embodiments, the mature Siglec-5 protein is expressed on the surface of cells such as human dendritic cells, human macrophages, human monocytes, human osteoclasts, human neutrophils, human B cells, human T cells, human helper T cells, human cytotoxic T cells, human granulocytes, and human microglia. Agents of this disclosure, such as the anti-Siglec-5 antibody of this disclosure, can bind to any Siglec-5 protein of this disclosure expressed on any cell disclosed herein.
[0129] The Siglec-5 protein disclosed herein, such as human Siglec-5, contains several domains, including but not limited to the signal sequence located at amino acid residues 1-16 of SEQ ID NO:1, the extracellular immunoglobulin-like variant (IgV) domain located at amino acid residues 19-136 of SEQ ID NO:1, two Ig-like C2 domains located at amino acid residues 146-229 and 236-330 of SEQ ID NO:1, the transmembrane domain located at amino acid residues 442-462 of SEQ ID NO:1, the ITIM motif 1 located at amino acid residues 518-523 of SEQ ID NO:1, and the SLAM-like motif located at amino acid residues 542-547 of SEQ ID NO:1. As those skilled in the art will understand, the start and end residues of the domains of this disclosure may vary depending on the computer modeling program used or the method used to determine the domains.
[0130] Some aspects of this disclosure provide anti-Siglec-5 antibodies that bind to human Siglec-5. Other aspects of this disclosure provide anti-Siglec-5 antibodies that bind to human Siglec-5 but not to cynomolgus monkey Siglec-5.
[0131] Therefore, as used herein, the “Siglec-5” protein of this disclosure includes, but is not limited to, mammalian Siglec-5 protein, human Siglec-5 protein, and primate Siglec-5 protein. Furthermore, the anti-Siglec-5 antibody of this disclosure can bind to epitopes within one or more of the mammalian Siglec-5 protein, human Siglec-5 protein, and primate Siglec-5 protein. In some embodiments, the anti-Siglec-5 antibody of this disclosure can specifically bind to human Siglec-5 protein.
[0132] In some embodiments, the disclosed anti-Siglec-5 antibodies that reduce cellular levels of Siglec-5 can bind to Siglec-5 in a pH-dependent manner. In some embodiments, the disclosed anti-Siglec-5 antibodies can bind to Siglec-5 at neutral pH and be internalized without dissociating from the Siglec-5 protein. Alternatively, at acidic pH, the disclosed anti-Siglec-5 antibodies, once internalized, can dissociate from Siglec-5 and then degrade via an endosome / lysosome pathway. In some embodiments, the disclosed anti-Siglec-5 antibodies bind to Siglec-5 at pH values ranging from 5.5 to 8.0, 5.5 to 7.5, 5.5 to 7.0, 5.5 to 6.5, 5.5 to 6.0, 6.0 to 8.0, 6.5 to 8.0, 7.0 to 8.0, 7.5 to 8.0, 6.0 to 7.5, 6.0 to 7.0, and 6.5 to 7.5. In some embodiments, the anti-Siglec-5 antibody dissociates from Siglec-5 at pH values less than 6.0, less than 5.5, less than 5.0, less than 4.5, less than 4.0, less than 3.5, less than 3.0, less than 2.5, or less than 2.0.
[0133] In some embodiments, the anti-Siglec-5 antibody of this disclosure (such as the anti-Siglec-5 antibody of this disclosure) that reduces or does not inhibit the interaction between Siglec-5 and one or more Siglec-5 ligands or binds to or interacts with Siglec-5 binds to the wild-type Siglec-5 protein of this disclosure, its naturally occurring variants and / or its disease variants.
[0134] In some embodiments, the presently disclosed anti-Siglec-5 antibody, which reduces cellular levels of Siglec-5 and / or does not inhibit the interaction between Siglec-5 and one or more Siglec-5 ligands, binds to a variant of human Siglec-5. In some embodiments, the presently disclosed anti-Siglec-5 antibody, which reduces cellular levels of Siglec-5 and / or does not inhibit the interaction between Siglec-5 and one or more Siglec-5 ligands, does not bind to human Siglec-14. In some embodiments, the presently disclosed anti-Siglec-5 antibody, which reduces cellular levels of Siglec-5 and / or does not inhibit the interaction between Siglec-5 and one or more Siglec-5 ligands, does not bind to cynomolgus monkey Siglec-5.
[0135] In some embodiments, the anti-Siglec-5 antibody of this disclosure, which reduces cellular levels of Siglec-5, binds to the Siglec-5 protein expressed on the surface of cells, including but not limited to human dendritic cells, human macrophages, human NK cells, human monocytes, human osteoclasts, human neutrophils, human B cells, human T cells, human T helper cells, human cytotoxic T cells, human granulocytes, and human microglia. In some embodiments, the anti-Siglec-5 antibody of this disclosure, which reduces cellular levels of Siglec-5, binds to the Siglec-5 protein expressed on the surface of cells and, upon binding to the surface-expressed Siglec-5 protein, modulates (e.g., induces or inhibits) at least one of the Siglec-5 activities of this disclosure. In some embodiments of this disclosure, the anti-Siglec-5 antibody specifically binds to the Siglec-5 protein.
[0136] Siglec-5 ligand
[0137] Exemplary Siglec-5 ligands include, but are not limited to, sialic acid, sialic acid-containing glycolipids, sialic acid-containing glycoproteins, glycolipids containing α-2,8-diasialic acid groups, branched α-2,6-linked sialic acid glycoproteins, terminal α-2,6-linked sialic acid glycolipids, terminal α-2,3-linked sialic acid glycoproteins, disialic gangliosides (e.g., gangliosides or glycolipids containing ceramides linked to sialylated glycans), secreted mucins, and Siglec-5 ligands expressed on erythrocytes. Siglec-5 ligand expressed on bacterial cells, apoptotic cells, nerve cells, glial cells, microglia, astrocytes, tumor cells, viruses, and dendritic cells. Siglec-5 ligand, Siglec-5 ligand binding to β-amyloid plaques, Siglec-5 ligand binding to Tau tangles, Siglec-5 ligand on pathogenic proteins, Siglec-5 ligand on pathogenic peptides, Siglec-5 ligand expressed on macrophages, Siglec-5 ligand expressed on neutrophils, Siglec-5 ligand expressed on natural killer cells, Siglec-5 ligand expressed on monocytes, and Siglec-5 ligand expressed on T cells. Siglec-5 ligand, Siglec-5 ligand expressed on T helper cells, Siglec-5 ligand expressed on cytotoxic T cells, Siglec-5 ligand expressed on B cells, Siglec-5 ligand expressed on tumor-embedded immunosuppressive dendritic cells, Siglec-5 ligand expressed on tumor-embedded immunosuppressive macrophages, Siglec-5 ligand expressed on myeloid-derived suppressor cells, and Siglec-5 ligand expressed on regulatory T cells. In some embodiments, the Siglec-5 ligand disclosed herein is a ganglioside (e.g., disialic acid ganglioside). Disialic acid gangliosides typically share a common lactoceramide core and one or more sialic acid residues.
[0138] Table A lists further examples of suitable ganglioside (e.g., disialotylganglioside) ligands. Generally, gangliosides (e.g., disialotylgangliosides) are molecules composed of glycosphingolipids linked to one or more sialic acids (e.g., n-acetyl-neuraminic acid, NANA) on a sugar chain.
[0139] Table A: Structure of exemplary ganglioside Siglec-5 ligands
[0140] Anti-Siglec-5 antibody
[0141] Certain aspects of this disclosure relate to anti-Siglec-5 antibodies that reduce cellular levels of Siglec-5. In some embodiments, the anti-Siglec-5 antibodies of this disclosure reduce cellular levels of Siglec-5. In some embodiments, the anti-Siglec-5 antibodies of this disclosure may have one or more activities attributable at least in part to the ability of the anti-Siglec-5 antibodies to reduce cellular expression (e.g., cell surface expression) of Siglec-5 by inducing degradation, downregulation, cleavage, receptor desensitization, and / or lysosomal targeting of Siglec-5. In some embodiments, the anti-Siglec-5 antibodies reduce or decrease cell surface levels of Siglec-5 in vitro. In some embodiments, the anti-Siglec-5 antibodies of this disclosure reduce or decrease cell surface levels of Siglec-5 in vivo. In some embodiments, the anti-Siglec-5 antibodies of this disclosure reduce or decrease cell surface levels of Siglec-5 in cells expressing recombinant human Siglec-5 (e.g., CHO cells). In some embodiments, the anti-Siglec-5 antibody of this disclosure reduces or decreases the cell surface level of Siglec-5 in immune cells, including, for example, primary immune cells (e.g., B cells). In some embodiments, the anti-Siglec-5 antibody of this disclosure reduces or decreases the cell surface level of Siglec-5 in macrophages (e.g., human macrophages). In some embodiments, the anti-Siglec-5 antibody of this disclosure reduces or decreases the cell surface level of Siglec-5 in polarized macrophages (e.g., polarized human macrophages). In some embodiments, the anti-Siglec-5 antibody of this disclosure reduces or decreases the cell surface level of Siglec-5 in M0 macrophages, M1 macrophages, and / or M2a macrophages.
[0142] In some embodiments, the anti-Siglec-5 antibody of this disclosure does not inhibit the interaction (e.g., binding) between Siglec-5 and one or more Siglec-5 ligands. In some embodiments, the anti-Siglec-5 antibody of this disclosure reduces the cellular level of Siglec-5 and does not inhibit the interaction (e.g., binding) between Siglec-5 and one or more Siglec-5 ligands. Other aspects of this disclosure relate to anti-Siglec-5 antibodies that induce reactive oxygen species (ROS) production in neutrophils and / or induce neutrophil extracellular trap (NET) formation in neutrophils. Other aspects of this disclosure relate to anti-Siglec-5 antibodies that reduce or decrease reactive oxygen species (ROS) production in neutrophils and / or reduce or decrease neutrophil extracellular trap (NET) formation in neutrophils.
[0143] As disclosed herein, Siglec-5 can be constitutively recycled on cells, and therefore any agent (e.g., antibody) that binds to Siglec-5 on the cell surface can be recycled into the cell (e.g., endocytosis). However, such endocytosis may not result in a decrease in the cellular level of Siglec-5 (e.g., cell surface level). Although it has been shown that acute myeloid leukemia (AML) cells can mediate the endocytosis of anti-Siglec-5 antibodies that bind to surface-expressed Siglec-5, a decrease in the cellular level of Siglec-5 has not been shown. Therefore, certain aspects of this disclosure involve anti-Siglec-5 antibodies that not only bind to Siglec-5 expressed on the cell surface but also reduce the cellular level of Siglec-5. In some embodiments, the anti-Siglec-5 antibody of this disclosure binds to Siglec-5 expressed on the cell surface and is further endocytosed into the cell. In some embodiments, the anti-Siglec-5 antibody of this disclosure binds to Siglec-5 expressed on the cell surface without being endocytosed into the cell.
[0144] The cellular level of Siglec-5 can refer to, but is not limited to, the cell surface level of Siglec-5, the intracellular level of Siglec-5, and the total level of Siglec-5. In some embodiments, a decrease in the cellular level of Siglec-5 includes a decrease in the cell surface level of Siglec-5. As used herein, the cell surface level of Siglec-5 is measured by any cell-based in vitro assay or suitable in vivo model known herein or in the art, such as using flow cytometry like fluorescence activated cell sorting (FACS), and if an anti-Siglec-5 antibody induces a decrease in the cell surface level of Siglec-5 of 20% or more, then it reduces the cell surface level of Siglec-5. In some embodiments, a decrease in the cellular level of Siglec-5 includes a decrease in the intracellular level of Siglec-5. As used herein, if an anti-Siglec-5 antibody induces a 20% or greater reduction in the intracellular level of Siglec-5 by any cell-based in vitro assay or suitable in vivo model assay known herein or in the art, such as immunostaining, Western blot analysis, co-immunoprecipitation, and cytometry, then it reduces the intracellular level of Siglec-5. In some embodiments, the reduction in the cellular level of Siglec-5 includes a reduction in the total level of Siglec-5. As used herein, if an anti-Siglec-5 antibody induces a 20% or greater reduction in the total level of Siglec-5 by any cell-based in vitro assay or suitable in vivo model assay known herein or in the art, such as immunostaining, Western blot analysis, co-immunoprecipitation, and cytometry, then it reduces the total level of Siglec-5. In some embodiments, the anti-Siglec-5 antibody induces Siglec-5 degradation, Siglec-5 cleavage, Siglec-5 internalization, Siglec-5 shedding, and / or downregulation of Siglec-5 expression. In some implementations, in vitro cell assays are used to measure the cellular levels of Siglec-5 in primary cells (e.g., dendritic cells, bone marrow-derived dendritic cells, monocytes, microglia, and macrophages) or cell lines.
[0145] In some embodiments, compared to Siglec-5 cellular levels in the absence of anti-Siglec-5 antibodies, the anti-Siglec-5 antibodies of this disclosure reduce Siglec-5 cellular levels by at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, and at least 53%. At least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more.
[0146] Any cell-based in vitro assay or suitable in vivo model described herein or known in the art can be used to measure the inhibition of the interaction (e.g., binding) between Siglec-5 and one or more Siglec-5 ligands. In some embodiments, the anti-Siglec-5 antibody of this disclosure binds to Siglec-5 and does not inhibit the interaction (e.g., binding) between Siglec-5 and one or more Siglec-5 ligands.
[0147] As used herein, using any in vitro assay or cell culture-based assay known in the art or described herein, if an anti-Siglec-5 antibody at a saturated antibody concentration reduces binding to Siglec-5 ligands by less than 20%, it does not inhibit the interaction (e.g., binding) between Siglec-5 and one or more Siglec-5 ligands. In some embodiments, using any in vitro assay or cell culture-based assay known in the art or described herein, the anti-Siglec-5 antibody of this disclosure at a saturated antibody concentration inhibits the interaction (e.g., binding) between Siglec-5 and one or more Siglec-5 ligands by less than 20%, less than 19%, less than 18%, less than 17%, less than 16%, less than 15%, less than 14%, less than 13%, less than 12%, less than 11%, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1%.
[0148] As used herein, Siglec-5 level can refer to the expression level of the gene encoding Siglec-5; the expression level of one or more transcripts encoding Siglec-5; the expression level of Siglec-5 protein; and / or the amount of Siglec-5 protein present intracellularly and / or on the cell surface. Any method known in the art for measuring levels of gene expression, transcription, translation, and / or protein abundance or localization can be used to determine Siglec-5 level.
[0149] In addition, the anti-Siglec-5 antibody disclosed herein can be used for the prevention, risk reduction, or treatment of dementia, frontotemporal dementia, Alzheimer's disease, vascular dementia, mixed dementia, tau proteinosis, infection, and / or cancer. In some embodiments, the anti-Siglec-5 antibody disclosed herein can be used to induce or promote the survival, maturation, function, migration, or proliferation of one or more immune cells in individuals in need; or to reduce the activity, function, or survival of regulatory B cells, regulatory T cells, tumor-embedded immunosuppressive dendritic cells, tumor-embedded immunosuppressive macrophages, immunosuppressive neutrophils, myeloid-derived suppressor cells, tumor-associated macrophages, acute myeloid leukemia (AML) cells, chronic lymphocytic leukemia (CLL) cells, and / or chronic myeloid leukemia (CML) cells in individuals in need. In some embodiments, the anti-Siglec-5 antibody disclosed herein is a monoclonal antibody.
[0150] In some embodiments, the isolated anti-Siglec-5 antibody of this disclosure reduces cellular levels of Siglec-5 (e.g., cell surface levels, intracellular levels, and / or total levels). In some embodiments, the isolated anti-Siglec-5 antibody of this disclosure induces downregulation of Siglec-5. In some embodiments, the isolated anti-Siglec-5 antibody of this disclosure induces cleavage of Siglec-5. In some embodiments, the isolated anti-Siglec-5 antibody of this disclosure induces internalization of Siglec-5. In some embodiments, the isolated anti-Siglec-5 antibody of this disclosure induces detachment of Siglec-5. In some embodiments, the isolated anti-Siglec-5 antibody of this disclosure induces degradation of Siglec-5. In some embodiments, the isolated anti-Siglec-5 antibody of this disclosure induces desensitization of Siglec-5. In some embodiments, the isolated anti-Siglec-5 antibody of this disclosure acts as a ligand mimic that transiently activates Siglec-5. In some embodiments, the isolated anti-Siglec-5 antibody of this disclosure acts as a ligand mimic and transiently activates Siglec-5 prior to inducing a decrease in cellular levels of Siglec-5. In some embodiments, the isolated anti-Siglec-5 antibody of this disclosure acts as a ligand mimic and transiently activates Siglec-5 prior to inducing degradation of Siglec-5. In some embodiments, the isolated anti-Siglec-5 antibody of this disclosure acts as a ligand mimic and transiently activates Siglec-5 prior to inducing cleavage of Siglec-5. In some embodiments, the isolated anti-Siglec-5 antibody of this disclosure acts as a ligand mimic and transiently activates Siglec-5 prior to inducing internalization of Siglec-5. In some embodiments, the isolated anti-Siglec-5 antibody of this disclosure acts as a ligand mimic and transiently activates Siglec-5 prior to inducing detachment of Siglec-5. In some embodiments, the isolated anti-Siglec-5 antibody of this disclosure acts as a ligand mimic and transiently activates Siglec-5 prior to inducing downregulation of Siglec-5 expression.
[0151] In some embodiments, anti-Siglec-5 antibodies that reduce cellular levels of Siglec-5 and / or do not inhibit the interaction between Siglec-5 and one or more Siglec-5 ligands are anti-Siglec-5 antibodies that bind to or physically interact with Siglec-5. Anti-Siglec-5 antibodies may have nanomolar or even picomolar affinity for the target antigen (e.g., Siglec-5). In some embodiments, the Kd of the antibody is from about 10 pM to about 100 nM. The Kd values of the antibodies are approximately 100 nM, 50 nM, 10 nM, 1 nM, 900 pM, 800 pM, 790 pM, 780 pM, 770 pM, 760 pM, 750 pM, 740 pM, 730 pM, 720 pM, 710 pM, 700 pM, 650 pM, 600 pM, 590 pM, 580 pM, 570 pM, 560 pM, 550 pM, 540 pM, 530 pM, 520 pM, 510 pM, 500 pM, 450 pM, 400 pM, and so on. The amounts are approximately 350 pM, 300 pM, 290 pM, 280 pM, 270 pM, 260 pM, 250 pM, 240 pM, 230 pM, 220 pM, 210 pM, 200 pM, 150 pM, 100 pM, 50 pM, 40 pM, 30 pM, 20 pM, or 15 pM, up to approximately 1 pM, 2 pM, 3 pM, 4 pM, 5 pM, 6 pM, 7 pM, 8 pM, 9 pM, 10 pM, 11 pM, 12 pM, 13 pM, or 14 pM. This document describes methods for preparing and selecting antibodies that specifically interact with and / or bind to Siglec-5.
[0152] In some embodiments, the isolated anti-Siglec-5 antibody of this disclosure is a mouse antibody. In some embodiments, the isolated anti-Siglec-5 antibody of this disclosure is a human antibody, a humanized antibody, a bispecific antibody, a monoclonal antibody, a multivalent antibody, or a chimeric antibody. Exemplary descriptions of such antibodies are found throughout this disclosure.
[0153] In some embodiments, the anti-Siglec-5 antibody of this disclosure binds to human Siglec-5. In some embodiments, the anti-Siglec-5 antibody of this disclosure specifically binds to human Siglec-5. In some embodiments, the anti-Siglec-5 antibody of this disclosure binds to Siglec-5 but not to Siglec-14. In some embodiments, the anti-Siglec-5 antibody of this disclosure binds to human Siglec-5 but not to human Siglec-14. In some embodiments, the anti-Siglec-5 antibody of this disclosure binds to human Siglec-5 but not to cynomolgus monkey Siglec-5. In some embodiments, the anti-Siglec-5 antibody of this disclosure does not block ligand binding to Siglec-5.
[0154] In some embodiments, the anti-Siglec-5 antibody of this disclosure induces or increases the production of reactive oxygen species (ROS) in cells. In some embodiments, the anti-Siglec-5 antibody of this disclosure induces or increases the production of reactive oxygen species (ROS) in cells in vitro. In some embodiments, the anti-Siglec-5 antibody of this disclosure induces or increases the production of reactive oxygen species (ROS) in cells in vivo. In some embodiments, the anti-Siglec-5 antibody of this disclosure induces or increases the production of reactive oxygen species (ROS) in neutrophils, primary neutrophils, human neutrophils, and / or primary human neutrophils.
[0155] In some embodiments, the anti-Siglec-5 antibody of this disclosure reduces the production of reactive oxygen species (ROS) in cells. In some embodiments, the anti-Siglec-5 antibody of this disclosure reduces the production of reactive oxygen species (ROS) in cells in vitro. In some embodiments, the anti-Siglec-5 antibody of this disclosure reduces the production of reactive oxygen species (ROS) in cells in vivo. In some embodiments, the anti-Siglec-5 antibody of this disclosure reduces the production of reactive oxygen species (ROS) in neutrophils, primary neutrophils, human neutrophils, and / or primary human neutrophils.
[0156] In some embodiments, the anti-Siglec-5 antibody of this disclosure induces or increases the production or formation of neutrophil extracellular traps (NETs) in cells. In some embodiments, the anti-Siglec-5 antibody of this disclosure induces or increases the production or formation of neutrophil extracellular traps (NETs) in cells in vitro. In some embodiments, the anti-Siglec-5 antibody of this disclosure induces or increases the production or formation of neutrophil extracellular traps (NETs) in cells in vivo. In some embodiments, the anti-Siglec-5 antibody of this disclosure induces or increases the production or formation of neutrophil extracellular traps (NETs) in neutrophils, primary neutrophils, human neutrophils, and / or primary human neutrophils.
[0157] In some embodiments, the anti-Siglec-5 antibody of this disclosure reduces the production or formation of neutrophil extracellular traps (NETs) in cells. In some embodiments, the anti-Siglec-5 antibody of this disclosure reduces the production or formation of neutrophil extracellular traps (NETs) in cells in vitro. In some embodiments, the anti-Siglec-5 antibody of this disclosure reduces the production or formation of neutrophil extracellular traps (NETs) in cells in vivo. In some embodiments, the anti-Siglec-5 antibody of this disclosure reduces the production or formation of neutrophil extracellular traps (NETs) in neutrophils, primary neutrophils, human neutrophils, and / or primary human neutrophils.
[0158] In some embodiments, the anti-Siglec-5 antibody of this disclosure increases the expression of CD86 in myeloid-derived suppressor cells. In some embodiments, the anti-Siglec-5 antibody of this disclosure increases the expression of CCL4 in myeloid-derived suppressor cells.
[0159] In some embodiments, the anti-Siglec-5 antibody of this disclosure induces or enhances the phagocytic activity of macrophages. In some embodiments, the anti-Siglec-5 antibody of this disclosure induces or enhances the phagocytic activity of human macrophages. In some embodiments, the anti-Siglec-5 antibody of this disclosure induces or enhances the phagocytic activity of primary human macrophages. In some embodiments, the anti-Siglec-5 antibody of this disclosure induces or enhances the phagocytic activity of M0 macrophages, M1 macrophages, and / or M2a macrophages. In some embodiments, the anti-Siglec-5 antibody of this disclosure induces or enhances the phagocytic activity of macrophages in vitro. In some embodiments, the anti-Siglec-5 antibody of this disclosure induces or enhances the phagocytic activity of macrophages in vivo.
[0160] In some embodiments, the anti-Siglec-5 antibody of this disclosure is an agonist or antagonist antibody that binds to the Siglec-5 protein of this disclosure expressed on the surface of cells and modulates (e.g., induces or inhibits) one or more Siglec-5 activities of this disclosure upon binding to the surface-expressed Siglec-5 protein. In some embodiments, the anti-Siglec-5 antibody of this disclosure is an inert antibody.
[0161] Measurement
[0162] Anti-Siglec-5 antibodies that reduce cellular levels of Siglec-5 can be identified and / or characterized using methods well-known in the art, such as radiolabeled inhibitor assays, optical assays, protein binding assays, biochemical screening assays, immunoassays, mass displacement measurements, fluorescence assays, and / or fluorogenic peptide cleavage assays.
[0163] Combined with other measurements
[0164] In some embodiments, anti-Siglec-5 antibodies that bind to Siglec-5 and reduce cellular levels of Siglec-5 can be identified using techniques well known in the art for detecting the presence of interaction between the candidate anti-Siglec-5 antibody and Siglec-5 and / or binding affinity to Siglec-5.
[0165] In some embodiments, an inhibitor assay of radiolabeled material can be used to confirm the presence of anti-Siglec-5 antibodies that interact with Siglec-5. For example, a known amount of radiolabeled candidate material can be incubated with a known amount of immobilized Siglec-5 and a buffer. Subsequently, the immobilized Siglec-5 can be washed with the buffer, and the remaining presence of radiolabeled candidate anti-Siglec-5 antibodies in the immobilized Siglec-5 can be measured using techniques known in the art, such as a gamma counter. The measurement result indicating the presence of the radiolabeled material indicates that the radiolabeled candidate antibody is capable of interacting with and / or binding to Siglec-5.
[0166] In some implementations, optical techniques may be employed to identify antibodies that interact with Siglec-5. Exemplary optical techniques for detecting Siglec-5 antibodies may include, for example, attaching Siglec-5 to a colorimetric resonance graft surface, thereby shifting the wavelength of reflected light due to a change in the optical path the light must travel, and subsequently measuring further changes in the wavelength of the reflected light when the candidate is allowed to interact with Siglec-5. For example, no change in the measured wavelength of the reflected light when the candidate is incubated with Siglec-5 may indicate that the candidate does not interact with Siglec-5. A change in the measured wavelength of the reflected light when the candidate is incubated with Siglec-5 may indicate that the candidate antibody is able to bind to and / or interact with Siglec5.
[0167] In some embodiments, a protein binding assay may be used to identify antibodies interacting with Siglec-5. An exemplary protein binding assay for detecting Siglec-5 antibodies may include, for example, co-immunoprecipitation of Siglec-5 in the presence of a candidate antibody. For example, Siglec-5 may be incubated with the candidate antibody in a buffer, and then, during a washing procedure known in the art, Siglec-5 may be captured using an immobilized molecule specific for capturing Siglec-5, such as an anti-Siglec-5 antibody, in the presence of the candidate antibody, and potentially bound to the interacting candidate antibody. Subsequently, Siglec-5 may be potentially released along with the interacting candidate antibody, and the presence of the candidate antibody may be detected based on its properties using techniques such as mass spectrometry and / or Western blotting.
[0168] In some embodiments, biochemical and / or immunoassays well known in the art can be used to identify antibodies that interact with Siglec-5. Exemplary techniques may include, for example, assays that quantitatively measure changes in Siglec-5 concentration and / or protein half-life using techniques such as Western blotting, immunostaining, and co-immunoprecipitation. For example, a candidate antibody may be incubated with a sample containing Siglec-5, such as cells expressing Siglec-5, and then the amount and / or cellular level of Siglec-5 can be measured at time points during a time-course study. Changes in protein amount, cellular level, and / or protein half-life compared to a control treatment may indicate that the candidate Siglec-5 antibody can alter the Siglec-5 half-life and / or activity.
[0169] In some embodiments, mass displacement measurement assays can be used to confirm antibodies interacting with Siglec-5. Exemplary mass displacement measurement assays may include, for example, detecting the presence of strongly and / or covalently bound Siglec-5 antibodies by measuring changes in the mass of Siglec-5 using an instrument such as, but not limited to, a mass spectrometer, when a candidate antibody interacts with Siglec-5. For example, depending on the nature of the candidate antibody interaction, mass displacement measurements may be performed on whole-protein and / or peptide-based analyses. Detecting a mass displacement associated with the addition of the candidate antibody to Siglec-5 may indicate that the candidate antibody is capable of interacting with Siglec-5 or otherwise inhibiting Siglec-5. Additionally, exemplary mass displacement measurement assays may include, for example, detecting the mass addition to Siglec-5 associated with the mass of the corresponding candidate antibody when a candidate antibody interacts with Siglec-5 using techniques such as surface plasmon resonance. For example, changes in the refractive index of light may be measured and correlated with changes in the mass of Siglec-5 attached to a sensor surface.
[0170] In some embodiments, chemical crosslinking assays can be used to identify Siglec-5 antibodies that interact with Siglec-5. For example, a candidate antibody can be incubated with Siglec-5 in vivo or in vitro, wherein a molecular crosslinking agent is capable of covalently linking the candidate antibody interacting with Siglec-5 to the Siglec-5 molecule. Subsequently, techniques such as, but not limited to, mass spectrometry and / or Western blotting can be used to identify candidate antibodies that can interact with or otherwise inhibit Siglec-5. For example, the detection of Siglec-5 covalently crosslinked with a candidate antibody may indicate that the candidate antibody can interact with or otherwise inhibit Siglec-5.
[0171] In some embodiments, fluorescence assays can be used to confirm antibodies interacting with Siglec-5. For example, a known amount of candidate fluorescent antibody can be incubated together with a known amount of immobilized Siglec-5 and a buffer. Subsequently, the immobilized Siglec-5 can be washed with the buffer, and the remaining presence of candidate fluorescent Siglec-5 antibody in the immobilized Siglec-5 can be measured using techniques known in the art, such as, but not limited to, fluorescence detection. Measurements indicating the presence of a fluorescent substance can indicate that the candidate fluorescent antibody is capable of interacting with and / or binding to Siglec-5.
[0172] The assay described above for identifying antibodies of this disclosure that interact with or bind to Siglec-5 can also be used to identify anti-Siglec-5 antibodies that do not interact with or bind to Siglec-14.
[0173] Activity assay
[0174] Assays known in the art and / or described herein can be used to confirm and test the biological activity of the Siglec-5 antibodies of this disclosure. In some embodiments, an assay is provided for testing the ability of the Siglec-5 antibody to modulate one or more Siglec-5 activities.
[0175] Anti-Siglec-5 antibody binding region
[0176] Certain aspects of this disclosure provide an anti-Siglec-5 antibody that binds to one or more amino acids within amino acid residues 17-441, 19-360, 19-330, 19-229, 19-136, 146-229, or 236-330 of human Siglec-5 (SEQ ID NO:1), or on amino acid residues of a homolog or ortholog of SEQ ID NO:1. In some embodiments, the anti-Siglec-5 antibody binds to one or more amino acids within amino acid residues 63-71 of human Siglec-5 (SEQ ID NO:1), or on amino acid residues of a Siglec-5 homolog or ortholog of SEQ ID NO:1. In some embodiments, the anti-Siglec-5 antibody binds to one or more amino acids within amino acid residues 63-71, 83-92, and 125-132 of human Siglec-5 (SEQ ID NO:1), or to amino acid residues on a Siglec-5 homolog or ortholog corresponding to amino acid residues 63-71, 83-92, and 125-132 of SEQ ID NO:1. In some embodiments, the anti-Siglec-5 antibody binds to one or more amino acids within amino acid residues 65-71 of human Siglec-5 (SEQ ID NO:1), or to amino acid residues on a Siglec-5 homolog or ortholog corresponding to amino acid residues 65-71 of SEQ ID NO:1. In some embodiments, the anti-Siglec-5 antibody binds to one or more amino acids within amino acid residues 65-71 and 81-87 of human Siglec-5 (SEQ ID NO:1), or to amino acid residues on a Siglec-5 homolog or ortholog corresponding to amino acid residues 65-71 and 81-87 of SEQ ID NO:1. In some embodiments, the anti-Siglec-5 antibody binds to one or more amino acids within amino acid residues 65-71, 77-84, and 119-127 of human Siglec-5 (SEQ ID NO:1), or to amino acid residues on a Siglec-5 homolog or ortholog corresponding to amino acid residues 65-71, 77-84, and 119-127 of SEQ ID NO:1. In some embodiments, the anti-Siglec-5 antibody binds to one or more amino acids within amino acid residues 65-73 of human Siglec-5 (SEQ ID NO:1) or on an amino acid homolog or ortholog of Siglec-5 corresponding to amino acid residues 65-73 of SEQ ID NO:1.In some embodiments, the anti-Siglec-5 antibody binds to one or more amino acids within amino acid residues 77-84 of human Siglec-5 (SEQ ID NO:1) or on amino acid residues of a Siglec-5 homolog or ortholog corresponding to amino acid residues 77-84 of SEQ ID NO:1. In some embodiments, the anti-Siglec-5 antibody binds to one or more amino acids within amino acid residues 81-87 of human Siglec-5 (SEQ ID NO:1) or on amino acid residues of a Siglec-5 homolog or ortholog corresponding to amino acid residues 81-87 of SEQ ID NO:1. In some embodiments, the anti-Siglec-5 antibody binds to one or more amino acids within amino acid residues 83-92 of human Siglec-5 (SEQ ID NO:1) or on amino acid residues of a Siglec-5 homolog or ortholog corresponding to amino acid residues 83-92 of SEQ ID NO:1. In some embodiments, the anti-Siglec-5 antibody binds to one or more amino acids within amino acid residues 119-127 of human Siglec-5 (SEQ ID NO:1) or to amino acid residues on a Siglec-5 homolog or ortholog corresponding to amino acid residues 119-127 of SEQ ID NO:1. In some embodiments, the anti-Siglec-5 antibody binds to one or more amino acids within amino acid residues 125-132 of human Siglec-5 (SEQ ID NO:1) or to amino acid residues on a Siglec-5 homolog or ortholog corresponding to amino acid residues 125-132 of SEQ ID NO:1. In some embodiments, the anti-Siglec-5 antibody binds to one or more amino acids within amino acid residues 352-358 of human Siglec-5 (SEQ ID NO:1) or to amino acid residues on a Siglec-5 homolog or ortholog corresponding to amino acid residues 352-358 of SEQ ID NO:1.
[0177] Certain aspects of this disclosure provide an anti-Siglec-5 antibody that binds to one or more amino acids within amino acid residues 268-278, 226-244, or 228-238 of human Siglec-5 (SEQ ID NO:1), or on an amino acid protein, homolog, or ortholog corresponding to amino acid residues 268-278, 226-244, or 228-238 of SEQ ID NO:1. In some embodiments, the anti-Siglec-5 antibody binds to one or more amino acids within amino acid residues 268-278 of human Siglec-5 (SEQ ID NO:1), or on an amino acid protein, homolog, or ortholog corresponding to amino acid residues 268-278 of SEQ ID NO:1. In some embodiments, the anti-Siglec-5 antibody binds to one or more residues within the amino acid sequence LSWFQGSPALN (SEQ ID NO:221). In some embodiments, the anti-Siglec-5 antibody binds to one or more amino acid residues within amino acid residues 226-244 of human Siglec-5 (SEQ ID NO:1) or on the Siglec-5 protein, homolog, or ortholog corresponding to amino acid residues 226-244 of SEQ ID NO:1. In some embodiments, the anti-Siglec-5 antibody binds to one or more amino acid residues within the amino acid sequence QTITIFRNGIALEILQNTS (SEQ ID NO:220). In some embodiments, the anti-Siglec-5 antibody binds to one or more amino acid residues within amino acid residues 228-238 of human Siglec-5 (SEQ ID NO:1) or on the Siglec-5 protein, homolog, or ortholog corresponding to amino acid residues 228-238 of SEQ ID NO:1. In some embodiments, the anti-Siglec-5 antibody binds to one or more amino acid residues within the amino acid sequence ITIFRNGIALE (SEQ ID NO:219).
[0178] In some embodiments, the anti-Siglec-5 antibody of this disclosure can bind to a conformational epitope. In some embodiments, the anti-Siglec-5 antibody of this disclosure can bind to discontinuous Siglec-5 epitopes. In some embodiments, the discontinuous Siglec-5 epitopes may have two or more peptides, three or more peptides, four or more peptides, five or more peptides, six or more peptides, seven or more peptides, eight or more peptides, nine or more peptides, or ten or more peptides. As disclosed herein, the Siglec-5 epitope may comprise one or more peptides comprising five or more, six or more, seven or more, eight or more, nine or more, ten or more, eleven or more, twelve or more, thirteen or more, fourteen or more, fifteen or more, sixteen or more, seventeen or more, eighteen or more, nineteen or more, or twenty or more amino acid residues of the amino acid sequence of SEQ ID NO:1, or five or more, six or more, seven or more, eight or more, nine or more, ten or more, eleven or more, twelve or more, thirteen or more, fourteen or more, fifteen or more, sixteen or more, seventeen or more, eighteen or more, nineteen or more, or twenty or more amino acid residues of the mammalian Siglec-5 protein corresponding to the amino acid sequence of SEQ ID NO:1.
[0179] In some embodiments, the anti-Siglec-5 antibody of this disclosure competitively inhibits the binding of at least one antibody selected from any of the antibodies listed in Tables 2, 3, 6, and 7. In some embodiments, the anti-Siglec-5 antibody of this disclosure competitively inhibits the binding of an antibody selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H6, and S5-174-H. 1. The binding of at least one antibody of S5-174-H2, S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8 and S5-G-03-H9.
[0180] In some embodiments, the anti-Siglec-5 antibody of this disclosure binds to an epitope of human Siglec-5 that is identical to or overlaps with an epitope of Siglec-5 that binds to at least one antibody selected from any of the antibodies listed in Tables 2, 3, 6, and 7. In some embodiments, the anti-Siglec-5 antibody of this disclosure binds to an epitope of human Siglec-5 that is identical to or overlaps with an epitope of Siglec-5 that binds to at least one antibody selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H6, S5-174-H1, S5-172-H5 ...2-H5, S5-172-H5, S5-172-H5, S5-172-H5, S5-172-H5, S5-172-H5, S5-174-H1, S5- At least one antibody of S5-G-03-H1, S5-G-03-H2, S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8 and S5-G-03-H9 binds to an epitope that is identical to or overlaps with the Siglec-5 epitope.
[0181] In some embodiments, the anti-Siglec-5 antibody of this disclosure binds to substantially the same Siglec-5 epitope as at least one antibody selected from any of the antibodies listed in Tables 2, 3, 6, and 7. In some embodiments, the anti-Siglec-5 antibody of this disclosure binds to substantially the same Siglec-5 epitope as at least one antibody selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H6, S5-174-H1, and S5-174-H2. 2. At least one antibody of S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8, and S5-G-03-H9 binds to substantially the same Siglec-5 epitope. Morris (1996) “Epitope Mapping Protocols” in Methods in Molecular Biology, Volume 66 (Humana Press, Totowa, NJ) provides a detailed exemplary method for locating antibody-bound epitopes.
[0182] In some embodiments, the anti-Siglec-5 antibody of this disclosure, when compared to binding to Siglec-5 in the absence of anti-Siglec-5 antibody, exhibits a reduced binding intensity of the anti-Siglec-5 antibody selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172- H5, S5-172-H6, S5-174-H1, S5-174-H2, S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8 and S5-G-03-H9 and any combination thereof When one or more antibodies bind to Siglec-5 in an amount ranging from about 50% to 100%, the anti-Siglec-5 antibody is selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H6, S5-174-H 1. One or more antibodies of S5-174-H2, S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8, and S5-G-03-H9, and any combination thereof, compete for binding with Siglec-5. In some embodiments, the anti-Siglec-5 antibody of this disclosure binds to Siglec-5 more readily than when binding to Siglec-5 in the absence of an anti-Siglec-5 antibody.The anti-Siglec-5 antibody will be selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H6, S5-174-H1, S5-174-H2, S5-174-H3, S5-174-H4, S5- One or more antibodies of S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8, and S5-G-03-H9, or any combination thereof, reduce the binding of Siglec-5 by at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, or at least 75%. When the concentration is at least 80%, at least 85%, at least 90%, at least 95%, or 100%, the anti-Siglec-5 antibody is selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H6, or S5-174-H1. One or more antibodies, including S5-174-H2, S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8, and S5-G-03-H9, and any combination thereof, compete for binding with Siglec-5. In some embodiments,Selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H6, S5-174-H1, S5-174-H2, S5-174-H3, S5-174-H4, S The present disclosure discloses an anti-Siglec-5 antibody that reduces the binding of one or more antibodies of S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8 and S5-G-03-H9, and any combination thereof to Siglec-5 by 100%. The antibody indicating that anti-Siglec-5 essentially completely blocks the antibody selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H6, S5-174-H1, S5-174-H2, and S5-174-H2. The binding of one or more antibodies, including S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8, and S5-G-03-H9, and any combination thereof, to Siglec-5. In some embodiments,Anti-Siglec-5 antibody and antibodies selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H6, S5-174-H1, S5-174-H2, S5- One or more antibodies of S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8 and S5-G-03-H9, or any combination thereof, are present in a certain amount.The quantities correspond to ratios of 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 0.75:1, 0.5:1, 0.25:1, 0.1:1, 0.075:1, 0.050:1, 0.025:1, 0.01:1, 0.0075:1, 0.0050:1, 0.0025:1, 0.001:1, 0.00075:1, and 0.000 50:1 ratio, 0.00025:1 ratio, 0.0001:1 ratio, 1:10 ratio, 1:9 ratio, 1:8 ratio, 1:7 ratio, 1:6 ratio, 1:5 ratio, 1:4 ratio, 1:3 ratio, 1:2 ratio, 1:0.75 ratio, 1:0.5 ratio, 1:0.25 ratio, 1:0.1 ratio, 1:0.075 ratio, 1:0.050 ratio, 1:0.025 ratio, 1:0.01 ratio, 1:0.0075 ratio, 1:0.0050 ratio, 1:0.0025 ratio, 1:0.001 ratio Anti-Siglec-5 antibodies at ratios of 1:0.00075, 1:0.00050, 1:0.00025, or 1:0.0001, and selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, and S5-172-H5. One or more antibodies of 2-H6, S5-174-H1, S5-174-H2, S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8, and S5-G-03-H9, and any combination thereof. In some embodiments,and selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S 5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H6, S5-174-H1, S5-174-H2, S5-174-H3, S5-174-H4, S5-174 Compared to the amount of one or more antibodies of -H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8 and S5-G-03-H9 and any combination thereof, an excess of anti-Siglec-5 antibody is present, with the excess ranging from about 1.5 times to 100 times or greater than 100 times. In some implementations, the code selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H6, S5-174-H1, S5-174-H2, S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S... Compared to the amounts of one or more antibodies of S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8, and S5-G-03-H9, and any combination thereof, anti-Siglec-5 antibody is present in approximately 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 times excess.
[0183] The presence or absence of anti-Siglec-5 antibodies can be determined using any suitable competitive assay or Siglec-5 binding assay known in the art, such as BIAcore analysis, ELISA assay, or flow cytometry, to determine whether the antibody binds to a molecule selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H5, or S5-172-H5. One or more antibodies, including S5-174-H1, S5-174-H2, S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8 and S5-G-03-H9, and any combination thereof, compete for binding with Siglec-5. In an exemplary competitive assay, cells immobilized with Siglec-5 or expressing Siglec-5 on their cell surface are incubated in a solution containing a first labeled antibody and a second unlabeled antibody. The first labeled antibody binds to Siglec-5 (e.g., in human or non-human primates), and the second unlabeled antibody is tested for its ability to compete with the first antibody for binding to Siglec-5. The second antibody may be present in the hybridoma supernatant. As a control, cells immobilized with Siglec-5 or expressing Siglec-5 are incubated in a solution containing the first labeled antibody but not the second unlabeled antibody. After incubation under conditions allowing the first antibody to bind to Siglec-5, excess unbound antibody is removed, and the amount of label associated with the immobilized Siglec-5 or Siglec-5-expressing cells is measured. If the amount of label associated with the immobilized Siglec-5 or Siglec-5-expressing cells in the test sample is significantly reduced relative to the control sample, it indicates that the second antibody competes with the first antibody for binding to Siglec-5. See Harlow and Lane (1988) Antibodies: A Laboratory Manual, Chapter 14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).
[0184] Anti-Siglec-5 antibody light chain and heavy chain variable regions
[0185] In some embodiments, the anti-Siglec-5 antibody of this disclosure comprises (a) a light chain variable region comprising a region selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H6, S5-174-H1, S5-174-H2, S5-172-H5, S5-172-H6, S5-174-H1, S5-174-H2, S5-172-H5, S5-172-H5, S5-172-H6, S5-172-H1, S5-172-H5 ... The HVRs selected from any of the antibodies of 4-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8, S5-G-03-H9 and any combination thereof, including at least one, two or three HVRs selected from HVR-L1, HVR-L2 and HVR-L3;And / or (b) a heavy chain variable region comprising a region selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H6, S5-174-H1, S5-174-H2, S5-174-H3, S5-174 At least one, two, or three HVRs selected from any of the antibodies of S5-G-03-H1, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8, S5-G-03-H9, and any combination thereof, from HVR-H1, HVR-H2, and HVR-H3. In some embodiments, the anti-Siglec-5 antibody of this disclosure comprises at least one, two, three, four, five, or six HVRs selected from: (i) comprising HVRs selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H5, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H5, S5-172-H1, S5-172-H1, S5-172-H2 ...2, S5-172-H2, S5-172-H2, S5-172-H2, S5-172-H2, S5-17 The amino acid sequences of the antibodies -H6, S5-174-H1, S5-174-H2, S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8 and S5-G-03-H9 are HVR-L1.(ii) Contains data from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H6, S5-174-H1, S5-174-H2, S5 The amino acid sequences of the antibodies S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8 and S5-G-03-H9 are HVR-L2. (iii) Contains data from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H6, S5-174-H1, S5-174-H2, S5 The amino acid sequences of the antibodies S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8 and S5-G-03-H9 are HVR-L3.(iv) Contains data from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H6, S5-174-H1, S5-174-H2, S5 The amino acid sequences of antibodies S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8 and S5-G-03-H9 are HVR-H1. (v) Contains data from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H6, S5-174-H1, S5-174-H2, S5 The amino acid sequences of the antibodies S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8 and S5-G-03-H9 are HVR-H2;and (vi) contain terms selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H6, S5-174-H1, S5-174-H2, S5 The amino acid sequences of the antibodies S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8 and S5-G-03-H9 are HVR-H3. In some implementations, HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3 contain components selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, and S5-172-H6. The EU or Kabat CDR, Chothia CDR, or contact CDR sequences of antibodies of S5-174-H1, S5-174-H2, S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8, and S5-G-03-H9, and any combination thereof.
[0186] In some embodiments, the anti-Siglec-5 antibody of this disclosure comprises a light chain variable domain and a heavy chain variable domain, wherein the light chain variable domain comprises one or more of the following: (a) HVR-L1 comprising an amino acid sequence selected from SEQ ID NO:103-115; (b) HVR-L2 comprising an amino acid sequence selected from SEQ ID NO:127-135; and (c) HVR-L3 comprising an amino acid sequence selected from SEQ ID NO:153-163; and / or wherein the heavy chain variable domain comprises one or more of the following: (a) HVR-H1 comprising an amino acid sequence selected from SEQ ID NO:20-28; (b) HVR-H2 comprising an amino acid sequence selected from SEQ ID NO:39-51; and (c) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO:70-79.
[0187] In some embodiments, the anti-Siglec-5 antibody of this disclosure comprises a heavy chain variable domain and a light chain variable domain, wherein (a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:20, HVR-H2 comprises the amino acid sequence of SEQ ID NO:39, HVR-H3 comprises the amino acid sequence of SEQ ID NO:70, HVR-L1 comprises the amino acid sequence of SEQ ID NO:103, HVR-L2 comprises the amino acid sequence of SEQ ID NO:127, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:153; (b) HVR-H1 comprises the amino acid sequence of SEQ ID NO:21, HVR-H2 comprises the amino acid sequence of SEQ ID NO:40, HVR-H3 comprises the amino acid sequence of SEQ ID NO:71, HVR-L1 comprises the amino acid sequence of SEQ ID NO:104, HVR-L2 comprises the amino acid sequence of SEQ ID NO:128, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:154; (c) HVR-H1 comprises the amino acid sequence of SEQ ID NO:20, HVR-H2 comprises the amino acid sequence of SEQ ID NO:40, HVR-H3 comprises the amino acid sequence of SEQ ID NO:71, HVR-L1 comprises the amino acid sequence of SEQ ID NO:104, HVR-L2 comprises the amino acid sequence of SEQ ID NO:128, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:154; HVR-H2 contains the amino acid sequence of SEQ ID NO:22, HVR-H3 contains the amino acid sequence of SEQ ID NO:72, HVR-L1 contains the amino acid sequence of SEQ ID NO:105, HVR-L2 contains the amino acid sequence of SEQ ID NO:129, and HVR-L3 contains the amino acid sequence of SEQ ID NO:155; (d) HVR-H1 contains the amino acid sequence of SEQ ID NO:23, HVR-H2 contains the amino acid sequence of SEQ ID NO:42, HVR-H3 contains the amino acid sequence of SEQ ID NO:73, HVR-L1 contains the amino acid sequence of SEQ ID NO:106, HVR-L2 contains the amino acid sequence of SEQ ID NO:127, and HVR-L3 contains the amino acid sequence of SEQ ID NO:156; (e) HVR-H1 contains the amino acid sequence of SEQ ID NO:24, HVR-H2 contains the amino acid sequence of SEQ ID NO:43, and HVR-H3 contains the amino acid sequence of SEQ ID NO:22. The amino acid sequence NO:74, HVR-L1 contains the amino acid sequence of SEQ ID NO:107, HVR-L2 contains the amino acid sequence of SEQ ID NO:130, and HVR-L3 contains the amino acid sequence of SEQ ID NO:157.(f) HVR-H1 contains the amino acid sequence of SEQ ID NO:25, HVR-H2 contains the amino acid sequence of SEQ ID NO:44, HVR-H3 contains the amino acid sequence of SEQ ID NO:75, HVR-L1 contains the amino acid sequence of SEQ ID NO:108, HVR-L2 contains the amino acid sequence of SEQ ID NO:131, and HVR-L3 contains the amino acid sequence of SEQ ID NO:158; (g) HVR-H1 contains the amino acid sequence of SEQ ID NO:20, HVR-H2 contains the amino acid sequence of SEQ ID NO:39, HVR-H3 contains the amino acid sequence of SEQ ID NO:70, HVR-L1 contains the amino acid sequence of SEQ ID NO:109, HVR-L2 contains the amino acid sequence of SEQ ID NO:127, and HVR-L3 contains the amino acid sequence of SEQ ID NO:159; (h) HVR-H1 contains the amino acid sequence of SEQ ID NO:25, HVR-H2 contains the amino acid sequence of SEQ ID NO:44, HVR-H3 contains the amino acid sequence of SEQ ID NO:75, HVR-L1 contains the amino acid sequence of SEQ ID NO:108, HVR-L2 contains the amino acid sequence of SEQ ID NO:131, and HVR-L3 contains the amino acid sequence of SEQ ID NO:159; HVR-H3 contains the amino acid sequence of SEQ ID NO:45, HVR-H1 contains the amino acid sequence of SEQ ID NO:76, HVR-L1 contains the amino acid sequence of SEQ ID NO:110, HVR-L2 contains the amino acid sequence of SEQ ID NO:132, and HVR-L3 contains the amino acid sequence of SEQ ID NO:160; (i) HVR-H1 contains the amino acid sequence of SEQ ID NO:26, HVR-H2 contains the amino acid sequence of SEQ ID NO:46, HVR-H3 contains the amino acid sequence of SEQ ID NO:77, HVR-L1 contains the amino acid sequence of SEQ ID NO:111, HVR-L2 contains the amino acid sequence of SEQ ID NO:133, and HVR-L3 contains the amino acid sequence of SEQ ID NO:161; (j) HVR-H1 contains the amino acid sequence of SEQ ID NO:27, HVR-H2 contains the amino acid sequence of SEQ ID NO:47, HVR-H3 contains the amino acid sequence of SEQ ID NO:78, and HVR-L1 contains the amino acid sequence of SEQ ID NO:160. The amino acid sequence NO:112, HVR-L2 contains the amino acid sequence of SEQ ID NO:134, and HVR-L3 contains the amino acid sequence of SEQ ID NO:162;(k) HVR-H1 contains the amino acid sequence of SEQ ID NO:28, HVR-H2 contains the amino acid sequence of SEQ ID NO:48, HVR-H3 contains the amino acid sequence of SEQ ID NO:79, HVR-L1 contains the amino acid sequence of SEQ ID NO:113, HVR-L2 contains the amino acid sequence of SEQ ID NO:135, and HVR-L3 contains the amino acid sequence of SEQ ID NO:163; (l) HVR-H1 contains the amino acid sequence of SEQ ID NO:20, HVR-H2 contains the amino acid sequence of SEQ ID NO:49, HVR-H3 contains the amino acid sequence of SEQ ID NO:70, HVR-L1 contains the amino acid sequence of SEQ ID NO:114, HVR-L2 contains the amino acid sequence of SEQ ID NO:127, and HVR-L3 contains the amino acid sequence of SEQ ID NO:153; (m) HVR-H1 contains the amino acid sequence of SEQ ID NO:21, HVR-H2 contains the amino acid sequence of SEQ ID NO:28, HVR-H2 contains the amino acid sequence of SEQ ID NO:48, HVR-H3 contains the amino acid sequence of SEQ ID NO:79, HVR-L1 contains the amino acid sequence of SEQ ID NO:114, HVR-L2 contains the amino acid sequence of SEQ ID NO:127, and HVR-L3 contains the amino acid sequence of SEQ ID NO:153; The amino acid sequence NO:50, HVR-H3 contains the amino acid sequence of SEQ ID NO:71, HVR-L1 contains the amino acid sequence of SEQ ID NO:115, HVR-L2 contains the amino acid sequence of SEQ ID NO:128, and HVR-L3 contains the amino acid sequence of SEQ ID NO:154; and (n) HVR-H1 contains the amino acid sequence of SEQ ID NO:26, HVR-H2 contains the amino acid sequence of SEQ ID NO:51, HVR-H3 contains the amino acid sequence of SEQ ID NO:77, HVR-L1 contains the amino acid sequence of SEQ ID NO:111, HVR-L2 contains the amino acid sequence of SEQ ID NO:133, and HVR-L3 contains the amino acid sequence of SEQ ID NO:161.
[0188] In some embodiments, the anti-Siglec-5 antibody of this disclosure comprises a subset selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H6, and S5-174. Antibodies for S5-174-H1, S5-174-H2, S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8 and S5-G-03-H9 The light chain variable region of any of the following; and / or selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H6, S5-174-H1, S5-174-H 2. The heavy chain variable region of any one of the antibodies S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8 and S5-G-03-H9.In some embodiments, the anti-Siglec-5 antibody of this disclosure comprises or is selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, and S5-172-H6 listed in Tables 2, 3, 6, and 7. Antibodies for S5-174-H1, S5-174-H2, S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8 and S5-G-03-H9 The light chain variable region of any of the following; and / or listed in or selected from Tables 2, 3, 6 and 7, or selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H6, S5-174-H1, The heavy chain variable region of any one of the antibodies S5-174-H2, S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8 and S5-G-03-H9.
[0189] In some embodiments, the anti-Siglec-5 antibody of this disclosure comprises a light chain variable region containing an amino acid sequence selected from any of SEQ ID NO:194-211; and / or a heavy chain variable domain containing an amino acid sequence selected from any of SEQ ID NO:174-193. In some embodiments, the light chain variable domain contains the amino acid sequence of SEQ ID NO:194; and the heavy chain variable domain contains the amino acid sequence of SEQ ID NO:174. In some embodiments, the light chain variable domain contains the amino acid sequence of SEQ ID NO:195; and the heavy chain variable domain contains the amino acid sequence of SEQ ID NO:175. In some embodiments, the light chain variable domain contains the amino acid sequence of SEQ ID NO:196; and the heavy chain variable domain contains the amino acid sequence of SEQ ID NO:176. In some embodiments, the light chain variable domain contains the amino acid sequence of SEQ ID NO:197; and the heavy chain variable domain contains the amino acid sequence of SEQ ID NO:177. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:198; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:178. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:199; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:179. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:200; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:174. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:201; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:180. In some embodiments, the light chain variable domain comprises the amino acid sequence SEQ ID NO:202; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:181. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:203; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:182. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:204; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:183. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:205; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:184. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:206; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:184.In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:205; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:185. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:206; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:185. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:205; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:186. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:206; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:186. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:207; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:187. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:208; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:187. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:207; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:188. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:208; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:188. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:207; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:189. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:208; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:189. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:207; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:190. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:208; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:190. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:209; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:191. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:210; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:191.In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:211; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:191. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:209; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:192. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:210; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:192. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:211; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:192. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:209; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:193. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:210; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:193. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:211; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:193.
[0190] In some embodiments, an anti-Siglec-5 antibody is provided, wherein the antibody comprises V as described in any of the embodiments provided above. H And V in any of the implementation schemes provided above L In one embodiment, the anti-Siglec-5 antibody of this disclosure comprises V selected from SEQ ID NO:174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192 and193. H Sequences; and V selected from SEQ ID NO: 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210 and 211. LSequences, including post-translational modifications of these sequences. In some embodiments, the anti-Siglec-5 antibody comprises a sequence selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H6, and S5-174-H1. The V antibodies of S5-174-H2, S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8 and S5-G-03-H9 H Sequence and V L sequence.
[0191] On the other hand, the anti-Siglec-5 antibody disclosed herein contains a heavy chain variable domain (V) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the amino acid sequences of SEQ ID NO: 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, or 193. H The sequence is described. In some embodiments, the amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with the amino acid sequence of SEQ ID NO: 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, or 193 is described. HThe sequence contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to the reference sequence, but the anti-Siglec-5 antibody containing this sequence retains its ability to bind to Siglec-5. In some embodiments, a total of 1 to 10 amino acids are substituted, inserted, and / or deleted in SEQ ID NO: 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, or 193. In some embodiments, a total of 1 to 5 amino acids in SEQ ID NO:174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, or 193 are substituted, inserted, and / or deleted. In some embodiments, the substitution, insertion, or deletion occurs in regions other than HVR (i.e., in FR). Optionally, the anti-Siglec-5 antibody comprises V of SEQ ID NO:174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, or 193. H The sequence, including its post-translational modifications. In a particular implementation, V H The HVR may contain one, two, or three HVRs selected from the following: (a) HVR-H1 containing the amino acid sequence of HVR-H1 shown in Table 2 and / or Table 6; (b) HVR-H2 containing the amino acid sequence of HVR-H1 shown in Table 2 and / or Table 6; and (c) HVR-H3 containing the amino acid sequence of HVR-H1 shown in Table 2 and / or Table 6.
[0192] On the other hand, the anti-Siglec-5 antibody disclosed herein contains a light chain variable domain (V) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the amino acid sequences of SEQ ID NO: 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211. L In some embodiments, V has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with the amino acid sequences of SEQ ID NO: 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211.L The sequence contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to a reference sequence, but the anti-Siglec-5 antibody containing this sequence retains its ability to bind to Siglec-5. In some embodiments, a total of 1 to 10 amino acids are substituted, inserted, and / or deleted in SEQ ID NO: 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211. In some embodiments, a total of 1 to 5 amino acids are substituted, inserted, and / or deleted in SEQ ID NO: 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211. In some embodiments, substitution, insertion, or deletion occurs in regions outside the HVR (i.e., in the FR). Optionally, the anti-Siglec-5 antibody comprises V of SEQ ID NO: 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211. L The sequence, including its post-translational modifications. In a particular implementation, V L It includes one, two or three HVRs selected from the following: (a) HVR-L1 containing the amino acid sequence of HVR-H1 shown in Table 3 and / or Table 7; (b) HVR-L2 containing the amino acid sequence of HVR-H1 shown in Table 3 and / or Table 7; and (c) HVR-L3 containing the amino acid sequence of HVR-H1 shown in Table 3 and / or Table 7.
[0193] In some embodiments, this document provides an anti-Siglec-5 antibody comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:20; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:39; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:70; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:103; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:127; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:153. In some embodiments, the anti-Siglec-5 antibody is an anti-Siglec-5 monoclonal antibody S5-172.
[0194] In some embodiments, this document provides an anti-Siglec-5 antibody comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:21; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:40; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:71; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:104; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:128; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:154. In some embodiments, the anti-Siglec-5 antibody is the anti-Siglec-5 monoclonal antibody S5-174.
[0195] In some embodiments, this document provides an anti-Siglec-5 antibody comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:22; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:41; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:72; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:105; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:129; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:155. In some embodiments, the anti-Siglec-5 antibody is an anti-Siglec-5 monoclonal antibody S5-175.
[0196] In some embodiments, this document provides an anti-Siglec-5 antibody comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:23; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:42; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:73; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:106; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:127; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:156. In some embodiments, the anti-Siglec-5 antibody is the anti-Siglec-5 monoclonal antibody S5-176.
[0197] In some embodiments, this document provides an anti-Siglec-5 antibody comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:24; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:43; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:74; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:107; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:130; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:157. In some embodiments, the anti-Siglec-5 antibody is an anti-Siglec-5 monoclonal antibody S5-182.
[0198] In some embodiments, this document provides an anti-Siglec-5 antibody comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:25; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:44; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:75; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:108; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:131; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:158. In some embodiments, the anti-Siglec-5 antibody is an anti-Siglec-5 monoclonal antibody S5-183.
[0199] In some embodiments, this document provides an anti-Siglec-5 antibody comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:20; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:39; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:70; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:109; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:127; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:159. In some embodiments, the anti-Siglec-5 antibody is the anti-Siglec-5 monoclonal antibody S5-190.
[0200] In some embodiments, this document provides an anti-Siglec-5 antibody comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:25; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:45; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:76; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:110; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:132; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:160. In some embodiments, the anti-Siglec-5 antibody is an anti-Siglec-5 monoclonal antibody S5-202.
[0201] In some embodiments, this document provides an anti-Siglec-5 antibody comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:26; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:46; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:77; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:111; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:133; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:161. In some embodiments, the anti-Siglec-5 antibody is an anti-Siglec-5 monoclonal antibody S5-G-03.
[0202] In some embodiments, this document provides an anti-Siglec-5 antibody comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:27; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:47; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:78; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:112; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:134; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:162. In some embodiments, the anti-Siglec-5 antibody is an anti-Siglec-5 monoclonal antibody S5-G-07.
[0203] In some embodiments, this document provides an anti-Siglec-5 antibody comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:28; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:48; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:79; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:113; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:135; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:163. In some embodiments, the anti-Siglec-5 antibody is an anti-Siglec-5 monoclonal antibody S5-G-10.
[0204] In some embodiments, this document provides an anti-Siglec-5 antibody comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:20; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:49; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:70; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:114; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:127; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:153. In some embodiments, the anti-Siglec-5 antibody is an anti-Siglec-5 monoclonal antibody S5-172-H1. In some embodiments, the anti-Siglec-5 antibody is an anti-Siglec-5 monoclonal antibody S5-172-H2. In some embodiments, the anti-Siglec-5 antibody is an anti-Siglec-5 monoclonal antibody S5-172-H3. In some embodiments, the anti-Siglec-5 antibody is anti-Siglec-5 monoclonal antibody S5-172-H4. In some embodiments, the anti-Siglec-5 antibody is anti-Siglec-5 monoclonal antibody S5-172-H5. In some embodiments, the anti-Siglec-5 antibody is anti-Siglec-5 monoclonal antibody S5-172-H6.
[0205] In some embodiments, this document provides an anti-Siglec-5 antibody comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:21; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:50; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:71; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:115; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:128; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:154. In some embodiments, the anti-Siglec-5 antibody is an anti-Siglec-5 monoclonal antibody S5-174-H1. In some embodiments, the anti-Siglec-5 antibody is an anti-Siglec-5 monoclonal antibody S5-174-H2. In some embodiments, the anti-Siglec-5 antibody is an anti-Siglec-5 monoclonal antibody S5-174-H3. In some embodiments, the anti-Siglec-5 antibody is anti-Siglec-5 monoclonal antibody S5-174-H4. In some embodiments, the anti-Siglec-5 antibody is anti-Siglec-5 monoclonal antibody S5-174-H5. In some embodiments, the anti-Siglec-5 antibody is anti-Siglec-5 monoclonal antibody S5-174-H6. In some embodiments, the anti-Siglec-5 antibody is anti-Siglec-5 monoclonal antibody S5-174-H7. In some embodiments, the anti-Siglec-5 antibody is anti-Siglec-5 monoclonal antibody S5-174-H8.
[0206] In some embodiments, this document provides an anti-Siglec-5 antibody comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:26; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:51; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:77; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:111; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:133; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:161. In some embodiments, the anti-Siglec-5 antibody is the anti-Siglec-5 monoclonal antibody S5-G-03-H1. In some embodiments, the anti-Siglec-5 antibody is the anti-Siglec-5 monoclonal antibody S5-G-03-H2. In some embodiments, the anti-Siglec-5 antibody is the anti-Siglec-5 monoclonal antibody S5-G-03-H3. In some embodiments, the anti-Siglec-5 antibody is anti-Siglec-5 monoclonal antibody S5-G-03-H4. In some embodiments, the anti-Siglec-5 antibody is anti-Siglec-5 monoclonal antibody S5-G-03-H5. In some embodiments, the anti-Siglec-5 antibody is anti-Siglec-5 monoclonal antibody S5-G-03-H6. In some embodiments, the anti-Siglec-5 antibody is anti-Siglec-5 monoclonal antibody S5-G-03-H7. In some embodiments, the anti-Siglec-5 antibody is anti-Siglec-5 monoclonal antibody S5-G-03-H8. In some embodiments, the anti-Siglec-5 antibody is anti-Siglec-5 monoclonal antibody S5-G-03-H9.
[0207] In some embodiments, the anti-Siglec-5 antibody of this disclosure is associated with V containing a protein selected from SEQ ID NO: 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, and 193. H The sequence and V selected from SEQ ID NO: 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210 and 211 LThe antibody sequence competes for binding with human Siglec-5. In some embodiments, the anti-Siglec-5 antibody of this disclosure binds to a sequence selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H6, and S5-174-H1. The antibodies of S5-174-H2, S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8 and S5-G-03-H9 competitively bind.
[0208] In some embodiments, the anti-Siglec-5 antibody of this disclosure competes with an anti-Siglec-5 antibody comprising a heavy chain variable domain and a light chain variable domain for binding to human Siglec-5, wherein the heavy chain variable domain comprises HVR-H1, HVR-H2 and / or HVR-H3, and the light chain variable domain comprises HVR-L1 and HVR-L2 and / or HVR-L3, wherein (a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:20, HVR-H2 comprises the amino acid sequence of SEQ ID NO:39, HVR-H3 comprises the amino acid sequence of SEQ ID NO:70, HVR-L1 comprises the amino acid sequence of SEQ ID NO:103, HVR-L2 comprises the amino acid sequence of SEQ ID NO:127, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:153; (b) HVR-H1 comprises the amino acid sequence of SEQ ID NO:21, HVR-H2 comprises the amino acid sequence of SEQ ID NO:40, and HVR-H3 comprises the amino acid sequence of SEQ ID NO:21. (c) HVR-H1 contains the amino acid sequence of SEQ ID NO:71, HVR-L1 contains the amino acid sequence of SEQ ID NO:104, HVR-L2 contains the amino acid sequence of SEQ ID NO:128, and HVR-L3 contains the amino acid sequence of SEQ ID NO:154; (d) HVR-H1 contains the amino acid sequence of SEQ ID NO:22, HVR-H2 contains the amino acid sequence of SEQ ID NO:41, HVR-H3 contains the amino acid sequence of SEQ ID NO:72, HVR-L1 contains the amino acid sequence of SEQ ID NO:105, HVR-L2 contains the amino acid sequence of SEQ ID NO:129, and HVR-L3 contains the amino acid sequence of SEQ ID NO:155; (e) HVR-H1 contains the amino acid sequence of SEQ ID NO:23, HVR-H2 contains the amino acid sequence of SEQ ID NO:42, HVR-H3 contains the amino acid sequence of SEQ ID NO:73, HVR-L1 contains the amino acid sequence of SEQ ID NO:106, and HVR-L2 contains the amino acid sequence of SEQ ID NO:154. (e) HVR-H1 contains the amino acid sequence of SEQ ID NO:127, and HVR-L3 contains the amino acid sequence of SEQ ID NO:156; HVR-H1 contains the amino acid sequence of SEQ ID NO:24, HVR-H2 contains the amino acid sequence of SEQ ID NO:43, HVR-H3 contains the amino acid sequence of SEQ ID NO:74, HVR-L1 contains the amino acid sequence of SEQ ID NO:107, HVR-L2 contains the amino acid sequence of SEQ ID NO:130, and HVR-L3 contains the amino acid sequence of SEQ ID NO:157;(f) HVR-H1 contains the amino acid sequence of SEQ ID NO:25, HVR-H2 contains the amino acid sequence of SEQ ID NO:44, HVR-H3 contains the amino acid sequence of SEQ ID NO:75, HVR-L1 contains the amino acid sequence of SEQ ID NO:108, HVR-L2 contains the amino acid sequence of SEQ ID NO:131, and HVR-L3 contains the amino acid sequence of SEQ ID NO:158; (g) HVR-H1 contains the amino acid sequence of SEQ ID NO:20, HVR-H2 contains the amino acid sequence of SEQ ID NO:39, HVR-H3 contains the amino acid sequence of SEQ ID NO:70, HVR-L1 contains the amino acid sequence of SEQ ID NO:109, HVR-L2 contains the amino acid sequence of SEQ ID NO:127, and HVR-L3 contains the amino acid sequence of SEQ ID NO:159; (h) HVR-H1 contains the amino acid sequence of SEQ ID NO:25, HVR-H2 contains the amino acid sequence of SEQ ID NO:44, HVR-H3 contains the amino acid sequence of SEQ ID NO:75, HVR-L1 contains the amino acid sequence of SEQ ID NO:108, HVR-L2 contains the amino acid sequence of SEQ ID NO:131, and HVR-L3 contains the amino acid sequence of SEQ ID NO:159; HVR-H3 contains the amino acid sequence of SEQ ID NO:45, HVR-H1 contains the amino acid sequence of SEQ ID NO:76, HVR-L1 contains the amino acid sequence of SEQ ID NO:110, HVR-L2 contains the amino acid sequence of SEQ ID NO:132, and HVR-L3 contains the amino acid sequence of SEQ ID NO:160; (i) HVR-H1 contains the amino acid sequence of SEQ ID NO:26, HVR-H2 contains the amino acid sequence of SEQ ID NO:46, HVR-H3 contains the amino acid sequence of SEQ ID NO:77, HVR-L1 contains the amino acid sequence of SEQ ID NO:111, HVR-L2 contains the amino acid sequence of SEQ ID NO:133, and HVR-L3 contains the amino acid sequence of SEQ ID NO:161; (j) HVR-H1 contains the amino acid sequence of SEQ ID NO:27, HVR-H2 contains the amino acid sequence of SEQ ID NO:47, HVR-H3 contains the amino acid sequence of SEQ ID NO:78, and HVR-L1 contains the amino acid sequence of SEQ ID NO:160. The amino acid sequence NO:112, HVR-L2 contains the amino acid sequence of SEQ ID NO:134, and HVR-L3 contains the amino acid sequence of SEQ ID NO:162;(k) HVR-H1 contains the amino acid sequence of SEQ ID NO:28, HVR-H2 contains the amino acid sequence of SEQ ID NO:48, HVR-H3 contains the amino acid sequence of SEQ ID NO:79, HVR-L1 contains the amino acid sequence of SEQ ID NO:113, HVR-L2 contains the amino acid sequence of SEQ ID NO:135, and HVR-L3 contains the amino acid sequence of SEQ ID NO:163; (l) HVR-H1 contains the amino acid sequence of SEQ ID NO:20, HVR-H2 contains the amino acid sequence of SEQ ID NO:49, HVR-H3 contains the amino acid sequence of SEQ ID NO:70, HVR-L1 contains the amino acid sequence of SEQ ID NO:114, HVR-L2 contains the amino acid sequence of SEQ ID NO:127, and HVR-L3 contains the amino acid sequence of SEQ ID NO:153; (m) HVR-H1 contains the amino acid sequence of SEQ ID NO:21, HVR-H2 contains the amino acid sequence of SEQ ID NO:21, HVR-H2 contains the amino acid sequence of SEQ ID NO:28, HVR-H2 contains the amino acid sequence of SEQ ID NO:48, HVR-H3 contains the amino acid sequence of SEQ ID NO:79, HVR-L1 contains the amino acid sequence of SEQ ID NO:114, HVR-L2 contains the amino acid sequence of SEQ ID NO:127, and HVR-L3 contains the amino acid sequence of SEQ ID NO:153; The amino acid sequence NO:50; HVR-H3 contains the amino acid sequence of SEQ ID NO:71; HVR-L1 contains the amino acid sequence of SEQ ID NO:115; HVR-L2 contains the amino acid sequence of SEQ ID NO:128; and HVR-L3 contains the amino acid sequence of SEQ ID NO:154; and (n) HVR-H1 contains the amino acid sequence of SEQ ID NO:26; HVR-H2 contains the amino acid sequence of SEQ ID NO:51; HVR-H3 contains the amino acid sequence of SEQ ID NO:77; HVR-L1 contains the amino acid sequence of SEQ ID NO:111; HVR-L2 contains the amino acid sequence of SEQ ID NO:133; and HVR-L3 contains the amino acid sequence of SEQ ID NO:161.
[0209] In some embodiments, the anti-Siglec-5 antibody of this disclosure competes with antibodies comprising: a light chain variable domain comprising the amino acid sequence of SEQ ID NO:194 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:174; a light chain variable domain comprising the amino acid sequence of SEQ ID NO:195 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:175; a light chain variable domain comprising the amino acid sequence of SEQ ID NO:196 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:176; a light chain variable domain comprising the amino acid sequence of SEQ ID NO:197 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:177; a light chain variable domain comprising the amino acid sequence of SEQ ID NO:198 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:178; a light chain variable domain comprising the amino acid sequence of SEQ ID NO:199 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:199; and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:199. Heavy chain variable domain of amino acid sequence NO:179; light chain variable domain of amino acid sequence containing SEQ ID NO:200 and heavy chain variable domain of amino acid sequence containing SEQ ID NO:174; light chain variable domain of amino acid sequence containing SEQ ID NO:201 and heavy chain variable domain of amino acid sequence containing SEQ ID NO:180; light chain variable domain of amino acid sequence containing SEQ ID NO:202 and heavy chain variable domain of amino acid sequence containing SEQ ID NO:181; light chain variable domain of amino acid sequence containing SEQ ID NO:203 and heavy chain variable domain of amino acid sequence containing SEQ ID NO:182; light chain variable domain of amino acid sequence containing SEQ ID NO:204 and heavy chain variable domain of amino acid sequence containing SEQ ID NO:183; light chain variable domain of amino acid sequence containing SEQ ID NO:205 and heavy chain variable domain of amino acid sequence containing SEQ ID NO:184; containing SEQ ID The light chain variable domain of the amino acid sequence NO:206 and the heavy chain variable domain of the amino acid sequence containing SEQ ID NO:184; the light chain variable domain of the amino acid sequence containing SEQ ID NO:205 and the heavy chain variable domain of the amino acid sequence containing SEQ ID NO:185; the light chain variable domain of the amino acid sequence containing SEQ ID NO:206 and the heavy chain variable domain of the amino acid sequence containing SEQ ID NO:185;The following amino acid sequences are included: a light chain variable domain containing the amino acid sequence of SEQ ID NO:205 and a heavy chain variable domain containing the amino acid sequence of SEQ ID NO:186; a light chain variable domain containing the amino acid sequence of SEQ ID NO:206 and a heavy chain variable domain containing the amino acid sequence of SEQ ID NO:186; a light chain variable domain containing the amino acid sequence of SEQ ID NO:207 and a heavy chain variable domain containing the amino acid sequence of SEQ ID NO:187; a light chain variable domain containing the amino acid sequence of SEQ ID NO:208 and a heavy chain variable domain containing the amino acid sequence of SEQ ID NO:187; a light chain variable domain containing the amino acid sequence of SEQ ID NO:207 and a heavy chain variable domain containing the amino acid sequence of SEQ ID NO:188; a light chain variable domain containing the amino acid sequence of SEQ ID NO:208 and a heavy chain variable domain containing the amino acid sequence of SEQ ID NO:188; a light chain variable domain containing the amino acid sequence of SEQ ID NO:207 and a heavy chain variable domain containing the amino acid sequence of SEQ ID NO:188; a light chain variable domain containing the amino acid sequence of SEQ ID NO:207 and a heavy chain variable domain containing the amino acid sequence of SEQ ID NO:188. Heavy chain variable domain of amino acid sequence NO:189; light chain variable domain of amino acid sequence NO:208 and heavy chain variable domain of amino acid sequence NO:189; light chain variable domain of amino acid sequence NO:207 and heavy chain variable domain of amino acid sequence NO:190; light chain variable domain of amino acid sequence NO:208 and heavy chain variable domain of amino acid sequence NO:190; light chain variable domain of amino acid sequence NO:209 and heavy chain variable domain of amino acid sequence NO:191; light chain variable domain of amino acid sequence NO:210 and heavy chain variable domain of amino acid sequence NO:191; light chain variable domain of amino acid sequence NO:211 and heavy chain variable domain of amino acid sequence NO:191; containing SEQ ID NO:189; The light chain variable domain of the amino acid sequence NO:209 and the heavy chain variable domain of the amino acid sequence containing SEQ ID NO:192; the light chain variable domain of the amino acid sequence containing SEQ ID NO:210 and the heavy chain variable domain of the amino acid sequence containing SEQ ID NO:192; the light chain variable domain of the amino acid sequence containing SEQ ID NO:211 and the heavy chain variable domain of the amino acid sequence containing SEQ ID NO:192;The variable domain comprising the light chain of the amino acid sequence SEQ ID NO: 209 and the variable domain comprising the amino acid sequence SEQ ID NO: 193; the variable domain comprising the light chain of the amino acid sequence SEQ ID NO: 210 and the variable domain comprising the amino acid sequence SEQ ID NO: 193; and / or the variable domain comprising the light chain of the amino acid sequence SEQ ID NO: 211 and the variable domain comprising the amino acid sequence SEQ ID NO: 193.
[0210] In some embodiments, the anti-Siglec-5 antibody of this disclosure binds to an epitope of human Siglec-5, said epitope being associated with a V-type of SEQ ID NO: 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, and 193. H The sequence and V selected from SEQ ID NO: 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210 and 211 L The epitopes that bind to the anti-Siglec-5 antibody of this disclosure are identical or overlap. In some embodiments, the anti-Siglec-5 antibody of this disclosure binds to human Siglec-5 epitopes selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H6, S5-174-H1, S5-1 Anti-Siglec-5 antibodies binding to epitopes that are identical or overlapping with those of S5-174-H2, S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8, and S5-G-03-H9 bind to epitopes that are identical or overlapping with those of S5-G-03-H9.
[0211] In some embodiments, the anti-Siglec-5 antibody of this disclosure binds to an epitope of human Siglec-5 that is identical to or overlaps with the epitope of the anti-Siglec-5 antibody comprising a variable heavy chain domain and a variable light chain domain, wherein the variable heavy chain domain comprises HVR-H1, HVR-H2 and / or HVR-H2, and the variable light chain domain comprises HVR-L1, HVR-L2 and / or HVR-L3, wherein (a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:20, HVR-H2 comprises the amino acid sequence of SEQ ID NO:39, HVR-H3 comprises the amino acid sequence of SEQ ID NO:70, HVR-L1 comprises the amino acid sequence of SEQ ID NO:103, HVR-L2 comprises the amino acid sequence of SEQ ID NO:127, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:153; (b) HVR-H1 comprises the amino acid sequence of SEQ ID NO:21, HVR-H2 comprises the amino acid sequence of SEQ ID NO:21, and HVR-H2 comprises the amino acid sequence of SEQ ID NO:20. (c) HVR-H1 contains the amino acid sequence of SEQ ID NO:40, HVR-H2 contains the amino acid sequence of SEQ ID NO:71, HVR-L1 contains the amino acid sequence of SEQ ID NO:104, HVR-L2 contains the amino acid sequence of SEQ ID NO:128, and HVR-L3 contains the amino acid sequence of SEQ ID NO:154; (d) HVR-H1 contains the amino acid sequence of SEQ ID NO:22, HVR-H2 contains the amino acid sequence of SEQ ID NO:41, HVR-H3 contains the amino acid sequence of SEQ ID NO:72, HVR-L1 contains the amino acid sequence of SEQ ID NO:105, HVR-L2 contains the amino acid sequence of SEQ ID NO:129, and HVR-L3 contains the amino acid sequence of SEQ ID NO:155; (e) HVR-H1 contains the amino acid sequence of SEQ ID NO:23, HVR-H2 contains the amino acid sequence of SEQ ID NO:42, HVR-H3 contains the amino acid sequence of SEQ ID NO:73, and HVR-L1 contains the amino acid sequence of SEQ ID NO:154. (e) HVR-L1 contains the amino acid sequence of SEQ ID NO:106, HVR-L2 contains the amino acid sequence of SEQ ID NO:127, and HVR-L3 contains the amino acid sequence of SEQ ID NO:156; HVR-H1 contains the amino acid sequence of SEQ ID NO:24, HVR-H2 contains the amino acid sequence of SEQ ID NO:43, HVR-H3 contains the amino acid sequence of SEQ ID NO:74, HVR-L1 contains the amino acid sequence of SEQ ID NO:107, HVR-L2 contains the amino acid sequence of SEQ ID NO:130, and HVR-L3 contains the amino acid sequence of SEQ ID NO:157;(f) HVR-H1 contains the amino acid sequence of SEQ ID NO:25, HVR-H2 contains the amino acid sequence of SEQ ID NO:44, HVR-H3 contains the amino acid sequence of SEQ ID NO:75, HVR-L1 contains the amino acid sequence of SEQ ID NO:108, HVR-L2 contains the amino acid sequence of SEQ ID NO:131, and HVR-L3 contains the amino acid sequence of SEQ ID NO:158; (g) HVR-H1 contains the amino acid sequence of SEQ ID NO:20, HVR-H2 contains the amino acid sequence of SEQ ID NO:39, HVR-H3 contains the amino acid sequence of SEQ ID NO:70, HVR-L1 contains the amino acid sequence of SEQ ID NO:109, HVR-L2 contains the amino acid sequence of SEQ ID NO:127, and HVR-L3 contains the amino acid sequence of SEQ ID NO:159; (h) HVR-H1 contains the amino acid sequence of SEQ ID NO:25, HVR-H2 contains the amino acid sequence of SEQ ID NO:44, HVR-H3 contains the amino acid sequence of SEQ ID NO:75, HVR-L1 contains the amino acid sequence of SEQ ID NO:108, HVR-L2 contains the amino acid sequence of SEQ ID NO:131, and HVR-L3 contains the amino acid sequence of SEQ ID NO:159; HVR-H3 contains the amino acid sequence of SEQ ID NO:45, HVR-H1 contains the amino acid sequence of SEQ ID NO:76, HVR-L1 contains the amino acid sequence of SEQ ID NO:110, HVR-L2 contains the amino acid sequence of SEQ ID NO:132, and HVR-L3 contains the amino acid sequence of SEQ ID NO:160; (i) HVR-H1 contains the amino acid sequence of SEQ ID NO:26, HVR-H2 contains the amino acid sequence of SEQ ID NO:46, HVR-H3 contains the amino acid sequence of SEQ ID NO:77, HVR-L1 contains the amino acid sequence of SEQ ID NO:111, HVR-L2 contains the amino acid sequence of SEQ ID NO:133, and HVR-L3 contains the amino acid sequence of SEQ ID NO:161; (j) HVR-H1 contains the amino acid sequence of SEQ ID NO:27, HVR-H2 contains the amino acid sequence of SEQ ID NO:47, HVR-H3 contains the amino acid sequence of SEQ ID NO:78, and HVR-L1 contains the amino acid sequence of SEQ ID NO:160. The amino acid sequence NO:112, HVR-L2 contains the amino acid sequence of SEQ ID NO:134, and HVR-L3 contains the amino acid sequence of SEQ ID NO:162;(k) HVR-H1 contains the amino acid sequence of SEQ ID NO:28, HVR-H2 contains the amino acid sequence of SEQ ID NO:48, HVR-H3 contains the amino acid sequence of SEQ ID NO:79, HVR-L1 contains the amino acid sequence of SEQ ID NO:113, HVR-L2 contains the amino acid sequence of SEQ ID NO:135, and HVR-L3 contains the amino acid sequence of SEQ ID NO:163; (l) HVR-H1 contains the amino acid sequence of SEQ ID NO:20, HVR-H2 contains the amino acid sequence of SEQ ID NO:49, HVR-H3 contains the amino acid sequence of SEQ ID NO:70, HVR-L1 contains the amino acid sequence of SEQ ID NO:114, HVR-L2 contains the amino acid sequence of SEQ ID NO:127, and HVR-L3 contains the amino acid sequence of SEQ ID NO:153; (m) HVR-H1 contains the amino acid sequence of SEQ ID NO:21, HVR-H2 contains the amino acid sequence of SEQ ID NO:28, HVR-H2 contains the amino acid sequence of SEQ ID NO:48, HVR-H3 contains the amino acid sequence of SEQ ID NO:79, HVR-L1 contains the amino acid sequence of SEQ ID NO:114, HVR-L2 contains the amino acid sequence of SEQ ID NO:127, and HVR-L3 contains the amino acid sequence of SEQ ID NO:153; The amino acid sequence NO:50, HVR-H3 contains the amino acid sequence of SEQ ID NO:71, HVR-L1 contains the amino acid sequence of SEQ ID NO:115, HVR-L2 contains the amino acid sequence of SEQ ID NO:128, and HVR-L3 contains the amino acid sequence of SEQ ID NO:154; and (n) HVR-H1 contains the amino acid sequence of SEQ ID NO:26, HVR-H2 contains the amino acid sequence of SEQ ID NO:51, HVR-H3 contains the amino acid sequence of SEQ ID NO:77, HVR-L1 contains the amino acid sequence of SEQ ID NO:111, HVR-L2 contains the amino acid sequence of SEQ ID NO:133, and HVR-L3 contains the amino acid sequence of SEQ ID NO:161.
[0212] In some embodiments, the anti-Siglec-5 antibody of this disclosure binds to an epitope of human Siglec-5 that is identical to or overlaps with an epitope containing the following: a light chain variable domain containing the amino acid sequence of SEQ ID NO:194 and a heavy chain variable domain containing the amino acid sequence of SEQ ID NO:174; a light chain variable domain containing the amino acid sequence of SEQ ID NO:195 and a heavy chain variable domain containing the amino acid sequence of SEQ ID NO:175; a light chain variable domain containing the amino acid sequence of SEQ ID NO:196 and a heavy chain variable domain containing the amino acid sequence of SEQ ID NO:176; a light chain variable domain containing the amino acid sequence of SEQ ID NO:197 and a heavy chain variable domain containing the amino acid sequence of SEQ ID NO:177; a light chain variable domain containing the amino acid sequence of SEQ ID NO:198 and a heavy chain variable domain containing the amino acid sequence of SEQ ID NO:178; a light chain variable domain containing the amino acid sequence of SEQ ID NO:199 and a heavy chain variable domain containing the amino acid sequence of SEQ ID NO:198; a light chain variable domain containing the amino acid sequence of SEQ ID NO:199 and a heavy chain variable domain containing the amino acid sequence of SEQ ID NO:198; a light chain variable domain containing the amino acid sequence of SEQ ID NO:199 and a heavy chain variable domain containing the amino acid sequence of SEQ ID NO:198; a light chain variable domain containing the amino acid sequence of SEQ ID NO:199; and a heavy chain variable domain containing the amino acid sequence of SEQ ID NO:198. Heavy chain variable domain of amino acid sequence NO:179; light chain variable domain of amino acid sequence containing SEQ ID NO:200 and heavy chain variable domain of amino acid sequence containing SEQ ID NO:174; light chain variable domain of amino acid sequence containing SEQ ID NO:201 and heavy chain variable domain of amino acid sequence containing SEQ ID NO:180; light chain variable domain of amino acid sequence containing SEQ ID NO:202 and heavy chain variable domain of amino acid sequence containing SEQ ID NO:181; light chain variable domain of amino acid sequence containing SEQ ID NO:203 and heavy chain variable domain of amino acid sequence containing SEQ ID NO:182; light chain variable domain of amino acid sequence containing SEQ ID NO:204 and heavy chain variable domain of amino acid sequence containing SEQ ID NO:183; light chain variable domain of amino acid sequence containing SEQ ID NO:205 and heavy chain variable domain of amino acid sequence containing SEQ ID NO:184; containing SEQ ID The light chain variable domain of the amino acid sequence NO:206 and the heavy chain variable domain of the amino acid sequence containing SEQ ID NO:184; the light chain variable domain of the amino acid sequence containing SEQ ID NO:205 and the heavy chain variable domain of the amino acid sequence containing SEQ ID NO:185; the light chain variable domain of the amino acid sequence containing SEQ ID NO:206 and the heavy chain variable domain of the amino acid sequence containing SEQ ID NO:185;The following amino acid sequences are included: a light chain variable domain containing the amino acid sequence of SEQ ID NO: 205 and a heavy chain variable domain containing the amino acid sequence of SEQ ID NO: 186; a light chain variable domain containing the amino acid sequence of SEQ ID NO: 206 and a heavy chain variable domain containing the amino acid sequence of SEQ ID NO: 186; a light chain variable domain containing the amino acid sequence of SEQ ID NO: 207 and a heavy chain variable domain containing the amino acid sequence of SEQ ID NO: 187; a light chain variable domain containing the amino acid sequence of SEQ ID NO: 208 and a heavy chain variable domain containing the amino acid sequence of SEQ ID NO: 187; a light chain variable domain containing the amino acid sequence of SEQ ID NO: 208 and a heavy chain variable domain containing the amino acid sequence of SEQ ID NO: 188; a light chain variable domain containing the amino acid sequence of SEQ ID NO: 207 and a heavy chain variable domain containing the amino acid sequence of SEQ ID NO: 188; a light chain variable domain containing the amino acid sequence of SEQ ID NO: 207 and a heavy chain variable domain containing the amino acid sequence of SEQ ID NO: 188; a light chain variable domain containing the amino acid sequence of SEQ ID NO: 207 and a heavy chain variable domain containing the amino acid sequence of SEQ ID NO: 188. Heavy chain variable domain of amino acid sequence NO:189; light chain variable domain of amino acid sequence SEQ ID NO:208 and heavy chain variable domain of amino acid sequence SEQ ID NO:189; light chain variable domain of amino acid sequence SEQ ID NO:207 and heavy chain variable domain of amino acid sequence SEQ ID NO:190; light chain variable domain of amino acid sequence SEQ ID NO:208 and heavy chain variable domain of amino acid sequence SEQ ID NO:190; light chain variable domain of amino acid sequence SEQ ID NO:209 and heavy chain variable domain of amino acid sequence SEQ ID NO:191; light chain variable domain of amino acid sequence SEQ ID NO:210 and heavy chain variable domain of amino acid sequence SEQ ID NO:191; light chain variable domain of amino acid sequence SEQ ID NO:211 and heavy chain variable domain of amino acid sequence SEQ ID NO:191; containing SEQ ID NO:189; The light chain variable domain of the amino acid sequence NO:209 and the heavy chain variable domain of the amino acid sequence containing SEQ ID NO:192; the light chain variable domain of the amino acid sequence containing SEQ ID NO:210 and the heavy chain variable domain of the amino acid sequence containing SEQ ID NO:192; the light chain variable domain of the amino acid sequence containing SEQ ID NO:211 and the heavy chain variable domain of the amino acid sequence containing SEQ ID NO:192;The variable domain comprising the light chain containing the amino acid sequence of SEQ ID NO:209 and the variable domain comprising the amino acid sequence of SEQ ID NO:193; the variable domain comprising the light chain containing the amino acid sequence of SEQ ID NO:210 and the variable domain comprising the amino acid sequence of SEQ ID NO:193; and / or the variable domain comprising the light chain containing the amino acid sequence of SEQ ID NO:211 and the variable domain comprising the amino acid sequence of SEQ ID NO:193.
[0213] Any anti-Siglec-5 antibody of this disclosure can be generated from cell lines. In some embodiments, the cell line may be a mammalian cell line. In some embodiments, the cell line may be a hybridoma cell line. In other embodiments, the cell line may be a yeast cell line. Any cell line known in the art suitable for antibody production can be used to generate the antibodies of this disclosure. Exemplary cell lines for antibody production are described throughout this disclosure.
[0214] In some implementations, the anti-Siglec-5 antibody is selected from S5-172, S5-174, S5-175, S5-176, S5-182, S5-183, S5-190, S5-202, S5-G-03, S5-G-07, S5-G-10, S5-172-H1, S5-172-H2, S5-172-H3, S5-172-H4, S5-172-H5, S5-172-H6, S5-174-H1, and S5-172-H5. Anti-Siglec-5 monoclonal antibodies against S5-G-03-H2, S5-174-H3, S5-174-H4, S5-174-H5, S5-174-H6, S5-174-H7, S5-174-H8, S5-G-03-H1, S5-G-03-H2, S5-G-03-H3, S5-G-03-H4, S5-G-03-H5, S5-G-03-H6, S5-G-03-H7, S5-G-03-H8, and S5-G-03-H9. In some embodiments, the anti-Siglec-5 antibody is an antagonist antibody. In some embodiments, the anti-Siglec-5 antibody is an agonist antibody or an inert antibody.
[0215] Anti-Siglec-5 antibody binding affinity
[0216] The dissociation constant (K) of anti-Siglec-5 antibodies against human Siglec-5, mammalian Siglec-5, or both. D(Can be less than 100nM, less than 75nM, less than 50nM, less than 25nM, less than 20nM, less than 15nM, less than 10nM, less than 9nM, less than 8nM, less than 7nM, less than 6nM, less than 5nM, less than 4nM, less than 3nM, less than 2nM, less than 1nM, less than 0.95nM, less than 0.9nM, less than 0.85nM, less than 0.8nM, less than 0.75nM, less than 0.70nM, less than 0.69nM, less than 0.68nM, less than 0.67nM, less than 0.66nM) M, less than 0.65nM, less than 0.64nM, less than 0.63nM, less than 0.62nM, less than 0.61nM, less than 0.6nM, less than 0.59nM, less than 0.58nM, less than 0.57nM, less than 0.56nM, less than 0.55nM, less than 0.54nM, less than 0.53nM, less than 0.52nM, less than 0.51nM, less than 0.50nM, less than 0.49nM, less than 0.48nM, less than 0.47nM, less than 0.46nM, less than 0.45nM, less than 0.44n M, less than 0.43nM, less than 0.42nM, less than 0.41nM, less than 0.4nM, less than 0.39nM, less than 0.38nM, less than 0.37nM, less than 0.36nM, less than 0.35nM, less than 0.34nM, less than 0.33nM, less than 0.32nM, less than 0.31nM, less than 0.3nM, less than 0.29nM, less than 0.28nM, less than 0.27nM, less than 0.26nM, less than 0.25nM, less than 0.24nM, less than 0.23nM, less than 0.22nM <0.21 nM, <0.2 nM, <0.19 nM, <0.18 nM, <0.17 nM, <0.16 nM, <0.15 nM, <0.14 nM, <0.13 nM, <0.12 nM, <0.11 nM, <0.1 nM, <0.09 nM, <0.08 nM, <0.07 nM, <0.06 nM, <0.05 nM, <0.04 nM, <0.03 nM, <0.02 nM, or <0.01 nM (i.e., 10 pM). In some embodiments, the dissociation constant (Ki) of antibodies against human Siglec-5, mammalian Siglec-5, or both is specified. D The dissociation constant (Ki) of the human Siglec-5 antibody is in the range of less than 80 nM to less than 0.4 nM. In some embodiments, the dissociation constant (Ki) of the human Siglec-5 antibody is... D The dissociation constant (Ki) of the antibody against human Siglec-5 is in the range of approximately 400 pm to approximately 80 nM. In some embodiments, the dissociation constant (Ki) of the antibody against human Siglec-5 is... DThe values are approximately 0.42 nM, 0.85 nM, 1.1 nM, 1.5 nM, 1.7 nM, 5.3 nM, 7.1 nM, 15 nM, 31 nM, 61 nM, or 79 nM.
[0217] In some implementations of any of the antibodies provided herein, the dissociation constant (K) of the antibody is... D <1 μM, <100 nM, <10 nM, <1 nM, <0.1 nM, <0.01 nM, or <0.001 nM (e.g., 10 μM). -8 M or smaller, such as 10 -8 M to 10 -13 M, for example, 10 -9 M to 10 -13 M). The dissociation constant can be determined by any analytical technique, including any biochemical or biophysical technique such as ELISA, surface plasmon resonance (SPR), biolayer interferometry (see, for example, ForteBio's Octet system), isothermal titration calorimetry (ITC), differential scanning calorimetry (DSC), circular dichroism spectroscopy (CD), stop-flow analysis, and colorimetric or fluorescent protein melting analysis. In one embodiment, K is measured by radiolabeled antigen binding assay (RIA). D In some embodiments, such as those described in Chen et al., J. Mol. Biol. 293:865-881 (1999), RIA is performed using the Fab form of the antibody of interest and its antigen. In some embodiments, K is measured using the BIACORE surface plasmon resonance assay. D For example, assays using BIACORE-2000 or BIACORE-3000 (BIAcore, Inc., Piscataway, NJ) are performed at 25°C using an immobilized antigen CM5 chip with ~10 response units (RU). In some embodiments, such as those discussed in the examples herein, ForteBio is used. The Red384 system (ForteBio, Menlo Park, CA) measures K. D In some implementations, K is measured at a temperature of approximately 25°C. D .
[0218] The physical / chemical properties and / or biological activity of additional anti-Siglec-5 antibodies (e.g., antibodies that specifically bind to the Siglec-5 protein of this disclosure) can be confirmed, screened, and / or characterized by various assays known in the art.
[0219] Anti-Siglec-5 antibodies capable of binding to Fcγ receptors
[0220] In some embodiments, the anti-Siglec-5 antibodies of this disclosure retain the ability to bind to the Fcγ receptor. In some embodiments, such antibodies, when they possess the correct epitope specificity compatible with receptor activation, may have the characteristic of enabling them to aggregate and transiently stimulate, for example, the Siglec-5 receptor. In some embodiments, such antibodies may subsequently act as long-term inhibitors of Siglec-5 expression and / or one or more activities of the Siglec-5 protein by inducing Siglec-5 degradation, Siglec-5 desensitization, Siglec-5 cleavage, Siglec-5 internalization, Siglec-5 shedding, downregulation of Siglec-5 expression, and / or lysosomal degradation of Siglec-5.
[0221] In vivo, the anti-Siglec-5 antibody of this disclosure can aggregate receptors and transiently activate Siglec-5 through any one or more of a variety of potential mechanisms. Some isotypes of human antibodies, such as IgG2, have the intrinsic ability to aggregate receptors or retain receptors in aggregate configurations due to their unique structure, thereby transiently activating receptors such as Siglec-5 without binding to Fc receptors (e.g., White et al., (2015) Cancer Cell 27, 138-148).
[0222] In some embodiments, other antibodies may aggregate receptors (e.g., Siglec-5) by binding to Fcg receptors on neighboring cells. In some embodiments, binding of the constant IgG Fc region of an antibody to an Fcg receptor may lead to antibody aggregation, which in turn may aggregate through its variable region to the receptors to which it binds (Chu et al. (2008) Mol Immunol, 45:3926-3933; and Wilson et al. (2011) Cancer Cell 19, 101-113). In some embodiments, binding to the inhibitory Fcg receptor FcgR (FcgRIIB), which does not induce cytokine secretion, oxidative burst, increased phagocytosis, or enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), is a preferred mode of antibody aggregation in vivo because binding to FcgRIIB is not associated with adverse immune response effects.
[0223] The anti-Siglec-5 antibodies of this disclosure can aggregate the receptor via other mechanisms. For example, as described above, cross-linked antibody fragments (e.g., Fab fragments) can be used to aggregate the receptor (e.g., Siglec-5) in a manner similar to that of antibodies having an Fc region that binds to the Fcg receptor. In some embodiments, they can transiently act as agonist antibodies if the cross-linked antibody fragments (e.g., Fab fragments) induce receptor aggregation on the cell surface and bind to the appropriate epitope on the target (e.g., Siglec-5).
[0224] Therefore, in some embodiments, antibodies of this disclosure that bind to the Siglec-5 protein may include agonist antibodies that bind to Siglec-5 due to their epitope specificity and transiently activate one or more Siglec-5 activities, inhibit one or more Siglec-5 activities (e.g., due to decreased cellular levels of Siglec-5) before they, for example, reduce cellular levels of Siglec-5, and / or inhibit interactions (e.g., binding) between Siglec-5 and one or more Siglec-5 ligands (e.g., due to decreased cellular levels of Siglec-5). In some embodiments, such antibodies may bind to ligand-binding sites on Siglec-5 and transiently mimic the action of natural ligands. Alternatively, such antibodies may stimulate target antigen transduction signaling by binding to one or more domains that are not ligand-binding sites. In some embodiments, such antibodies do not interfere with ligand binding. In some implementations, regardless of whether the antibody binds to the ligand-binding site on Siglec-5 or not, the antibody can subsequently act as a long-term inhibitor of Siglec-5 expression and / or one or more activities of the Siglec-5 protein by inducing Siglec-5 degradation, Siglec-5 desensitization, Siglec-5 cleavage, Siglec-5 internalization, Siglec-5 shedding, downregulation of Siglec-5 expression and / or lysosomal degradation of Siglec-5.
[0225] Exemplary antibody Fc isotypes and modifications are provided in Table B below. In some embodiments, the anti-Siglec-5 antibody of this disclosure capable of binding to the Fcγ receptor has the Fc isotypes listed in Table B below.
[0226] Table B: Exemplary anti-Siglec-5 antibody Fc isotypes capable of binding to the Fcγ receptor
[0227]
[0228]
[0229]
[0230] In addition to the isotypes described in Table B, and not wanting to be bound by theory, it is believed that antibodies and mutants of human IgG1 or IgG3 isotypes that bind to human Fcg receptors I, IIA, IIC, IIIA, IIIB and / or mouse Fcg receptors I, III and IV (e.g. Strohl (2009) Current Opinion in Biotechnology 2009, 20: 685-691) can also act as transient agonist antibodies.
[0231] In some embodiments, the Fcγ receptor-binding antibody belongs to the IgG, IgM, or IgA class. In some embodiments, the Fcγ receptor-binding antibody has an IgG1, IgG2, IgG3, or IgG4 isotype.
[0232] In some embodiments, the Fcγ receptor-binding antibody has an IgG2 isotype. In some embodiments, the Fcγ receptor-binding antibody contains a human IgG2 constant region. In some embodiments, the human IgG2 constant region includes an Fc region. In some embodiments, the Fcγ receptor-binding antibody binds to an inhibitory Fc receptor. In some embodiments, the inhibitory Fc receptor is an inhibitory Fc-γ receptor IIB (FcγIIB). In some embodiments, the Fc region contains one or more modifications. For example, in some embodiments, the Fc region contains one or more amino acid substitutions (e.g., relative to the same isotype wild-type Fc region). In some embodiments, one or more amino acid substitutions are selected from V234A (Alegre et al., (1994) Transplantation 57:1537-1543.31; Xu et al., (2000) Cell Immunol, 200:16-26), G237A (Cole et al., (1999) Transplantation, 68:563-571), H268Q, V309L, A330S, P331S (US 2007 / 0148167; Armour et al., (1999) Eur J Immunol 29:2613-2624; Armour et al., (2000) The Haematology Journal 1 (Supplement 1):27; Armour et al., (2000) The Haematology Journal 1(Supplement 1):27), C232S and / or C233S (White et al., (2015) Cancer Cell 27, 138-148), S267E, L328F (Chu et al., (2008) Mol Immunol, 45:3926-3933), M252Y, S254T and / or T256E, wherein the amino acid positions are in accordance with EU numbering convention.
[0233] In some implementations, the Fcγ receptor-binding antibody has an IgG2 isotype with a heavy chain constant domain containing a C127S amino acid substitution, wherein the amino acid positions are in accordance with EU numbering conventions (White et al., (2015) Cancer Cell 27, 138-148; Lightle et al., (2010) PROTEIN SCIENCE 19:753-762; and WO2008079246).
[0234] In some implementations, the Fcγ receptor-binding antibody has an IgG2 isotype with a constant κ light chain domain containing a C214S amino acid substitution, wherein the amino acid positions are in accordance with EU numbering conventions (White et al., (2015) Cancer Cell 27, 138-148; Lightle et al., (2010) PROTEIN SCIENCE 19:753-762; and WO2008079246).
[0235] In some embodiments, the Fcγ receptor-binding antibody has an IgG1 isotype. In some embodiments, the Fcγ receptor-binding antibody contains a mouse IgG1 constant region. In some embodiments, the Fcγ receptor-binding antibody contains a human IgG1 constant region. In some embodiments, the human IgG1 constant region includes an Fc region. In some embodiments, the Fcγ receptor-binding antibody binds to an inhibitory Fc receptor. In some embodiments, the inhibitory Fc receptor is an inhibitory Fc-γ receptor IIB (FcγIIB). In some embodiments, the Fc region contains one or more modifications. For example, in some embodiments, the Fc region contains one or more amino acid substitutions (e.g., relative to the same isotype wild-type Fc region). In some embodiments, one or more amino acid substitutions are selected from N297A (Bolt S et al., (1993) Eur J Immunol 23:403-411), D265A (Shields et al., (2001) RJBiol.Chem.276,6591–6604), D270A, L234A, L235A (Hutchins et al., (1995) Proc Natl Acad Sci USA,92:11980-11984; Alegre et al., (1994) Transplantation 57:1537-1543.31; Xu et al., (2000) Cell Immunol,200:16-26), G237A (Alegre et al., (1994) Transplantation 57:1537-1543.31; Xu et al., (2000) Cell Immunol, 200:16-26), P238D, L328E, E233D, G237D, H268D, P271G, A330R, C226S, C229S, E233P, L234V, L234F, L235E (McEarchern et al., (2007) Blood, 109:1185-1192), P331S (Sazinsky et al., (2008) Proc NatlAcad Sci USA 2008,105:20167-20172), C127S, V263L, V266L, S267E, V273C, V273E, V273F, V273L, V273M, V273S, V273Y, L328F, A330L, M252Y, S254T, T256E, N297Q, P238S, P238A, V305K, V305W, A327Q, A327G, P329A, K322A, T394D and / or E430G, wherein the amino acid positions are in accordance with EU numbering conventions.
[0236] In some embodiments, the antibody comprises an IgG2 isotype heavy chain constant domain 1 (CH1) and a hinge region (White et al., (2015) Cancer Cell 27, 138-148). In some embodiments, the IgG2 isotype CH1 and hinge region contain the amino acid sequence ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCP (SEQ ID NO: 218). In some embodiments, the antibody Fc region contains an S267E amino acid substitution, an L328F amino acid substitution, or both and / or an N297A or N297Q amino acid substitution, wherein the amino acid positions are in accordance with EU numbering conventions.
[0237] In some embodiments, the Fcγ receptor-binding antibody has an IgG4 isotype. In some embodiments, the Fcγ receptor-binding antibody contains a human IgG4 constant region. In some embodiments, the human IgG4 constant region includes an Fc region. In some embodiments, the Fcγ receptor-binding antibody binds to an inhibitory Fc receptor. In some embodiments, the inhibitory Fc receptor is an inhibitory Fc-γ receptor IIB (FcγIIB). In some embodiments, the Fc region contains one or more modifications. For example, in some embodiments, the Fc region contains one or more amino acid substitutions (e.g., relative to the wild-type Fc region of the same isotype). In some embodiments, the one or more amino acid substitutions are selected from L235A, G237A, S228P, L236E (Reddy et al., (2000) J Immunol, 164:1925-1933), S267E, E318A, L328F, M252Y, S254T and / or T256E, wherein the amino acid positions are according to EU numbering convention. In some embodiments, one or more amino acid substitutions are selected from S228P, F234A, and L235A, wherein the amino acid positions are according to EU numbering conventions. In some embodiments, one or more amino acid substitutions are selected from S228P at Fc residue position 228, F234A at Fc residue position 234, and L235A at Fc residue position 235, wherein the amino acid positions are according to EU numbering conventions.
[0238] In some embodiments, the Fcγ receptor-binding antibody has a heterozygous IgG2 / 4 isotype. In some embodiments, the Fcγ receptor-binding antibody comprises an amino acid sequence containing amino acids 118 to 260 according to the EU or Kabat numbering scheme for human IgG2 and amino acids 261-447 according to the EU or Kabat numbering scheme for human IgG4 (WO 1997 / 11971; WO 2007 / 106585).
[0239] In some implementations, the antibody contains the mouse IgG4 constant region (Bartholomaeus et al., (2014). J. Immunol. 192, 2091-2098).
[0240] In some embodiments, the Fc region further contains one or more additional amino acid substitutions selected from A330L, L234F, L235E or P331S according to EU or Kabat numbering scheme; and any combination thereof.
[0241] Antagonist anti-Siglec-5 antibody
[0242] The third class of anti-Siglec-5 antibodies disclosed herein includes antagonist antibodies. In some embodiments, antibodies binding to the Siglec-5 protein may include antagonist antibodies that reduce cellular levels of Siglec-5 and / or inhibit one or more activities of the Siglec-5 protein. These antibodies inhibit one or more activities of the Siglec-5 protein by blocking the interaction (e.g., binding) between Siglec-5 and one or more Siglec-5 ligands (e.g., indirectly, such as by reducing Siglec-5 cellular levels) or by blocking signal transduction from the extracellular domain of Siglec-5 to the cytoplasm in the presence of one or more Siglec-5 ligands. Antagonist antibodies may also inhibit one or more activities of the Siglec-5 protein by reducing cellular surface levels of Siglec-5 through inducing Siglec-5 degradation, Siglec-5 desensitization, Siglec-5 cleavage, Siglec-5 internalization, Siglec-5 shedding, downregulation of Siglec-5 expression, and / or lysosomal degradation of Siglec-5. In some implementations, these antagonistic anti-Siglec-5 antibodies can activate Siglec-5 without transiently activating it.
[0243] In some embodiments, the antagonist anti-Siglec-5 antibody of this disclosure may have the epitope specificity of the transient agonist anti-Siglec-5 antibody of this disclosure, but have an Fc domain that cannot bind to the Fcg receptor and therefore cannot, for example, transiently aggregate and activate Siglec-5.
[0244] In some embodiments, the antagonistic anti-Siglec-5 antibody of this disclosure has (but is not limited to) one or more of the following activities: reducing the ability of inhibitors of cytokine signaling (SOCS) proteins (e.g., SOCS3 protein) to bind to Siglec-5 protein; increasing the ability of Siglec-5 protein to undergo proteasome degradation; reducing the ability of Siglec-5 to functionally express on the surface of circulating dendritic cells, macrophages, monocytes, T cells, and / or microglia; and reducing or inhibiting the phosphorylation of Tyr-520 and Tyr-544 by Src family tyrosine kinases such as Syk, LCK, FYM, and / or ZAP70. The ability to: inhibit the recruitment and binding of tyrosine-specific protein phosphatases SHP1 and SHP2; inhibit the recruitment and binding of PLC-γ1, which acts as a guanine nucleotide exchange factor for Dynamini-1; inhibit the recruitment and binding of proteins containing SH2 domains (e.g., Crkl); inhibit the recruitment and binding of spleen tyrosine kinase Syk; inhibit the recruitment and binding of SH3-SH2-SH3 growth factor receptor-binding protein 2 (Grb2); inhibit the recruitment and binding of multiple SH2-containing proteins; and regulate the expression of one or more pro-inflammatory cytokines, optionally one or more anti-inflammatory cytokines. Cytokines are selected from IFN-α4, IFN-β, IL-1β, IL-1α, TNF-α, IL-6, IL-8, CRP, IL-20 family members, LIF, IFN-γ, OSM, CNTF, GM-CSF, IL-11, IL-12, IL-17, IL-18, IL-33, MCP-1, and MIP-1-β; regulation is provided by one or more pro-inflammatory cytokines selected from macrophages, neutrophils, B cells, NK cells, dendritic cells, bone marrow-derived dendritic cells, monocytes, osteoclasts, T cells, T helper cells, cytotoxic T cells, granulocytes, and microglia. The ability to express; the ability to regulate the expression of one or more anti-inflammatory cytokines, wherein one or more anti-inflammatory cytokines are selected from IL-4, IL-10, IL-13, IL-35, IL-16, TGF-β, IL-1Ra, G-CSF, and soluble receptors for TNF, IFN-β1a, IFN-β1b, or IL-6; the ability to regulate the expression of one or more anti-inflammatory cytokines in one or more cells selected from macrophages, neutrophils, B cells, NK cells, dendritic cells, bone marrow-derived dendritic cells, monocytes, osteoclasts, T cells, T helper cells, cytotoxic T cells, granulocytes, and microglia;The ability to regulate the expression of one or more proteins selected from C1qa, C1qB, C1qC, C1s, C1R, C4, C2, C3, ITGB2, HMOX1, LAT2, CASP1, CSTA, VSIG4, MS4A4A, C3AR1, GPX1, TyroBP, ALOX5AP, ITGAM, SLC7A7, CD4, ITGAX, and PYCARD; the ability to counteract the inhibition of extracellular signal-regulated kinase (ERK) phosphorylation; and the ability to prevent the reduction of tyrosine phosphorylation on one or more cellular proteins, optionally one or more of which contain ZAP-70 and tyrosine... Acid phosphorylation occurs on Tyr-319 of ZAP-70; the ability to regulate the expression of CC chemokine receptor 7 (CCR7); the ability to inhibit the chemotaxis of microglia to cells expressing CCL19 and CCL21; and the ability to inhibit the reduction of T cell proliferation induced by one or more of the following cell types: dendritic cells, bone marrow-derived dendritic cells, B cells, regulatory B cells, plasma cells, monocytes, microglia, M1 microglia, activated M1 microglia, M2 microglia, macrophages, neutrophils, NK cells, M1 macrophages, M1 neutrophils, M1 NK cells, activated M1 macrophages, activated M1 neutrophils, activated M1 NK cells, M2 macrophages, M2 neutrophils, and M2 NK cells; the ability to prevent inhibition of osteoclast production, the ability to prevent a decrease in the rate of osteoclast production, or both; the ability to prevent a reduction in the survival of one or more cells selected from the following: dendritic cells, bone marrow-derived dendritic cells, macrophages, neutrophils, NK cells, B cells, regulatory B cells, plasma cells, M1 macrophages, M1 neutrophils, M1 NK cells, activated M1 macrophages, activated M1 neutrophils, activated M1 NK cells, M2 macrophages, M2 neutrophils, M2 NK cells, monocytes, osteoclasts, T cells, T helper cells, cytotoxic T cells, granulocytes, neutrophils, microglia, M1 microglia, activated M1 microglia, and M2 microglia;The ability to inhibit the reduced proliferation of one or more cells selected from the following: dendritic cells, bone marrow-derived dendritic cells, macrophages, neutrophils, NK cells, B cells, regulatory B cells, plasma cells, M1 macrophages, M1 neutrophils, M1 NK cells, activated M1 macrophages, activated M1 neutrophils, activated M1 NK cells, M2 macrophages, M2 neutrophils, M2 NK cells, monocytes, osteoclasts, T cells, T helper cells, cytotoxic T cells, granulocytes, neutrophils, microglia, M1 microglia, activated M1 microglia, and M2 microglia; The ability to enhance the migration of one or more cells selected from the following: dendritic cells, bone marrow-derived dendritic cells, macrophages, neutrophils, NK cells, B cells, regulatory B cells, plasma cells, M1 macrophages, M1 neutrophils, M1 NK cells, activated M1 macrophages, activated M1 neutrophils, activated M1 NK cells, M2 macrophages, M2 neutrophils, M2 NK cells, monocytes, osteoclasts, T cells, T helper cells, cytotoxic T cells, granulocytes, neutrophils, microglia, M1 microglia, activated M1 microglia, and M2 microglia; the ability to prevent the reduction of one or more functions of one or more cells selected from the following: dendritic cells, bone marrow-derived dendritic cells, macrophages, neutrophils, NK cells, B cells, regulatory B cells, plasma cells, M1 macrophages, M1 neutrophils, M1 NK cells, activated M1 macrophages, activated M1 neutrophils, activated M1 NK cells, M2 macrophages, M2 neutrophils, M2 NK cells, monocytes, osteoclasts, T cells, T helper cells, cytotoxic T cells, granulocytes, neutrophils, microglia, M1 microglia, activated M1 microglia, and M2 microglia; enhance the ability to mature one or more of the following cells: dendritic cells, bone marrow-derived dendritic cells, macrophages, neutrophils, NK cells, B cells, regulatory B cells, plasma cells, M1 macrophages, M1 neutrophils, M1 NK cells, activated M1 macrophages, activated M1 neutrophils, activated M1 NK cells, M2 macrophages, M2 neutrophils, M2 NK cells, monocytes, osteoclasts, T cells, T helper cells, cytotoxic T cells, granulocytes, neutrophils, microglia, M1 microglia, activated M1 microglia, and M2 microglia;Enhance the ability to clear one or more types of pathogens selected from apoptotic neurons, neural tissue debris, dysfunctional synapses, non-neural tissue debris, bacteria, other foreign bodies, pathogenic proteins, pathogenic peptides, and tumor cells; among which, the pathogenic proteins are selected from amyloid-β, oligoamyloid-β, amyloid-β plaques, amyloid precursor protein or fragments thereof, Tau, IAPP, α-synuclein, TDP-43, FUS protein, C9orf72 (chromosome 9 open reading frame 72), c9RAN protein, prion protein, PrPSc, huntingtin protein, calcitonin, superoxide dismutase, ataxia protein, ataxia protein 1, ataxia protein 2, ataxia protein 3, ataxia protein 7, ataxia protein 8, ataxia protein 10, Lewy body, atrial natriuretic factor, pancreatic amyloid peptide, insulin, apolipoprotein AI, serum amyloid A, and medin. Prolactin, thyroxine transporter, lysozyme, β2-microglobulin, coagulant, corneal epithelial protein, cystatin, immunoglobulin light chain (AL), S-IBM protein, repeat-associated non-ATG (RAN) translation products, dipeptide repeat (DPR) peptide, glycine-alanine (GA) repeat peptide, glycine-proline (GP) repeat peptide, glycine-arginine (GR) repeat peptide, proline-alanine (PA) repeat peptide, ubiquitin, and proline-arginine (PR) repeat peptide. Peptides, and tumor cells derived from cancers selected from bladder cancer, brain cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, renal cell carcinoma, renal pelvis cancer, leukemia, lung cancer, melanoma, non-Hodgkin's lymphoma, pancreatic cancer, prostate cancer, ovarian cancer, fibrosarcoma, and thyroid cancer; inhibiting the phagocytic activity of one or more of apoptotic neurons, neural tissue debris, dysfunctional synapses, non-neural tissue debris, bacteria, other foreign bodies, pathogenic proteins, pathogenic peptides, pathogenic nucleic acids, or tumor cells;The pathogenic nucleic acid is selected from the antisense GGCCCC(G2C4) (SEQ ID NO:225) repeat amplified RNA. The pathogenic protein is selected from amyloid β, oligoamyloid β, amyloid β plaque, amyloid precursor protein or fragment thereof, Tau, IAPP, α-synuclein, TDP-43, FUS protein, C9orf72 (chromosome 9 open reading frame 72), c9RAN protein, prion protein, PrPSc, huntingtin protein, calcitonin, superoxide dismutase, ataxia protein, ataxia protein 1, ataxia protein 2, ataxia protein 3, ataxia protein 7, ataxia protein 8, ataxia protein 10, Lewy body, atrial natriuretic factor, pancreatic islet amyloid polypeptide, insulin, apolipoprotein The tumor cells were selected from bladder cancer, brain cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, renal cell carcinoma, medin, prolactin, thyroxine transporter, lysozyme, β2-microglobulin, coagulin, corneal epithelial protein, cystatin, immunoglobulin light chain AL, S-IBM protein, repeat-associated non-ATG (RAN) translation products, dipeptide repeat (DPR) peptide, glycine-alanine (GA) repeat peptide, glycine-proline (GP) repeat peptide, glycine-arginine (GR) repeat peptide, proline-alanine (PA) repeat peptide, ubiquitin, and proline-arginine (PR) repeat peptide, and the tumor cells were selected from bladder cancer, brain cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, renal cell carcinoma, renal pelvis cancer, and leukemia. Cancers including lung cancer, melanoma, non-Hodgkin's lymphoma, pancreatic cancer, prostate cancer, ovarian cancer, fibrosarcoma, or thyroid cancer; binding to Siglec-5 ligands on tumor cells; binding to Siglec-5 ligands selected from neutrophils, dendritic cells, bone marrow-derived dendritic cells, monocytes, microglia, macrophages, and NK cells; inhibiting the killing of tumor cells by one or more of microglia, macrophages, neutrophils, NK cells, dendritic cells, bone marrow-derived dendritic cells, neutrophils, T cells, T helper cells, or cytotoxic T cells; activating the killing of tumor cells by microglia, macrophages, neutrophils, and NK cells. The ability to enhance the antitumor cell proliferation activity of one or more of the following: dendritic cells, bone marrow-derived dendritic cells, neutrophils, T cells, T helper cells, or cytotoxic T cells; the ability to enhance the antitumor cell metastasis activity of one or more of the following: microglia, macrophages, neutrophils, NK cells, dendritic cells, bone marrow-derived dendritic cells, neutrophils, T cells, T helper cells, or cytotoxic T cells; and the ability to enhance the activity of one or more receptors containing the ITAM motif, wherein one or more of the receptors containing the ITAM motif are selected from TREM1, TREM2, SIRPB1, Fcγ receptor (FcgR), DAP10, and DAP12.The ability to enhance signal transduction through one or more pattern recognition receptors (PRRs), wherein one or more PRRs are selected from receptors that recognize pathogen-associated molecular patterns (PAMPs), receptors that recognize damage-associated molecular patterns (DAMPs), and any combination thereof; enhancement includes motif D / Ex; 0-2 YxxL / IX 6-8The ability to enhance the activity of one or more receptors of YxxL / I (SEQ ID NO:4); the ability to enhance signal transduction via one or more Toll-like receptors; the ability to enhance the JAK-STAT signaling pathway; the ability to enhance the activity of nuclear factor κ-light chain enhancer (NFκB) activating B cells; the ability to increase the phosphorylation of receptors containing the ITAM motif; the ability to increase the expression of one or more inflammatory receptors, complement cascade proteins, and / or receptors expressed on immune cells, wherein one or more inflammatory receptors, complement cascade proteins, and / or receptors expressed on immune cells include CD86, C1qa, C1qB, C1qC, C1s, C1R, C4, C2, C3, ITGB2, HMOX1, LAT2, CASP1, CSTA, VSIG4, MS4A4A, C3AR1, GPX1, TyroBP, ALOX5AP, ITGAM, SLC7A7, CD4, ITGAX, and / or PYCARD, and one or more inflammatory receptors, complement cascade proteins, and / or receptors expressed on immune cells are expressed on one or more of microglia, macrophages, neutrophils, NK cells, B cells, dendritic cells, bone marrow-derived dendritic cells, neutrophils, T cells, T helper cells, or cytotoxic T cells; the ability to reduce the expression of one or more Siglec-5-dependent genes; the ability to enhance the expression of one or more Siglec-5-dependent genes. The ability to express multiple ITAM-dependent genes, including one or more ITAM-dependent genes, activated by nuclear factor activating T cells (NFAT); reducing or otherwise inhibiting the differentiation of one or more of the following: immunosuppressive dendritic cells, immunosuppressive macrophages, immunosuppressive neutrophils, immun...
Claims
1. An isolated monoclonal anti-Siglec-5 antibody, wherein the anti-Siglec-5 antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the light chain variable domain comprises HVR-L1, HVR-L2 and HVR-L3, and the heavy chain variable domain comprises HVR-H1, HVR-H2 and HVR-H3, in: The HVR-L1 is shown in the amino acid sequence of SEQ ID NO:103, the HVR-L2 is shown in the amino acid sequence of SEQ ID NO:127, the HVR-L3 is shown in the amino acid sequence of SEQ ID NO:153, the HVR-H1 is shown in the amino acid sequence of SEQ ID NO:20, the HVR-H2 is shown in the amino acid sequence of SEQ ID NO:39, and the HVR-H3 is shown in the amino acid sequence of SEQID NO:
70.
2. The anti-Siglec-5 antibody according to claim 1, wherein The light chain variable domain comprises the amino acid sequence of SEQ ID NO:194, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:
174.
3. The anti-Siglec-5 antibody according to claim 1 or 2, wherein the antibody belongs to the IgG class, the IgM class or the IgA class.
4. The anti-Siglec-5 antibody of claim 3, wherein the anti-Siglec-5 antibody has an IgG1, IgG2, IgG3 or IgG4 isotype.
5. The anti-Siglec-5 antibody of claim 4, wherein the antibody binds to an inhibitory Fc receptor.
6. The anti-Siglec-5 antibody of claim 5, wherein the inhibitory Fc receptor is inhibitory Fc-γ receptor IIB (FcγIIB).
7. The anti-Siglec-5 antibody according to claim 6, in: (a) the anti-Siglec-5 antibody has a human or mouse IgG1 isotype and comprises one or more amino acid substitutions at residue positions in the Fc region selected from the group consisting of: N297A, D265A, D270A, L234A, L235A, G237A, P238D, L328E, E233D, G237D, H268D, P271G, A330R, C226S, C229S, E233P, L234V, L234F, L235E, P331S, S267E, L328F, A330L, M252Y, S254T, T256E, N297Q, P238S, P238A, A327Q, A327G, P329A, K322A, T394D, E430G, V263L, V266L, V273C, V273E, V273F, V273L, V273M, V273S, V273Y, V305K, V305W, and any combination thereof, wherein the numbering of the residues is according to the EU numbering convention, or comprises an amino acid deletion at the position corresponding to glycine 236 in the Fc region; (b) the anti-Siglec-5 antibody has an IgG1 isotype and comprises an IgG2 isotype heavy chain constant domain 1 (CH1) and a hinge region, optionally wherein the IgG2 isotype CH1 and hinge region comprise the amino acid sequence of ASTKGPSVFP LAPCSRSTSESTAALGCLVK DYFPE PVTVS WNSGALTSGVHTFPAVLQSS GLYSLSSVVT VPSSNFGTQ T YTCNVDHKPSNTKVDKTVERKCCVECPPCP (SEQ ID NO: 218), and optionally wherein the antibody Fc region comprises an S267E amino acid substitution, an L328F amino acid substitution, or both and / or an N297A or N297Q amino acid substitution, wherein the numbering of the residues is according to the EU numbering method; (c) the anti-Siglec-5 antibody has an IgG2 isotype and comprises one or more amino acid substitutions at a residue position in the Fc region selected from the group consisting of: P238S, V234A, G237A, H268A, H268Q, V309L, A330S, P331S, C214S, C232S, C233S, S267E, L328F, M252Y, S254T, T256E, H268E, N297A, N297Q, A330L, C127S, E430G, and any combination thereof, wherein the numbering of the residues is according to the EU numbering system; (d) the anti-Siglec-5 antibody has a human or mouse IgG4 isotype and comprises one or more amino acid substitutions at residue positions in the Fc region selected from the group consisting of: L235A, G237A, S228P, L236E, S267E, E318A, L328F, M252Y, S254T, T256E, E233P, F234V, L234A / F234A, S228P, S241P, L248E, T394D, N297A, N297Q, L235E, and any combination thereof, wherein the numbering of the residues is according to the EU numbering system; or (e) the anti-Siglec-5 antibody has a hybrid IgG2 / 4 isotype, and optionally wherein the antibody comprises an amino acid sequence comprising amino acids 118 to 260 of human IgG2 and amino acids 261 to 447 of human IgG4, wherein the numbering of the residues is according to the EU numbering method.
8. The anti-Siglec-5 antibody according to claim 7, in: (a) the anti-Siglec-5 antibody has a human or mouse IgG1 isotype and comprises one or more amino acid substitutions at residue positions in the Fc region selected from the group consisting of: N297A, N297Q, D270A, D265A, L234A, L235A, C226S, C229S, P238S, E233P, L234V, P238A, A327Q, A327G, P329A, K322A, L234F, L235E, P331S, T394D, A330L, M252Y, S254T, T256E, and any combination thereof, wherein the numbering of the residues is according to the EU numbering system; (b) the anti-Siglec-5 antibody has an IgG2 isotype and comprises one or more amino acid substitutions at a residue position in the Fc region selected from the group consisting of: P238S, V234A, G237A, H268A, H268Q, H268E, V309L, N297A, N297Q, A330S, P331S, C232S, C233S, M252Y, S254T, T256E, C127S, E430G, and any combination thereof, wherein the numbering of the residues is according to the EU numbering system; or (c) the anti-Siglec-5 antibody has an IgG4 isotype and comprises one or more amino acid substitutions at residue positions in the Fc region selected from the group consisting of: E233P, F234V, L234A / F234A, L235A, G237A, E318A, S228P, L236E, S241P, L248E, T394D, M252Y, S254T, T256E, N297A, N297Q and any combination thereof, wherein the numbering of the residues is according to the EU numbering method.
9. The anti-Siglec-5 antibody according to claim 8, in: (a) the Fc region further comprises one or more additional amino acid substitutions at a position selected from the group consisting of A330L, L234F; L235E, P331S, and any combination thereof, wherein the numbering of the residues is according to the EU numbering system; (b) the Fc region further comprises one or more additional amino acid substitutions at a position selected from the group consisting of M252Y, S254T, T256E, and any combination thereof, wherein the numbering of the residues is according to the EU numbering system; or (c) the Fc region further comprises an S228P amino acid substitution according to EU numbering.
10. The anti-Siglec-5 antibody of any one of claims 1-4, wherein the antibody has an IgG4 isotype.
11. An anti-Siglec-5 antibody as described in claim 10, wherein the anti-Siglec-5 antibody comprises an S228P amino acid substitution at residue position 228, a F234A amino acid substitution at residue position 234, and an L235A amino acid substitution at residue position 235, wherein the numbering of the residue positions is according to the EU numbering method.
12. The anti-Siglec-5 antibody of claim 1 or 2, wherein the anti-Siglec-5 antibody is an antibody fragment that binds to an epitope comprising amino acid residues on a human Siglec-5 protein.
13. An anti-Siglec-5 antibody as described in claim 12, wherein the antibody fragment is cross-linked with a second antibody fragment, and the second antibody fragment binds to one or more human proteins selected from the group consisting of human Siglec-5, naturally occurring variants of human Siglec-5, and disease variants of human Siglec-5.
14. The anti-Siglec-5 antibody of claim 12 or 13, wherein the fragment is a Fab, Fab', Fab'-SH, F(ab')2, Fv or scFv fragment.
15. The anti-Siglec-5 antibody of any one of claims 1-14, wherein the anti-Siglec-5 antibody is a murine antibody.
16. The anti-Siglec-5 antibody of any one of claims 1 to 14, wherein the anti-Siglec-5 antibody is a humanized antibody, a bispecific antibody, a multivalent antibody, a conjugated antibody, or a chimeric antibody.
17. The anti-Siglec-5 antibody of any one of claims 1 to 14, wherein the anti-Siglec-5 antibody is a bispecific antibody that recognizes a first antigen and a second antigen.
18. The anti-Siglec-5 antibody of claim 17, wherein the first antigen is Siglec-5, and the second antigen is: (a) Antigens that promote transport across the blood-brain barrier; (b) an antigen that promotes transport across the blood-brain barrier selected from the group consisting of transferrin receptor (TR), insulin receptor (HIR), insulin-like growth factor receptor (IGFR), low-density lipoprotein receptor-related proteins 1 and 2 (LPR-1 and 2), diphtheria toxin receptor, CRM197, llama single domain antibody, TMEM 30 (A), protein transduction domain, TAT, Syn-B, penetratin, polyarginine peptide, angiopeptide and ANG1005; (c) a pathogenic factor selected from the group consisting of a pathogenic peptide or protein or a pathogenic nucleic acid, wherein the pathogenic nucleic acid is an antisense GGCCCC (G2C4) (SEQ ID NO: 225) repeat expansion RNA, and wherein the pathogenic peptide or protein is selected from amyloid β, oligomeric amyloid β, amyloid β plaques, amyloid precursor protein or fragments thereof, Tau, IAPP, α-synuclein, TDP-43, FUS protein, C9orf72 (chromosome 9 open reading frame 72), c9RAN protein, prion protein, PrPSc, huntingtin protein, calcitonin, superoxide dismutase, ataxia protein, Lewy body, atrial natriuretic factor, islet amyloid polypeptide, insulin, apolipoprotein the group consisting of protein AI, serum amyloid A, medin, prolactin, transthyretin, lysozyme, beta 2 microglobulin, gelsolin, corneal epithelial protein, cystatin, immunoglobulin light chain AL, S-IBM protein, repeat-associated non-ATG (RAN) translation products, dipeptide repeat (DPR) peptides, glycine-alanine (GA) repeat peptides, glycine-proline (GP) repeat peptides, glycine-arginine (GR) repeat peptides, proline-alanine (PA) repeat peptides, ubiquitin, and proline-arginine (PR) repeat peptides; or (d) ligands and / or proteins expressed on immune cells, wherein the ligands and / or proteins are selected from the group consisting of PD-1 / PD-L1, CD40, OX40, ICOS, CD28, CD137 / 4-1BB, CD27, GITR, PD-L1, CTLA4, PD-L2, PD-1, B7-H3, B7-H4, HVEM, LIGHT, BTLA, CD30, TIGIT, VISTA, KIR, GAL9, TIM1, TIM3, TIM4, A2AR, LAG3, DR-5, CD2, CD5, CD39, CD73 and phosphatidylserine.
19. The anti-Siglec-5 antibody of claim 18, wherein the ataxin is selected from the group consisting of ataxin 1, ataxin 2, ataxin 3, ataxin 7, ataxin 8, and ataxin 10.
20. The anti-Siglec-5 antibody of any one of claims 1-19, wherein the anti-Siglec-5 antibody is a conjugated antibody.
21. The anti-Siglec-5 antibody of claim 20, wherein the anti-Siglec-5 antibody is conjugated to a detectable label, a toxin, or a therapeutic agent.
22. The anti-Siglec-5 antibody of claim 21, wherein the anti-Siglec-5 antibody is conjugated to a toxin selected from the group consisting of ricin, ricin A chain, doxorubicin, daunomycin, maytansine, paclitaxel, ethidium bromide, mitomycin, etoposide, teniposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin, diphtheria toxin, Pseudomonas exotoxin (PE) A, PE40, abrin, abrin A chain, modinomycin A chain, α-sarcin, gelonin, mitogillin, restrictocin, phenomycin, enomycin, curcas toxin, crotonin, calicheamicin, physostigmine inhibitor, glucocorticoid, auristatin, chlortetracycline, yttrium, bismuth, comprestatin, duocarmycin, aplysia, cc1065, and cisplatin.
23. An isolated nucleic acid comprising a nucleic acid sequence encoding the anti-Siglec-5 antibody of any of the preceding claims.
24. A vector comprising the nucleic acid of claim 23.
25. An isolated host cell comprising the vector of claim 24.
26. A method for producing an anti-Siglec-5 antibody, comprising culturing the host cell of claim 25 so as to produce the anti-Siglec-5 antibody.
27. The method of claim 26, further comprising recovering the anti-Siglec-5 antibody produced by the host cell.
28. An isolated anti-Siglec-5 antibody produced by the method of claim 26 or 27.
29. A pharmaceutical composition comprising the anti-Siglec-5 antibody of any one of claims 1 to 22 and a pharmaceutically acceptable carrier.
Citation Information
Patent Citations
Antibody heteroconjugates for the killing of HIV-infected cells
EP0308936A2
Bispecific and oligospecific, mono- and oligovalent receptors, production and applications thereof
EP0404097A2
Non-immunostimulatory antibody and compositions containing the same
US20070148167A1
Methods for treating lymphocyte-associated disorders by modulation of siglec activity
US20070244038A1
Rationally Designed, Synthetic Antibody Libraries and Uses Therefor
US20090181855A1
